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Tijd
Tijd – het is vreemd, het is vreemd mooi ook
nooit te weten wat het is
en toch, hoeveel van wat er in ons leeft is ouder
dan wij, hoeveel daarvan zal ons overleven
zoals een pasgeboren kind kijkt alsof het kijkt
naar iets in zichzelf, iets ziet daar
wat het meekreeg
zoals Rembrandt kijkt op de laatste portretten
van zichzelf alsof hij ziet waar hij heengaat
een verte voorbij onze ogen
het is vreemd maar ook vreemd mooi te bedenken
dat ooit niemand meer zal weten
dat we hebben geleefd
te bedenken hoe we nu leven, hoe hier
maar ook hoe niets ons leven zou zijn zonder
de echo’s van de onbekende diepten in ons hoofd
niet de tijd gaat voorbij, maar jij, en ik
buiten onze gedachten is geen tijd
we stonden deze zomer op de rand van een dal
om ons heen alleen de wind.
Rutger Kopland
Uit: Over het verlangen naar een sigaret, uitg. Van Oorschot, 2001
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PART I  
General introduction

CHAPTER 1
Background and objectives of the thesis
Preeclampsia is a disease exclusive for pregnancy. At the beginning of the
twentieth century it was recognised for the ﬁrst time that hypertension
and proteinuria were symptoms preceding an eclamptic insult. Only ﬁf-
teen years ago endothelial dysfunction was recognised as the key mark of
preeclampsia, associated with systemic vasoconstriction and glomerular
endothelial damage. Reactive oxygen species are considered as possible
causative factors of endothelial dysfunction. The origin of preeclampsia
is founded in early pregnancy, at the time of trophoblast invasion and
subsequent placentation. Starting from 10 weeks of gestation, maternal
blood ﬂows through the intervillous space with a concomitant increased
oxygen tension, which creates considerable oxidative stress in the foeto-
placental unit. If at that time the maternal antioxidant capacity fails;
more extended oxidative stress may have adverse consequences for fur-
ther placentation. At some stage, a situation of chronic oxidative stress
will develop. During the second trimester of pregnancy reactive oxygen
species and other vasoactive factors will increasingly circulate in the
maternal circulation.
Back in 1995, a collaborative research on the role of the maternal detoxi-
ﬁcation systems in complicated and uncomplicated pregnancies, with
special attention for preeclampsia and the Haemolysis – Elevated Liver
enzymes – Low Platelets (hellp) syndrome, was started at the depart-
ments of Obstetrics and Gynaecology and Gastroenterology.
Initially, the thesis by Maarten F.C.M. Knapen (Nijmegen, 2000) was
focused on glutathione S-transferases – important detoxifying enzymes
– and their role in preeclampsia and hellp syndrome. Whole blood glu-
tathione concentrations seemed to be lower in patients with severe
preeclampsia in comparison with control pregnancies, indicating
decreased detoxiﬁcation and free radical scavenging capacity. The Glu-
tathione S-Transferase (gst) alpha and pi enzyme levels in blood plasma
turned out to correlate with hepatocellular damage and haemolysis. The
gener a l i n t roduction 13
next thesis, by Petra L.M. Zusterzeel (Nijmegen, 2002), was mainly direct-
ed to the genetic variation in detoxifying enzymes in relation to the devel-
opment of preeclampsia and hellp syndrome. Polymorphic variants of
the gst pi and epoxide hydrolase genes were found to be more frequent
in women with a history of preeclampsia. Remarkably, a polymorphism
in the gst pi was also found more frequently in partners and offspring
of preeclamptic women as compared to controls. Maarten T.M. Raijmak-
ers (Nijmegen, 2003) dedicated his thesis to the study of oxidative stress
in patients with preeclampsia and hellp syndrome by quantiﬁcation of
oxidised and total levels of glutathione and other thiols in whole blood
and plasma as well as in foetal and placental tissue. Plasma cysteine and
homocysteine levels were shown to be substantially higher in preeclamp-
tic pregnancies. Using the redox balance of free thiols vs. oxidised thiols,
he demonstrated the presence of oxidative stress during pregnancy,
being even more pronounced in preeclampsia and disappearing after
delivery. Increased homocysteine and antioxidant concentrations longer
than six months after their last pregnancy, in women with a history of
severe preeclampsia and/or hellp syndrome, might serve as predictor
for the development of cardiovascular problems later in life.
Oxidative stress and the failure of maternal antioxidative capacity, as
demonstrated in the previous theses, directed the concept from which
the studies in the current thesis were initiated. It was postulated, that
administration of the glutathione precursor N-acetylcysteine to women
with severe preeclampsia and/or hellp syndrome could stabilise the
disease process, leading to prolongation of pregnancy. Clinical trials on
the treatment of other diseases with lowered glutathione levels, such as
septic shock, adult respiratory distress syndrome (a r ds) or aceta-
minophen intoxication, had demonstrated an advantageous effect of N-
acetylcysteine administration. In chapter 2 this hypothesis is further
elaborated. 
The main objectives of this thesis are:
1. To assess the effects of N-acetylcysteine administration in:
a. healthy non-pregnant volunteers with and without oxidative stress
b. women with severe preeclampsia and/or hellp syndrome
2. To search for additional biochemical parameters of preeclampsia/
hellp syndrome – mainly related to maternal detoxiﬁcation – either
in blood or urine.
14 pa rt i
3. To study the balance between oxidants and antioxidants in normal
pregnancy and puerperium.
4. To search for additional risk factors for preeclampsia and to investi-
gate physical and mental health after severe preeclampsia and/or
hellp syndrome.
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CHAPTER 2
Deﬁcient detoxifying capacity in 
the pathophysiology of preeclampsia
Eva Maria Roes, Maarten T.M. Raijmakers, 
Petra L.M. Zusterzeel, Maarten F.C.M. Knapen,
Wilbert H.M. Peters, Eric A.P. Steegers
Medical Hypotheses 2000; 55:415-418
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a bst r act
An imbalance between oxidative stress and maternal detoxiﬁcation or
antioxidant capacity may explain the symptoms of preeclampsia and the
haemolysis – elevated liver enzymes – low platelets (hellp) syndrome.
Oxidative stress is known to induce damage of the endothelium, which is
one of the pathophysiological features of preeclampsia and the hellp
syndrome. Administration of N-acetylcysteine, an antioxidant itself and
a precursor of the endogenous antioxidant glutathione, might stabilise or
even partly recover the process of endothelial damage and may lead to
prolongation of pregnancy.
i n t roduct ion
Hypertensive disorders in pregnancy have an incidence of 6-20% and
belong to the four most common causes of maternal and perinatal mor-
tality in the world. When hypertension is accompanied by proteinuria
and is manifested after the 20th week it is called preeclampsia, compli-
cating 2-4% of all pregnancies [1]. The hellp syndrome (haemolysis –
elevated liver enzymes – low platelets) may be considered as a variant of
this disease with different symptoms [2]. 
Preeclampsia is a systemic disorder associated with the presence of
placental tissue [3]. However, the exact pathogenic mechanism is still
unclear and there is no speciﬁc diagnostic test or curative treatment
available as yet. Next to toxic metabolites of ovum or placenta many dif-
ferent factors, of renal, immunological, endocrinological, vascular or
nutritional origin have been, and some of them still are, thought to play a
role in the development of hypertension in pregnancy [1]. Nowadays,
endothelial cell dysfunction is considered to play a pivotal role in the
pathogenesis of preeclampsia and the hellp syndrome [4]. The under-
lying cause of this endothelial damage is still unknown and different
hypotheses have been investigated on this subject. Several studies
demonstrated an increase in blood levels of lipid peroxides in women
with preeclampsia [5-8] and a decrease in antioxidant capacity [7-11],
indicating oxidative stress. Oxidative stress may initiate endothelial
damage and in this way contribute to the pathophysiological features
seen in preeclampsia [12,13]
Our research group studied the decrease in antioxidant capacity in
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severe preeclamptic and hellp patients by measuring glutathione con-
centrations in whole blood and plasma. Compared to those with uncom-
plicated pregnancies, preeclamptic patients showed a signiﬁcant decrease
in glutathione concentrations in whole blood and plasma [11,14]. 
Oxidative stress and preeclampsia
Oxidative stress is a disturbance in the oxidant-antioxidant balance in
favour of the oxidants [15]. In normal pregnancies there is an increase in
free radical activity and in the concentration of lipid peroxides [6,16].
This may be explained either by increased cell turnover and cell damage,
or a decline in antioxidants or free radical scavenging mechanisms [5].
The antioxidant capacity gradually increases with duration of gestation
in uncomplicated pregnancies [17,18], whereas postpartum it declines to
pre-pregnancy levels within 24 hours [18].
A signiﬁcant decrease of iron binding capacity as well as several
important antioxidants, such as vitamin e , β-carotene, ascorbic acid, and
glutathione have been demonstrated in preeclamptic patients [9-11,19-
21]. However, other maternal antioxidants (ceruloplasmin, uric acid) are
increased in preeclampsia, possibly due to a compensatory response to
increased peroxide levels [19,22]. Several studies demonstrated a higher
increase in circulating lipid peroxides in preeclampsia compared with
uncomplicated pregnancies [5-8]. Lipid peroxidation may subsequently
lead to a depletion of glutathione and other protective compounds [23].
We earlier showed a signiﬁcant decrease of whole blood glutathione in
preeclamptic patients during illness [11]. In addition, we measured lower
plasma glutathione levels in women with preeclampsia compared with
women during uncomplicated pregnancies [14]. This disturbance in glu-
tathione levels might either be due to an excess of circulating oxidants or
a primary deﬁciency of glutathione or a less effective working of its relat-
ed enzymes. Unfortunately, no data are available on glutathione levels
before pregnancy or in early pregnancy. This makes it difﬁcult to distin-
guish whether lowered glutathione concentrations are primary or sec-
ondary to the cause of preeclampsia. The decrease in glutathione con-
centration could be an initial deﬁciency in antioxidant capacity or an
exhaustion of antioxidant sources as a result of the increased lipid perox-
idation [22]. The constant exposure to lipid peroxides makes the
endothelium very susceptible to oxidative or free radical mediated dam-
age. Oxidative stress may impair important functions of the endotheli-
um, such as the selective permeable barrier function and the vessel tone
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regulator function [12]. Preeclampsia is a multisystem disorder, which
could be well explained as a generalised endothelial cell dysfunction [4].
The following features of preeclampsia can therefore all be explained by
an increase in oxidative stress: imbalance of increased thromboxane and
decreased prostacyclin [7]; hypertension [12]; proteinuria and oedema
[12]; coagulation abnormalities, leukocyte activation [24]; and decreased
uteroplacental blood ﬂow [7,25]. Recently, Roberts and Hubel men-
tioned oxidative stress as the link between the reduced placental perfu-
sion and preeclampsia. According to them, this is based on the shared
risk factors of atherosclerosis and preeclampsia and the generally accept-
ed role of oxidative stress in atherosclerosis [26].
In the recent past, two trials with the antioxidants vitamin c and vita-
min e were performed as treatment of preeclampsia. Preeclamptic
patients who were treated during illness did not seem to beneﬁt from the
antioxidant therapy [27-28]. However, in a recently published placebo-
controlled trial, women at risk for preeclampsia started with vitamin c
and e supplementation as a preventive measure between the 16th and
22nd gestational week throughout pregnancy. The incidence of pre-
eclampsia was signiﬁcantly lower in the antioxidant group compared
with the placebo group [29].
Antioxidant therapy with N-acetylcysteine
Glutathione plays an important role in many detoxiﬁcation processes of
the human body and in addition it has several other important physiolog-
ical functions in storage and transport of cysteine, regulation of cellular
redox balance, leukotriene and prostaglandin metabolism, deoxyribonu-
cleotide synthesis, immune function, and cell proliferation [30]. Non-
hereditary glutathione depletion can be seen for example in oxidative
stress, acute alcohol- or acetaminophen intoxication [31]. 
Knowing the effect of N-acetylcysteine on glutathione depletion after
acetaminophen intoxication [32-34], we hypothesise that in patients with
severe preeclampsia and/or hellp syndrome, N-acetylcysteine supple-
mentation could also be beneﬁcial. It may result for these patients in sta-
bilisation of the disease process and prolongation of pregnancy.
Although nac was detectable in high levels in umbilical cord blood of
children from mothers treated for acetaminophen intoxication, no ter-
atogenic or toxic adverse effects have been mentioned [35,36]. After oral
intake, N-acetylcysteine is rapidly absorbed and deacetylated to cysteine,
which is a direct precursor of glutathione (see Figure 1) [37]. Apart from
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the indirect protection against oxygen radicals by forming glutathione,
N-acetylcysteine itself is able to scavenge oxygen radicals by nonenzy-
matic reduction [38]. 
N-acetylcysteine is used in several other diseases, either intravenous
or orally. Antioxidant replacement therapy with N-acetylcysteine com-
bined with ascorbic acid in patients with septic shock, caused signiﬁcant
hemodynamic improvement [39]. Patients with adult respiratory dis-
tress syndrome with lowered plasma and whole blood glutathione levels
were treated with N-acetylcysteine, which improved the glutathione con-
centrations, showed an increased oxygen delivery by improving the lung
compliance and resolution of pulmonary oedema [40]. N-acetylcysteine
was also used in clinical trials with asymptotic patients infected with the
gener a l i n t roduction 21
N-ACETYLCYSTEINE
GLUTAMATE CYSTEINE
 γ-GLUTAMYLCYSTEINE GLYCINE
GLUTATHIONE
γ-glutamylcysteine
synthetase
glutathione
synthetase
Simpliﬁed scheme of the formation of glutathione by amino acids cysteine, glutamine 
and glycine and the enzymes γ-glutamylcysteine synthetase and glutathione synthetase.
Figure 1 N-acetylcysteine and glutathione metabolism
Human Immunodeﬁciency Virus [41], in patients with the rheumatic dis-
ease progressive systemic sclerosis [42] and in patients with the neurode-
generative disease amyotrophic lateral sclerosis [43]. 
discussion
Severe preeclampsia and/or the hellp syndrome both are severe dis-
eases that seriously endanger the health of mother and child. The aetiol-
ogy of preeclampsia and the hellp syndrome is not clear, although
increased oxidative stress, as demonstrated by an excess of lipid perox-
ides and a reduction in antioxidant capacity, seems to play a role since the
clinical problems seen in preeclampsia and the hellp syndrome could
be very well explained by these phenomena. In accordance with these
ﬁndings, we recently demonstrated a signiﬁcant reduction of the antioxi-
dant glutathione level in whole blood and plasma of women with severe
preeclampsia and the hellp syndrome. We postulate that correction of
this imbalance with N-acetylcysteine may contribute to the stabilisation
of the disease process and therefore reduce maternal and foetal morbidi-
ty and mortality.
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PART I I
N-acetylcysteine as antioxidant

CHAPTER 3
Effects of oral N-acetylcysteine on plasma 
homocysteine and whole blood glutathione levels 
in healthy, non-pregnant females
Eva Maria Roes, Maarten T.M. Raijmakers, 
Wilbert H.M. Peters, Eric A.P. Steegers
Clin Chem Lab Medicine 2002; 40:496-498
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a bst r act
Oral N-acetylcysteine supplementation in nine young healthy females
induces a quick and highly signiﬁcant decrease in plasma homocysteine
levels and increases the whole blood concentrations of the antioxidant
glutathione. N-acetylcysteine impresses as an efﬁcient drug in lowering
homocysteine concentrations and might be beneﬁcial for individuals
with hyperhomocysteinemia at increased risk for cardiovascular disease.
i n t roduct ion
Hyperhomocysteinemia is an independent risk factor for vascular dis-
ease [1]. The exact mechanism by which homocysteine might cause 
vascular damage is still unrevealed. Homocysteine may promote athero-
genesis by facilitating oxidative stress [2]. Oxidative stress might be 
an important factor in the aetiology and pathophysiology of cardiovas-
cular disease by inducing arterial and endothelial damage [3,4]. Most
clinical trials concerning the reduction in homocysteine levels focus on
the effects of folic acid and vitamin b6 supplementation, which may 
have a positive preventive effect on (premature) vascular disease [1]. A
combination therapy, both lowering homocysteine levels as well as
oxidative stress, might be promising. N-acetylcysteine is an agent, which
may have both capacities. Several studies have already shown the poten-
tial homocysteine lowering effect of N-acetylcysteine [5-8]. In two
papers experiments with hyperlipidemic or haemodialysis patients were
performed [6,7] whereas in two other studies healthy controls were
investigated [5,8]. However, in the study of Ventura et al. [8] N-acetyl-
cysteine was given by intravenous infusion and the mean age of the sub-
jects at study was very high (73±15 years), whereas Hultberg et al. [5]
included only three subjects in their study. N-acetylcysteine may act 
as a precursor of glutathione by facilitating its biosynthesis via sup-
plementation of cysteine, and may be a direct scavenger of oxygen 
radicals by itself [9]. Glutathione is the most important component of
the pool of intracellular thiols, pivotal in detoxiﬁcation and protection
against oxidative stress [10]. N-acetylcysteine has been shown to be 
relatively well tolerated and has been applied in several treatment pro-
tocols [11,12].
In this study we evaluated the effects on plasma homocysteine and
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whole blood glutathione levels of short-term oral N-acetylcysteine sup-
plementation in nine young healthy females.
m at er i a l a nd methods
Nine young, healthy, non-pregnant women were recruited for this study.
The non-smoking volunteers varied in age from 23 to 31 years and in body
mass indexes from 18.4 to 28.4 kg/m2. Four volunteers used oral contra-
ceptives; one of them used the antidepressant Remeron (Mirtazapine).
The volunteers neither took drugs, nor multivitamins, nor alcoholic bev-
erages during the study period. All volunteers were asked to keep to their
usual diet; none of them was vegetarian. The local Ethics Committee
approved the study and written informed consent was obtained from
each volunteer. 
Throughout the ﬁrst study day, basal levels of plasma homocysteine
and whole blood glutathione were assessed three times by blood sam-
pling (8:00, 10:00, and 16:00 hrs); the eight o’clock sample was taken
after overnight fasting. On the second study day, three doses of 1800 mg
N-acetylcysteine effervescent tablets were given orally at 8:00, 16:00,
and 24:00 hrs respectively and a last dose of N-acetylcysteine was given
at 8:00 hr on the third study day. On the second and third day blood was
sampled at 10.00 hr. 
Blood samples were drawn in 4 ml ethylenediaminetetra-acetic acid
(edta) vacutainer tubes (Becton and Dickinson, Grenoble, France). For
the determination of plasma homocysteine and whole blood glutathione
concentrations samples were treated within one hour of sampling. Plas-
ma was obtained by centrifuging whole blood at 3,000 g for 10 minutes
and frozen until use at –30ºC. Whole blood samples were stored at
–80ºC until analysis, which took place within two weeks after sampling.
Total homocysteine concentrations in plasma, being the sum of reduced,
oxidised, and protein-bound homocysteine concentrations and free
(non-protein bound) glutathione concentrations in whole blood were
analysed hplc as described earlier [13].
Statistical analysis
Data are expressed as medians and ranges. Friedman analysis was used
to assess a possible variation in basal levels of homocysteine and glu-
tathione throughout the ﬁrst day. Wilcoxon signed rank test was per-
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formed to assess changes in concentration as result of N-acetylcysteine
supplementation. Statistical signiﬁcance was reached if p < 0.05. One
missing value on the ﬁrst day forced us to analyse glutathione levels of
eight subjects instead of nine.
r e sults
Before N-acetylcysteine supplementation, during the ﬁrst study day,
median basal plasma levels of homocysteine, sampled at 8:00, 10:00, and
16:00 hrs hours did not differ signiﬁcantly and were 11.7, 11.5, and 12.2
µmol/L, respectively. Throughout the ﬁrst study day no signiﬁcant dif-
ferences in basal whole blood glutathione concentrations were found
(806, 855, and 883 µmol/L, respectively). 
After N-acetylcysteine the median plasma homocysteine concentra-
tions signiﬁcantly decreased by 44% (p < 0.01) at the second day, reach-
ing a maximal decrease of 67% during the third day (p < 0.01). Median
whole blood glutathione levels were signiﬁcantly increased (p < 0.05) by
4.2% on the second day and remained stable on the third day (Table 1).
discussion
Besides a substantial reduction in total plasma homocysteine concentra-
tions this study showed a positive effect of N-acetylcysteine on the
antioxidant glutathione. Earlier studies had reported on the homocys-
teine lowering effect of N-acetylcysteine, in healthy controls [5,8] as well
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Table 1 Plasma homocysteine and whole blood glutathione levels before and after 
N-acetylcysteine
Day 1 (10.00hr) Day 2 (10.00hr) Day 3 (10.00hr)
before after after
Plasma homocysteine (µmol/L) 
n = 9 11.5 (5.8-22.4) 6.5 (4.3-10.0)** 3.8 (3.0-9.0)**
Whole blood glutathione (µmol/L)
n = 8 855 (742-1107) 891 (739-1231)* 891 (770-1118)
Data are presented as medians (min-max). ** p < 0.01 vs. day 1; * p < 0.05 vs. day 1
as in patients either requiring haemodialysis for chronic renal insufﬁ-
ciency [7] or with hyperlipoproteinemia [6]. However, only one study,
which in contrast to ours and the three other studies applied N-acetylcys-
teine intravenously, found such a large reduction of homocysteine con-
centrations in healthy controls as we did [8]. The intravenous dose of 50
mg/kg corresponded to the oral dose of 5600 mg we used. Hultberg et al.
demonstrated a dose related reduction of homocysteine concentrations
with a maximum reduction of 49% on an oral dose of 4000 mg [5]. Since
the amount of N-acetylcysteine given in our study was higher compared
to the three studies with oral N-acetylcysteine, this probably explains the
larger reduction we found. 
The decrease of plasma homocysteine concentration to 33% of the ini-
tial levels might be explained by displacement of homocysteine from its
protein binding sites, followed by renal clearance. This mechanism has
been reported by Hultberg et al. (1994) [5] and Ventura et al. (1999) [8]. 
The range of bmi varied in our study from 18.4 to 28.4 kg/m2 and is
probably of no importance for our results since an association between
bmi and increased homocysteine concentrations has been reported in
individuals with bmi ’s equal to or above 30.7 kg/m2 [14]. As a conse-
quence of the age and gender of our study population half of the group
used oral contraceptives and the other half had a menstrual cycle.
Reported associations between homocysteine concentrations, oral con-
traceptives, and menstrual cycle have been reported but are not consis-
tent [15-18], and when present, may be attributed to estradiol levels
[17,18]. N-acetylcysteine is not known to interact with estradiols. We
have not sampled the women in our study group at ﬁxed days during the
menstrual or oral contraceptive cycles. However, as they served as their
own controls during a short study period of three days, we do not expect
such association to have signiﬁcantly inﬂuenced our results, although
some effect cannot be ruled out completely.
Hyperhomocysteinemia is associated with cardiovascular disease by
formation of reactive oxygen species and by a direct effect on the
endothelial cell layer [4]. In general, antioxidants counteract oxidative
stress, although trials with vitamin e and c have not been found beneﬁ-
cial in improving cardiovascular disease endpoints [19]. 
In our study whole blood levels of the antioxidant glutathione
increased slightly though signiﬁcantly, after the ﬁrst day of N-acetylcys-
teine intake. Contradictory data on this subject have been reported in the
literature [20-25]. Under physiological circumstances glutathione exerts
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feedback inhibition on the enzyme γ-glutamylcysteine synthetase [26],
which might explain the moderate increase as found in our study, in
which only healthy subjects with normal glutathione levels were includ-
ed. Recently N-acetylcysteine was demonstrated to improve endotheli-
um-dependent vasodilatation in the coronary and peripheral circulation
in patients with and without atherosclerosis [27]. However, it has to be
realised that we are dealing with a small sample size and especially whole
blood glutathione concentrations should be further investigated in a
larger study design.
In conclusion, as a result of the rapid and large homocysteine lowering
effect and its antioxidant potential we recommend further studies on the
role of N-acetylcysteine in treatment and prevention of cardiovascular
disease.
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CHAPTER 4
N-acetylcysteine improves the disturbed thiol 
redox balance after methionine loading
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a bst r act
Methionine loading seems to be accompanied by increased oxidative
stress and damage. However, it is not known how this oxidative stress is
generated. We performed the present crossover study to further eluci-
date the effects of methionine loading on oxidative stress in the blood of
healthy volunteers, and to examine possible preventative effects of N-
acetylcysteine (nac) administration. A total of 18 healthy subjects were
given two oral methionine loads of 100 mg/kg bodyweight, 4 weeks
apart, one without nac (Met group), and one in combination with
administration of 2 x 900 mg nac (Met + nac group). Blood samples
were collected before and 2, 4, 8 and 24 h after methionine loading for
measurements of thiol levels, protein carbonyls, lipid peroxidation, cellu-
lar ﬁbronectin, and the ferric reducing ability in plasma (f r a p ; i.e.
antioxidant capacity). 
After methionine loading, whole blood levels of free and oxidised cys-
teine and homocysteine increased in both groups. Furthermore, the total
plasma levels of homocysteine were higher, whereas those of cysteine
were lower, after methionine loading in both groups. Lower levels of oxi-
dised homocysteine and a higher free-to-oxidised ratio were found in the
Met + nac group compared with the Met group. Although the antioxi-
dant capacity decreased after methionine loading, no major changes over
time were found for protein carbonyls or cellular ﬁbronectin in either
group. Our results suggest that methionine loading may initiate the gen-
eration of reactive oxygen species by the (auto)-oxidation of homocys-
teine. In addition, supplementation with nac seems to be able to partial-
ly prevent excessive increases in the levels of homocysteine in plasma and
oxidised homocysteine in whole blood, and might thereby contribute to
the prevention of oxidative stress.
i n t roduct ion
The essential amino acid methionine is of particular importance in
metabolism and protein synthesis. In the methylation of dna and pro-
teins, for example, methionine is converted to homocysteine, which
occupies a central position in both methionine and sulphur metabolism.
Homocysteine can be remethylated or it can be converted to cysteine in
the transsulphuration pathway [1-3]. Cysteine is the only thiol containing
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amino acid in proteins [1]. The metabolism of cysteine is complex; its
degradation proceeds by several pathways leading to the formation of
taurine or inorganic sulfate [4], and it is also the rate-limiting amino acid
in the synthesis of glutathione (gsh), providing the free –sh residue [1].
gsh is synthesised by two consecutive reactions catalysed by γ-glu-
tamylcysteine synthetase and glutathione synthetase, in which cysteine,
glutamate, and glycine are successively combined [5,6]. The capacity of a
particular cell to up-regulate gsh synthesis may be an adaptive cellular
response to an increase in oxidative stress, being deﬁned as a disturbance
in the (pro)oxidant-antioxidant balance in favour of the (pro)oxidant. 
Reactive oxygen species (ros) such as superoxide, hydrogen peroxide
and the perhydroxyl and hydroxyl radicals can be formed by several path-
ways, including metabolism of xenobiotics, physical factors, and as by-
products of physiological enzyme reactions. They can also be generated
by the (auto)-oxidation of thiols, especially cysteine and homocysteine
[6,7], which proceeds through oxidation of the free –sh group, resulting
in (mixed) disulphides. The thiol redox-scheme and the capacity for ros
formation are the keys to both the noxious properties and the cytopro-
tective functions of amino thiols [1]. 
Damage caused by ros is diverse, ranging from lipid peroxidation to
modiﬁcation of proteins or even damage to dna [7,8]. Glutathione and
the related enzyme glutathione peroxidase provide an import antioxi-
dant system against ros . gsh itself can serve as an antioxidant, in addi-
tion to its role as a co-factor in the reaction of glutathione peroxidases,
which scavenge ros upon oxidation of glutathione [6,9]. To maintain
the cellular redox-balance, the oxidised form of glutathione [6] is either
quickly reduced by glutathione reductase or excreted when excessive
amounts are formed [9]. Therefore, the ratio between the reduced form
(gsh) and the oxidised form of glutathione (gssg) may be an important
indicator of oxidative stress. N-acetylcysteine (nac) could be an impor-
tant metabolite, since its de-acetylation leads to increased availability of
cysteine, which may enhance glutathione synthesis [10]. Moreover, oral
administration of nac (600 mg, three times daily) has been shown to
increase antioxidant capacity [11]. 
During oral methionine loading, homocysteine concentrations are tran-
siently increased, which could result in increased oxidative stress
through the (auto)-oxidation of homocysteine, however the exact mecha-
nism by which homocysteine exerts this effect is not yet known. It has
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been shown that, during oral methionine loading, markers for oxidative
stress and endothelial dysfunction were elevated [12-14]. Furthermore,
pre-treatment with vitamin c could prevent the adverse effects of
increased homocysteine levels [15]. The present study was performed to
further elucidate the process of oxidative stress generation after methio-
nine loading, and to examine its possible prevention by nac , in an
attempt to provide more information about the occurrence of transient
oxidative stress during methionine loading, which can be used as a model
system for vascular oxidative stress in humans. 
m at er i a l a nd methods
Subjects and study design
The experimental protocol was approved by the Medical Ethical Review
Committee of the University Medical Center Nijmegen. We recruited 18
adult non-smoking subjects, comprising ten females and eight males,
who provided informed consent to the study. None of the subjects suf-
fered from diabetes mellitus or any vascular disease, was sensitive to
nac , or used vitamin supplements. All female subjects used contracep-
tive prophylactics. In this cross-over study subjects were randomly
assigned to one of the two treatment schedules (Figure 1): schedule A,
which consisted of methionine loading (100 mg/kg body weight) with
nac supplementation (900 mg) immediately and 4 h after methionine
loading on day 1 and methionine loading only on day 28 (n = 9); or to
treatment schedule B, which was the reversed protocol (n = 9). Blood
samples were drawn from the subjects before methionine loading and 2,
4, 8, and 24 h after loading in order to measure thiol concentrations, con-
tent of protein carbonyls, antioxidant capacity, cellular ﬁbronectin
(cf n), and thiobarbituric acid reactive substances (t ba r s). Samples
collected after methionine loading alone comprised the Met group,
whereas samples collected after methionine loading with nac supple-
mentation comprised the Met + nac group. To diminish hormonal
inﬂuences, a time interval of 4 weeks was allowed to elapse between the
two experiments, ensuring that the female participants were at the same
time period of their menstrual cycle. 
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Assay of thiol levels
Blood samples were collected into sterile tubes (Sherwood Medical, Bal-
lymore; Northern Ireland) containing edta , and were directly pro-
cessed on ice for the assessment of levels of free and oxidised thiol, as
described previously [9]. The remaining blood was centrifuged in a
Biofuge centrifuge at 10 000 g for 10 min, and plasma was stored in two
aliquots at –80ºC until analysis.
Total cysteine, homocysteine, cysteinylglycine and glutathione con-
centrations in plasma and free and oxidised levels of these thiols in whole
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Schedule A: 
Day 1: NAC supplementation (900 mg) immediately and 4 hours after methionine 
loading (100 mg/kg)
Day 28: methionine load (100 mg/kg)
Schedule B: 
Day 1: methionine loading (100 mg/kg)
Day 28: NAC supplementation (900 mg) immediately and 4 hours after methionine 
loading (100 mg/kg)
Treatment schedule A or B were randomly assigned to each subject.
At each day blood was sampled before and 2, 4, 8 and 24 hours after methionine 
loading.
Figure 1 Treatment schedules
blood were determined by high performance liquid chromatography
exactly as described previously [9,16]. From the free and oxidised thiol
levels the free-to-oxidised ratio of each thiol was calculated. A lower
free-to-oxidised ratio is indicative for a larger oxidised fraction in the
total thiol pool. Thiol levels were expressed in µmol/L, whereas the
dimension of the free-to-oxidised ratio is 1. 
Assays of oxidative stress parameters
The ferric reducing ability of plasma (f r a p) assay, as described by Ben-
zie and Strain [17] was used to assess the antioxidant capacity of the plas-
ma. This assay is based on the ability of plasma to reduce Fe(iii) to
Fe(ii). Antioxidant capacity was expressed in nmol Fe2+ equivalents/ml. 
Oxidative protein damage was assessed by the measurement of the
amount of protein carbonyls in plasma using an el isa as described by
Buss et al. [18]. Carbonyl levels were expressed in pmol/mg of protein. 
As a measure of endothelial damage, the amount of cf n in plasma was
determined using the el isa method adapted from Schultze et al. [19].
Due to instability of the puriﬁed cf n used in the calibration curve, cf n
was expressed as absorbance units, which can be justiﬁed by the meas-
urement of all samples from a subject on the same microtiter plate.
As a measure of lipid peroxidation, the amount of t ba r s was mea-
sured using the assay described by Conti et al. [20]. In short, a standard
curve was prepared using a stock solution of 1,1,3,4,-tetrametho-
xypropane. A 50 µL aliquot of sample or standard was added in duplicate
to a glass-tube containing 1 ml of 2-thiobarbituric acid solution. Tubes
were incubated for 1 h at 96 oC. After incubation, samples were cooled
on ice and t ba r s were extracted with 4 ml of butanol. The ﬂuorescence
(λex = 515nm and λem = 553nm) of the supernatant was measured on a
spectroﬂuorophotometer (r f-5000, Shimadzu, Kyoto, Japan). t ba r s
levels were expressed as nmol malondialdehyde/ml. 
Statistical analysis
Since data measured were normally distributed with some outliners on
either side, we used the Wilcoxon Signed Rank-test for statistical evalua-
tion. Differences were calculated between starting values and those after
methionine loading within a group, and between Met + nac group and
Met group values at any time point. To correct for multiple testing, the
Bonferroni correction was used. Therefore signiﬁcance was reached at 
p < 0.03.
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r e sults
Thiol levels after methionine loading
After methionine loading, both the Met as well as the Met + nac group
showed signiﬁcantly increased median plasma homocysteine levels at
each time point (p < 0.001), that reached a maximum after 8 h (Figure 2).
Plasma homocysteine increased signiﬁcantly more rapidly in the Met as
compared to the Met + nac group, which resulted in a 4-fold higher
median level 8 h after methionine loading in the Met group and a 3-fold
increase in the Met + nac group (p < 0.002). Both groups also displayed
signiﬁcant increases in the levels of free and oxidised homocysteine, with
a maximum after 4 h (p < 0.001) and 8 h (p < 0.001) respectively. At these
time points, the free homocysteine level in the Met + nac group tended
to be lower (p = 0.08), whereas the level of oxidised homocysteine was
signiﬁcantly lower (p < 0.01) compared with the Met group (p < 0.01).
Only in the Met group the median free/oxidised ratio of homocysteine
was signiﬁcantly decreased, reaching a minimum after 4 h (p < 0.03),
whereas no signiﬁcant decrease was found for the Met + nac group.
This resulted in a tendency to a higher ratio in the Met + nac group as
compared with the Met group after 8 h (p < 0.05). At 24 h after methion-
ine loading, whole blood free and oxidised homocysteine levels as well as
the free/oxidised ratio, had not yet recovered to the baseline values.
Median total cysteine concentrations in plasma decreased after
methionine loading in both the Met group and the Met + nac group,
reaching a minimum after 8 h (p < 0.001 and p < 0.01, respectively; 
Figure 2). At this time point, total cysteine levels tended to be lower in the
Met + nac group than in the Met group; however, signiﬁcance was not
reached (p = 0.1). In both groups, the median levels of free and oxidised
cysteine in whole blood were signiﬁcantly increased, reaching a peak 2 h
after methionine loading (p < 0.001). Levels of free and oxidised cysteine
in the Met + nac group were higher than those in the Met group after 2 h 
(p < 0.001). The free/oxidised ratio was signiﬁcantly higher compared
with the baseline value in both the Met and the Met + nac group 2 h after
methionine loading, and it was also higher in the Met + nac group in
comparison with the Met group (p < 0.01). All values recovered to base-
line levels in both groups, except for plasma and free levels in the Met
group, which remained depressed.
Plasma cysteinylglycine levels decreased signiﬁcantly after methion-
ine loading (Figure 3). 
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Results are expressed as medians. 
Met group (black circles; dotted lines); Met + NAC group (black triangles; 
continued lines)
† p < 0.001; ‡ p < 0.01; * p < 0.03 baseline value vs. indicated time point
A p < 0.002; B p < 0.001; C p < 0.01 Met vs. Met + NAC group
Figure 2 Homocysteine and cysteine concentrations after methionine loading 
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Results are expressed as medians. 
Met group (black circles; dotted lines); Met + NAC group (black triangles; 
continued lines)
† p < 0.001; ‡ p < 0.01; * p < 0.03 starting value vs. indicated time point
A p < 0.03; B p < 0.002 Met vs. Met + NAC-group
Figure 3 Cysteinylglycine and glutathione concentrations after methionine load
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Cysteinylglycine decreased more rapidly in the Met + nac group,
reaching a minimum after 4 h, which resulted in a signiﬁcantly lower
median level (p < 0.03) compared with that in the Met group, which
reached a minimum after 8 h. At that time a signiﬁcantly lower plasma
level was observed in the Met + nac group as compared with the corre-
sponding Met group value (p < 0.002). Although, the levels of free and
oxidised cysteinylglycine in whole blood showed a similar pattern to the
corresponding plasma values, no signiﬁcant differences between the
Met and Met + nac group were found after methionine loading. Also,
no signiﬁcant differences were found for the free/oxidised ratio of cys-
teinylglycine. All values recovered to the levels observed before methion-
ine loading, except for the plasma level in the Met group, which remained
lower (p < 0.03).
Plasma glutathione levels decreased signiﬁcantly in both groups after
methionine loading, and the lowest levels were found after 8 h (p < 0.001;
Figure 3). Glutathione levels decreased more rapidly in the Met + nac
group, than in the Met group, resulting in lower levels 2, 4 and 8 h after
methionine loading (p < 0.002, p < 0.03 and p < 0.03 respectively).
Although free glutathione levels seemed to ﬂuctuate after methionine
loading in both groups, no signiﬁcant differences were found. Similar
results were found for levels of oxidised glutathione and the free/oxi-
dised ratio. 
Oxidative stress parameters after methionine loading
The antioxidant capacity, as measured by the f r a p assay, decreased
slowly in both groups after methionine loading, reaching a minimum
after 8 h (p < 0.03; Table 1). The antioxidant capacity seemed to decrease
more rapidly in the Met + nac group. In both groups the f r a p was nor-
malised 24 h after methionine loading.
After methionine loading, no differences were seen in either group in
the levels of oxidative protein damage, as measured by plasma carbonyl
levels (Table 1). A lower level of oxidative lipid damage, as measured by
the t ba r s assay, was seen in the Met group after 2 h (p < 0.001). No sig-
niﬁcant differences were found between the groups for either parameter
of oxidative damage parameters. 
No signiﬁcant effects of methionine loading on the concentrations of
cellular ﬁbronectin were found in either group. A comparison between
the two groups did not reveal any signiﬁcant differences (Table 1).
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discussion
Evidence is accumulating that increased homocysteine levels, induced by
methionine loading, are accompanied by oxidative stress and endothelial
dysfunction [13,14,21]. Further studies have shown that the adverse
effects of methionine loading can be prevented, at least partially, by pre-
treatment with antioxidants such as vitamin c [15]. Our present study
supports the hypothesis that the increased homocysteine concentrations
that occur after methionine loading might have a pro-oxidant effect,
since a decreased antioxidant capacity was noted. In addition, nac
administration after methionine loading resulted in a lower plasma con-
centration of homocysteine as well as in a decreased concentration of
oxidised homocysteine in whole blood, indicating a beneﬁcial effect of
nac via regulation of the thiol redox balance. Therefore our results may
stimulate research on the use of nac to maintain vascular redox balance
in disorders in which oxidative stress plays a role. 
Thiol status after methionine loading
Reduced, oxidised and protein-bound forms of thiols interact via redox
and disulphide exchange reactions, and comprise an important compo-
nent of the total redox buffer system [9,22]. Our present results demon-
strate that, in addition to plasma levels, whole blood levels of free and
oxidised homocysteine were increased after methionine loading. The
higher oxidised levels may point to increased (auto)-oxidation, resulting
in superoxide radical and hydrogen peroxide formation that could either
induce or initiate oxidative stress. Since the free/oxidised ratio for homo-
cysteine was signiﬁcantly lowered only in the Met group, nac seemed to
prevent excessive oxidation of homocysteine, thereby probably amelio-
rating oxidative stress. A possible mechanism could be that, since over
50% of homocysteine in plasma is protein-bound, nac supplementation
may lead to displacement of protein-bound homocysteine by cysteine, as
seen by the elevation in both free and oxidised levels of cysteine. This
could lead to the formation of (mixed) disulphides, which have a high
renal clearance [23,24].
The results with regard to whole blood and plasma levels of cysteine
after methionine loading were ambiguous. Levels of both free and oxi-
dised cysteine in whole blood rose after methionine loading, with higher
levels in the Met + nac group after two hours, whereas levels in plasma
(where approximately 60% of cysteine is protein-bound [25]) were sig-
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niﬁcantly decreased. The elevation of free and oxidised levels can easily
be explained by the transsulphuration of methionine and deacetylation
of nac [10]. Since plasma cysteine is the main source of cysteine for
many cells and organs, and is essential for the synthesis of glutathione [1],
the lower plasma levels of cysteine may point to an increased utilisation
of plasma cysteine for the synthesis of glutathione as a reaction to the
formation of ros induced by the (auto)-oxidation of homocysteine. 
Since reduced glutathione is a well-known scavenger of ros and per-
oxides, we hypothesised that the free/oxidised ratio and the levels of glu-
tathione would decrease after methionine loading, and that nac might
prevent the loss of glutathione or boost its synthesis due to the increased
availability of cysteine [10]. However, we could not demonstrate any sig-
niﬁcant differences in the levels of free and oxidised glutathione, or in the
free/oxidised glutathione ratio, between the groups. This is most likely
explained by the rapid reduction of the oxidised form by glutathione
reductase. Cellular excretion of oxidised glutathione could lead to cellu-
lar loss of glutathione. To maintain cellular glutathione homeostasis, the
intracellular synthesis of glutathione would be increased, leading to
depletion of plasma cysteine, which was demonstrated in the present
study. In this way nac could prevent excessive depletion of plasma cys-
teine; however, the opposite was found. This might indicate that the
induced oxidative pressure after methionine loading did not exhaust the
intracellular glutathione or cysteine pool. In the absence of an increased
demand for glutathione or cysteine, it is unlikely that nac would be used
in the synthesis of glutathione [10]. The lower plasma glutathione levels
in the Met + nac group as compared with the Met group are more likely
to indicate the occurrence of increased renal clearance, which seems to
be facilitated by nac , as discussed above for homocysteine and cysteine.
Oxidative stress parameters after methionine loading
In line with the ﬁndings of Ventura et al. [12], antioxidant capacity
decreased in both the Met and the Met + nac group after methionine
loading, which might be indicative of higher levels of ros . These ﬁnd-
ings therefore support the hypothesis that increased homocysteine con-
centrations might have a pro-oxidant effect [26,27]. Although the f r a p
assay does not measure sh-containing antioxidants, we expected an
indirect inﬂuence on antioxidant capacity; since nac has antioxidant
properties and is also able to enhance glutathione synthesis, it could pre-
vent the use of other antioxidants [28]. The antioxidant capacity in both
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groups decreased after methionine loading, which might be due to gen-
eration of ros by (auto)-oxidation of homocysteine. Surprisingly the
antioxidant capacity decreased more rapidly in the Met + nac group. As
described above, ros such as superoxide and hydrogen peroxide are
reduced mainly by oxidation of the free –sh moiety of glutathione and
other thiols, whereas nac is a precursor of glutathione and provides free
–sh groups. Hypothetically, the increase in free –sh residues due to
nac administration may make other antioxidants redundant, resulting
in a lower antioxidant level as measured by the f r a p assay. 
Direct oxidative attack of amino acid residues, as well as modiﬁcation of
side chains by peroxidation products, will result in the generation of pro-
tein carbonyls. Therefore carbonyls may serve as a general marker of
oxidative stress. In contrast with the report of Ventura et al. [12], who
found 2.5 times higher levels of carbonyl groups after methionine load-
ing using the same amounts of methionine, the median levels of protein
carbonyls in our present study were not changed signiﬁcantly in either
group after methionine loading. This might indicate that proteins were
not exposed to oxidative stress. A possible explanation is that, in our sub-
jects the oxidoreductase capacity (which is able to regenerate oxidatively
damaged proteins) was not exceeded [29], or that the antioxidant capaci-
ty was sufﬁcient to cope with the increased superoxide production gen-
erated during (auto)-oxidation of homocysteine. 
t ba r s values also showed a considerable variation after methionine
loading. In the Met group, lower levels were found after 2 h and 4 h com-
pared with the baseline value. However, the baseline level was relatively
high compared with the other values, which might explain the difference
found. No signiﬁcant differences in t ba r s levels were found between
the two groups. This was in line with the ﬁndings of Chao et al. [21], and
provides another argument against the generation of lipid peroxides as a
result of methionine loading. Results in the literature with regard to lipid
peroxidation after methionine loading are conﬂicting: one study found
increased lipid peroxidation [12], whereas this is not demonstrated by
others [21]. However, different markers of lipid peroxidation, i.e.
phospatidylcholine hydroperoxide and malondialdehyde [21] or conju-
gated dienes [12], were studied, which complicates a comparison.
Total circulating ﬁbronectin is associated with tissue repair. Since the
cf n isoform is localised primarily to the endothelium, it is considered to
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be a speciﬁc marker of endothelial injury [30]. Recently Powers et al. [14]
showed that homocysteine-induced oxidative stress might result in
endothelial dysfunction, as measured by plasma cf n levels. Although
these workers were unable to demonstrate that the endothelial dysfunc-
tion was a direct effect of elevated homocysteine levels, in a previous
study they showed a positive correlation between cf n and homocysteine
levels in plasma of women with preeclampsia [31]. Therefore we expect-
ed to ﬁnd an increase of cf n levels after methionine loading. However,
we could not conﬁrm the results of Powers et al. [31], since no signiﬁcant
differences were found in cf n concentration between the Met and the
Met + nac group. Therefore we did not demonstrate clear evidence that
an increase in homocysteine is directly linked to endothelial dysfunction,
as measured by cf n . 
Conclusions
In summary, methionine loading generated acute increases in the plasma
levels of homocysteine, as well as in the whole blood levels of free and
oxidised homocysteine. The signiﬁcant shift to the oxidised form of
homocysteine in the Met group might indicate the induction of oxidative
stress by increased superoxide generation. Also, the decreased antioxi-
dant capacity in both groups points to an increased formation of ros .
However, no signiﬁcant changes were found in the levels of products of
oxidative damage (protein carbonyls and t ba r s), or of the endothelium
dysfunction marker cf n , which might indicate that ros generated by
homocysteine may be entirely counterbalanced by antioxidants, result-
ing in the lower antioxidant capacity as found in this study. 
When nac was administered after methionine loading, the increases
in total homocysteine levels in plasma, as well as in the levels of free and
oxidised homocysteine in whole blood, were smaller than in the absence
of nac . Additionally, nac prevented oxidative stress, since there was no
signiﬁcant shift to the oxidised form of homocysteine with nac . 
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CHAPTER 5
N-acetylcysteine restores nitric oxide-mediated 
effects in the foetoplacental circulation 
of preeclamptic patients
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Background: Preeclampsia is associated with an imbalance between oxi-
dants and anti-oxidants resulting in reduced effects of the endothelium-
derived, relaxing-factor nitric oxide (no). Antioxidants, like N-acetyl-
cysteine (nac) remove reactive oxygen species, resulting in an improve-
ment of endothelial function. We aimed to investigate the effect of nac
on the no-pathway in the human foetoplacental circulation in pre-
eclampsia and control pregnancies. 
Material and Methods: The no-pathway was investigated by use of the
no-synthase inhibitor l -na me in an ex vivo cotyledon perfusion
model. 
Results At baseline, foetoplacental arterial pressure was comparable in
preeclampsia (n = 8) and control pregnancies (n = 8), and increased dose-
dependently after l -na me . The maximal l -na me-induced rise in foe-
toplacental arterial pressure was attenuated in preeclampsia vs. controls
(20.8 ± 2.0 mmHg vs. 36.7 ± 3.5 mmHg, p < 0.05). Addition of nac
increased the l -na me-induced rise in foetoplacental arterial pressure
to 36.4 ± 3.4 mmHg in preeclampsia (p < 0.05) and to 49.2 ± 2.6 mmHg
in controls (p < 0.05). 
Conclusion: Preeclampsia is associated with a dysfunction of the no-
pathway. N-acetylcysteine increases no-mediated effects in the foeto-
placental circulation in preeclamptic placentas as well as in healthy con-
trol placentas.
i n t roduct ion
Preeclampsia, a major complication of pregnancy, is associated with
endothelial dysfunction in the maternal and foetal circulation. In this dis-
ease, there is probably an increase in oxidants, such as reactive oxygen
species (ros) [1,2] and increased lipid peroxidation, as well as a decrease
in several antioxidants, such as α-tocopherol, β-carotene, ascorbic acid
and glutathione [3-5]. This disbalance may be responsible for the
observed endothelial dysfunction. Recently, vitamin c and e supplemen-
tation to women with an increased risk for preeclampsia was shown ben-
eﬁcial in prevention of this disorder [6].
An optimal placental vascular function is important for normal foetal
growth and wellbeing. Because the placenta lacks autonomic innerva-
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tion, locally produced mediators like the endothelium derived relaxing
factor nitric oxide (no) play an important role in the maintenance of
normal foetal placental blood ﬂow. no is synthesised by the enzyme no-
synthase (nos) in the endothelial cell, after stimulation by various fac-
tors (e.g., shear stress, serotonin, bradykinin). no diffuses to the vascu-
lar smooth muscle cell, where it activates the guanylate cyclase to
increase intracellular cgmp . This is followed by a closure of calcium
channels, a fall in intracellular calcium, and a subsequent relaxation of
the vessel wall. 
no is inactivated by ros resulting in the formation of peroxynitrite.
As such, an increase in ros in patients with preeclampsia might induce
dysfunction of the no-pathway in the foetoplacental arterial circulation.
In the current study we tried to investigate whether the antioxidant sub-
stance N-acetylcysteine (nac) is able to affect the no-pathway. nac is a
pharmacological substance, which is rapidly deacetylated into cysteine, a
direct precursor of glutathione. Whole blood glutathione concentrations
were shown to increase after nac administration to healthy, non-preg-
nant women [7]. Short-term, intra-arterially administered glutathione
improves endothelial function in the femoral circulation in patients with
arteriosclerosis [8]. Apart from the indirect protection against ros ,
being a precursor of glutathione, N-acetylcysteine itself is able to scav-
enge ros by nonenzymatic reductions [9].
Along this line of reasoning, we hypothesise that administration of nac
in the foetoplacental vascular bed might improve endothelial function,
especially that mediated by the no-pathway, in the placenta from
women with preeclampsia. To address this, we investigated the effect on
the no-pathway of acute administration of nac in the foetoplacental
vascular bed of placentas from women with mild preeclampsia as com-
pared to placentas from healthy pregnant control women. 
m at er i a l a nd methods
The experimental protocol was approved by the Medical Ethical Review
Committee, and each subject gave written informed consent.
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Study population
Pregnant women with mild preeclampsia were eligible to participate in
this study. Mild preeclampsia was deﬁned as a diastolic blood pressure
90 mmHg or higher measured at least 2 times with an interval of 4 hours,
in combination with proteinuria deﬁned as a protein/creatinine ratio
greater than 30 mg/mmol, according to the criteria of the International
Society for the Study of Hypertension in Pregnancy. Controls were
healthy women after uncomplicated, normotensive pregnancy. Exclusion
criteria were diabetes mellitus, multiple pregnancy, premature birth (< 37
weeksgestation),foetalgrowthretardation,retainedplacenta,andhellp
syndrome (haemolysis – elevated liver enzymes – low platelets). 
Placenta perfusion 
Placentas were obtained immediately after delivery. Within 15 minutes, 2
suitable cotyledons were selected for ex-vivo dual perfusion [10]. Perfu-
sion of both these cotyledons was performed simultaneously on 2 identi-
cal perfusion devices. The third or fourth order artery and vein were can-
nulated just before passage through the chorionic plate. Foetal inﬂow
was gradually increased to 6 ml/min, at which the baseline foetoplacen-
tal arterial pressure equilibrates between 15 to 40 mmHg. The cotyledon
was placed in a chamber with the maternal side facing upward. Maternal
inﬂow was kept constant at 12 ml/min. The maternal outﬂow was collect-
ed and returned into the maternal reservoir. A recirculating system was
used for both foetal and maternal sides. The perfusion ﬂuid (Krebs-
Henseleit buffer without albumin, pH 7.4: 150 ml for both sides) was
37ºC, and was oxygenated with 95% O2 and 5% CO2. 
Because the foetal arterial inﬂow was kept constant, the foetoplacen-
tal arterial pressure was considered to be a reﬂection of the foetoplacen-
tal arterial resistance. After 30 minutes of equilibration, when the rem-
nant blood had been washed out and the foetoplacental arterial pressure
was stabilised, the experiment was started. The no-mediated compo-
nent of baseline vascular tone in the foetal circulation was investigated
by addition of the speciﬁc no-synthase blocker l -na me over a concen-
tration range from 1 to 500 µmol/L in a cumulative way. l -na me was
added to the foetal circulation in 6 dosages. After each addition, stabili-
sation of the foetoplacental arterial pressure was awaited, which took
maximally 30 min, before the next dose was added. Fifteen minutes
before the ﬁrst dose of l -na me , nac was dissolved in the Krebbs-
Henseleit buffer (k h buffer) in one of the perfusion devices, to a ﬁnal
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circulating concentration of 50 µmol/L, whereas k h buffer with no
additives (placebo) was added in the other device.
Material
A k h buffer containing 121 mM NaCl, 4 mM KCl, 0.95 mM KH2PO4, 1.2
mM MgSO4-7H2O, 22 mM NaHCO3, 11.1 mM glucose-H2O, and 2 mM
CaCl2 was used as perfusion ﬂuid. Heparin was used in a concentration
that does not affect vascular tone (2500 ie/l) [11]. l -na me and N-
acetylcysteine were obtained from Sigma (St. Louis, usa). The nac
concentration in the perfusion ﬂuid (50 µmol/L) was based on the plas-
ma levels in a clinical study of healthy volunteers who received 3 x 1800
mg N-acetylcysteine daily. The median plasma level of N-acetylcysteine
after three gifts of nac was 48 µmol/L (range 37-71 µmol/L).
Statistical analysis 
Comparison of the clinical characteristics was performed by a Mann-
Whitney-U test. Data on perfusion pressures were analysed using Prism
3.0 (Graphpad Software) by ﬁtting individual concentration-response
curves for each experiment. For each experiment, the curve characteris-
tics were calculated. These were baseline foetoplacental arterial pres-
sure, maximum l -na me-induced foetoplacental arterial pressure, net
l -na me-induced increase in foetoplacental arterial pressure and
logEC50. For differences between groups these curve characteristics
were compared by two-way analysis of variance (a nova), with group
(control or preeclampsia) and medication (vehicle or nac) as indepen-
dent factors. Differences were considered to be statistically signiﬁcant
when zero was not included in the 95% conﬁdence interval.
r e sults
Apart from the expected differences in diastolic blood pressure and pro-
teinuria, there were no statistically signiﬁcant differences in clinical
characteristics between the 2 groups (Table 1). In the control group, one
patient used vitamin b12; in the preeclampsia group, one patient used the
low molecular weight heparin nadroparine (thrombosis profylaxis) and
one used methyldopa.
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Effects of l -na m e in isolated cotyledons
Two cotyledons of 8 placentas from women with uncomplicated preg-
nancies and of 8 from women with mild preeclampsia were perfused.
The concentration-response curves for l -na me are presented in Figure
1. 
Baseline foetoplacental arterial pressure was comparable in all groups
(Table 2). l -na me elicited a concentration-dependent rise in foetopla-
cental arterial pressure. Maximum l -na me-induced foetoplacental
arterial pressure in the placentas from healthy controls was 60.5 ± 3.1
mmHg (mean ± sem). The absolute l -na me-induced rise in foetopla-
cental arterial pressure was 36.7 ± 3.5 mmHg. 
In preeclampsia, the maximum l -na me-induced foetoplacental arte-
rial pressure was 45.6 ± 4.5 mmHg. The absolute l -na me-induced
increase in foetoplacental arterial pressure was 20.8 ± 2.0 mmHg (p <
0.05 as compared to controls). 
There was no difference in logEC50 values between the groups.
Effects of nac
The addition of nac did not signiﬁcantly affect baseline foetoplacental
arterial pressure. After the addition of nac , the maximum l -na me-
induced foetoplacental arterial pressure was 72.2 ± 5.6 mmHg in the pla-
centas of healthy controls and 59.4 ± 6.7 mmHg in preeclampsia. The
absolute l -na me-induced increase in foetoplacental arterial pressure
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Table 1 Clinical characteristics 
Control Preeclampsia
n = 8 n = 8
Maternal age (yrs) 31.7 (28.2-38.0) 27.9 (26.3-41.3)
Parity (n) 1 (0-3) 0 (0-3)
Gestational age (wks) 39.5 (38.0-41.1) 39.1 (37.6-39.6)
Birth weight (g) 3757 (2610-3990) 3175 (2745-4035)
Placental weight (g) 595 (410-755) 582 (390-790)
Body Mass Index (kg/m2) 21.7 (18.9-28.8) 27.5 (19.4-43.6)
Diastolic blood pressure (mmHg) 77.5 (75.0-85.0) 98.0 (90.0-110.0) *
Caesarean section (n) 1 1
Smokers (number) 1 0
Protein/creatinine ratio (mg/mmol) n.m. 115 (59-338) *
Data are presented as medians (min-max) or numbers; * p < 0.05
n.m. = not measured (dipstick negative in all women)
was 49.2 ± 2.6 mmHg in controls and 36.4 ± 3.4 mmHg in preeclampsia.
This nac-effect reached statistical signiﬁcance in healthy controls (p <
0.05) as well as in the preeclampsia group (p < 0.05).
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Figure 1
L-NAME-induced rise in foetoplacental arterial pressure in healthy controls without
(open squares) and with (solid squares) addition of N-acetylcysteine, and women with
preeclampsia without (open circles) and with (solid circles) N-acetylcysteine. The hori-
zontal dotted line shows, that after NAC the net foetoplacental arterial pressure in the
placenta of women with preeclampsia is comparable to that in the placenta of healthy
controls without NAC.
Table 2 Characteristics of the ﬁtted concentration-response curves of the NO-synthase
inhibitor L-NAME 
Foetoplacental Arterial Control Control Preeclampsia Preeclampsia
Pressure (mmHg) + NAC + NAC
n = 8 n = 8 n = 8 n = 8
Before vehicle/NAC 23.9 ± 2.4 23.1 ± 3.2 24.6 ± 2.5 22.9 ± 2.4
After vehicle/NAC 23.7 ± 2.8 (3.2) 23.0 ± 3.6 24.8 ± 2.7 23.0 ± 2.5
At maximal response 
to L-NAME 60.5 ± 3.1 72.2 ± 5.6 * 45.6 ± 4.5 ¶ 59.4 ± 6.7 *
Log EC 50 (logmol/L) -4.7 ± 0.1 -4.9 ± 0.1 -4.5 ± 0.1 -4.5 ± 0.1
Data are presented as mean ± SEM. 
* p < 0.05 vs. addition of vehicle, ¶ p < 0.01 vs. controls with NAC
discussion
The two main observations of our study are that 1) the contribution of
no to baseline vascular tone is impaired in the foetoplacental circulation
of preeclamptic patients, and 2) the no-mediated effects can be amelio-
rated to normal levels by addition of the anti-oxidant N-acetylcysteine. 
Our conclusions on the no-pathway are based on the quantitive
assessment of the vasoconstrictor response to the no-synthase inhibitor
l -na me . This is an indirect measure of the functional vasodilator effect
of no in this speciﬁc vascular bed. An attenuated vasoconstrictor
response to l -na me can be interpreted as a reduced effect of functional
no in the circulation. In a previous study, we already reported on an
impaired effect of no in the placenta of preeclamptic patients [12]. This
reduced no-pathway in the foetoplacental vascular bed in preeclampsia
is expected to be associated with an increase in baseline foetoplacental
arterial pressure. In our study, however, we did not observe a difference
in baseline foetoplacental arterial pressure between patients with
preeclampsia and the healthy controls. Nevertheless, we did observe a
signiﬁcantly decreased response to l -na me in preeclampsia, which
proves that the no-pathway is impaired in this vascular bed in these
patients. Other vasodilator mechanisms might be compensating for the
dysfunction of the no-pathway in preeclampsia. Candidates for these
compensatory mechanisms are an increased release of prostacyclin or
endothelium-derived hyperpolarizing factor on the one hand, and a
reduced release of endothelin or vasoconstrictor prostanoids on the
other hand. This kind of compensation has also been observed in other
vascular beds with dysfunction of the no-pathway [13,14]. Additional
experiments with the combined blockade of the aforementioned mecha-
nisms are necessary to be sure whether this line of reasoning is correct. 
Other investigators have shown a decrease of no-products in the
urine of preeclamptic patients [15]. Of course, urinary no-products
reﬂect tubular or renal no-production and/or secretion rather than indi-
cating levels of no in the foetoplacental circulation. Interestingly, two
independent research groups reported an increase rather than a reduc-
tion in no-products in uteroplacental and foetoplacental plasma or
serum of preeclamptic women as compared to control pregnancies
[16,17]. This increase in no-products has been attributed to a compen-
satory mechanism to offset the impaired placental perfusion, as fre-
quently observed in preeclampsia [17]. The observations in our study can
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still be compatible with the reports on increased levels of no-products in
the preeclamptic placenta, because we quantiﬁed the vascular effects of
no , and not the concentrations of no itself, whereas functional effects
of no can be impaired because of a lower responsiveness of the tissue, or
due to mechanisms that inactivate no , like oxidative stress. 
The increase in foetoplacental arterial pressure in response to l -
na me could also be attributed to an excessive production of a vasocon-
stricting mediator. l -na me , however, is a speciﬁc blocker of the
endothelial no-synthase (enos). As such, the change in foetoplacental
arterial pressure somehow must be mediated by the no-pathway. Of
course, the observed increase in foetoplacental arterial pressure may be
an indirect effect of no , because there is much interaction between the
no-pathway and other endothelium mediated mechanisms, like the pro-
duction of endothelins, and prostanoids. This implies that the decreased
vasoconstrictor response to l -na me in the foetoplacental vascular bed
in preeclampsia could also be attributed to diminished effects of vaso-
constricting mediators.
In addition, alterations of vascular structure could play a role in the
observed functional differences between the foetoplacental vascular bed
from patients with preeclampsia as compared to healthy controls. On
average, however, we did not observe a difference in baseline pressure
between the preeclampsia and the control group. Because perfusion
ﬂow, vessel length, and viscosity of the perfusion ﬂow were similar, we
can conclude from Poisseuille’s Law that the diameters should be similar
in both groups. As such, differences in structure of the vessels do not
seem to be the underlying cause of the observed functional differences
between preeclampsia and controls.
The addition of N-acetylcysteine positively affected no-dependent
vasodilatation in our model. As such, a decrease in baseline foetoplacen-
tal arterial pressure would have been expected after the addition of nac .
In our study, however, baseline foetoplacental arterial pressure was not
affected by nac . Again, this lack of a vasodilator effect of nac can be
explained by the putative activation of compensatory mechanisms. In
addition, we have to assume that during the subsequent administration
of l -na me , the reductions in the no-pathway are so large that these
cannot be compensated for by the aforementioned mechanisms.
The effect of nac on the no-pathway could be explained in different
ways. At ﬁrst, nac has antioxidant properties and has the ability to scav-
enge ros [18]. In preeclampsia, oxidative stress is a mediator of endothe-
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lial cell dysfunction through the excess of superoxide anion and other
free radicals. Superoxide may have a direct vasoconstrictor effect on the
vasculature or it may react with no to produce peroxynitrite. Myatt et al.
[19] demonstrated the presence of nitrotyrosine residues in placental tis-
sue of preeclamptic pregnancies, indicating the presence of peroxyni-
trite. Thus, the availability of no to act as a vasorelaxant may be reduced,
directly resulting in vasoconstriction [20]. The addition of nac to the
perfusion ﬂuid may result in scavenging of superoxide anions and possi-
bly other ros , leading to an increased availability of no , resulting in
no-mediated vasodilatation [21]. 
Secondly, it is important to realise that no can easily react with albu-
min to form S-no-albumin, which is the predominant form of no in
plasma and is an efﬁcient no transporter to the smooth muscle cells of
the vessels. nac , being an aminothiol, might compete for no with albu-
min (by transnitrosation) and thus may cause decreased availability of 
S-no-albumin [22]. However, in the k h buffer we used during the per-
fusion experiments, no albumin was added and therefore this protein
was not available for the formation of S-no-albumin. 
In addition, N-acetylcysteine is rapidly deacetylated to cysteine, which
is the key substrate in glutathione synthesis. Glutathione, one of the
most important intracellular thiols, enhances the bioavailability of no
by forming a stable, biologically active S-nitrosoglutathione adduct, as
described in a group of patients with arteriosclerosis or risk factors for
arteriosclerosis [23]. Moreover, also the sulfhydryl groups of N-acetyl-
cysteine and cysteine will bind to nitric oxide resulting in formation of S-
nitrosothiols, a stored form of no . The S-nitrosothiol compounds acti-
vate the guanylate cyclase enzyme causing vasodilatation [24]. We do not
think that the latter mechanism was operative in our model because we
did not observe a vasodilator effect of nac alone on baseline vascular
tone in the foetoplacental circulation. 
In theory, the vasodilator effect could also be independent from no .
Because of the addition of N-acetylcysteine in the perfusion ﬂuid, an
excess of free sulfhydryl groups is present, which could result in their
auto-oxidation, with subsequent formation of superoxide and hydrogen
peroxide. This may directly lead to a vasoconstrictor response or indi-
rectly through the formation of peroxynitrite. Again, this is not plausible
because we did not observe an increase in foetoplacental arterial pres-
sure during our perfusion experiments after addition of nac . 
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Our results do not necessarily mean that oral nac treatment of
preeclamptic women will have comparable effects on the foetoplacental
circulation as described here in the ex vivo system. First, in vivo there may
be an equilibrium between free and bound nac , which is due to disul-
phide bonds [9]. In this ex vivo study, the availability of free nac (– sh)
probably is higher as compared to the in vivo situation, because the per-
fusion ﬂuid does not contain proteins, although we realise that nac may
be auto-oxidised. In addition, a dose-response study to estimate the opti-
mal dose for clinical use has not been performed yet. In vivo, more than
80% of nac is bound to plasma and tissue proteins by labile sulphide
bonds [9] and is therefore not available for scavenging of ros . Further,
the current study describes the effects of short-term administration of
nac to the perfusion buffer, resulting in an increase in the vasoconstric-
tor response to l -na me . This was in concordance with other studies
regarding vascular function after administration of an antioxidant [8,12].
Various studies showed anti-oxidant biochemical effects of nac without
investigating vascular function [6,7,21]. N-acetylcysteine is transported
across the placenta, suggesting that maternal nac supplementation
might reach the foetoplacental endothelium [25]. However, the effect on
the foetoplacental vascular function of long-term maternal nac admin-
istration remains unknown.
In conclusion, ex vivo the contribution of no to the baseline vascular
tone is impaired in the foetoplacental circulation of preeclamptic
patients. Moreover, the no-pathway can be ameliorated by addition of
the anti-oxidant N-acetylcysteine to the perfusion buffer. 
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a bst r act
Aim: To stabilise the disease process in women with early onset severe
preeclampsia and/or hellp syndrome by enhancing maternal antioxi-
dants effects of glutathione.
Material and methods: In a randomised, double-blind, placebo-con-
trolled trial women with severe preeclampsia and/or hellp syndrome
received oral N-acetylcysteine administration. Primary outcome meas-
ures were: disease stabilization expressed as treatment-to-delivery 
interval and biochemical assessment of glutathione and parameters of
oxidative stress. Secondary outcome measures were maternal complica-
tions, rate of caesarean section, stay at intensive care unit, postpartum
hospital stay and neonatal morbidity and mortality. Analyses were done
by intention to treat using Wilcoxon’s two-sample test and regression
analysis.
Results: Median treatment-to-delivery interval was not signiﬁcantly
different between the N-acetylcysteine and placebo group. The whole
blood and plasma levels of glutathione and other thiols were not affected
by N-acetylcysteine administration, except for plasma homocysteine
concentrations, which were lower in the N-acetylcysteine group. There
were no differences found in maternal nor neonatal secondary outcome
measures between both groups.
Conclusion: Oral N-acetylcysteine administration does not stabilise
the disease process of early onset severe preeclampsia and/or hellp
syndrome.
i n t roduct ion
Severe preeclampsia and hellp (haemolysis, elevated liver enzymes,
low platelets) syndrome belong to the most serious complications of
pregnancy and contribute substantially to maternal and perinatal mor-
bidity and mortality [1]. In the management of preeclamptic patients
there are two options being either temporising management or immedi-
ate delivery. In the past, randomised controlled trials of expectant man-
agement demonstrated improved perinatal outcome without signiﬁcant-
ly compromising the maternal condition [2,3].
Preeclampsia is associated with an imbalance of increased oxidative
stress vs. a deﬁciency of antioxidant protection [4,5]. The deﬁciency in
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antioxidant defence in women with preeclampsia is expressed by
decreased levels of several antioxidants, such as superoxide dismutase,
glutathione peroxidase, erythrocyte glutathione, ceruloplasmin, α-toco-
pherol, and ascorbic acid [6,7].
Glutathione is one of the antioxidants probably involved in the patho-
physiology of preeclampsia and hellp syndrome [7-11]. Human cells
are protected against reactive oxygen species and other noxious com-
pounds by a combined action of glutathione and the enzymes glu-
tathione S-transferase and glutathione peroxidase [12]. Several other
diseases such as acetaminophen intoxication, sepsis, adult respiratory
distress syndrome (a r ds), and acquired immune deﬁciency syndrome
(a ids) are related to a deﬁciency of the intracellular antioxidant glu-
tathione [13-17]. In these diseases N-acetylcysteine has been used as a
precursor in the synthesis of glutathione and as a direct radical scavenger
[18]. N-acetylcysteine, which is able to pass through biological mem-
branes, enhances thiol levels in cells exposed to oxidising agents [19].
These observations led us to hypothesise that recovery of the lowered
levels of glutathione by N-acetylcysteine might stabilise the underlying
disease process of severe, early onset preeclampsia and may result in pro-
longation of pregnancy beneﬁting neonatal survival [20]. We therefore
performed a randomised, double-blind, placebo-controlled trial of oral
administration with N-acetylcysteine in women with severe preeclamp-
sia and/or hellp syndrome.
m at er i a l a nd methods
This double-blind, placebo-controlled trial was conducted at the Univer-
sity Medical Center Nijmegen between January 1999 and October 2001.
The study protocol was approved by the Medical Ethical Review Com-
mittee of the University Medical Center Nijmegen, and informed con-
sent was obtained from each patient.
All patients with early onset severe preeclampsia and/or hellp syn-
drome between 25 and 33 weeks gestation and a singleton pregnancy
were invited to participate. Severe preeclampsia was deﬁned as a dia-
stolic blood pressure of 110 mmHg or higher, measured at least two times
with an interval of at least four hours, and a proteinuria of at least 0.3 g/L,
according to the deﬁnitions of the International Society for the Study of
Hypertension in Pregnancy (isshp). The hellp syndrome was bio-
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chemically characterised as lactate dehydrogenase concentration ≥ 600
iu/l , aminotransferases ≥ 70 iu/l and a platelet count < 100 x 109/L [21]. 
Primary outcome measures were: 1. disease stabilisation expressed as
treatment-to-delivery interval; 2. biochemical assessment of glutathione
and other parameters of oxidative stress. Secondary outcome measures
were: maternal complications, rate of caesarean section, stay at intensive
care unit, postpartum hospital stay, and neonatal morbidity and mortali-
ty. The neonatal medical records were reviewed for the outcomes shown
in Table 4.
Hypothesizing that oral N-acetylcysteine administration would result
in prolongation of pregnancy for seven days, it would be necessary to
enrol 35 patients in each arm of the study, either N-acetylcysteine or
placebo (estimated standard deviation 8 days, power 95%, signiﬁcance
level 0.05). Before start of the trial, all medication boxes were assigned
with a number by a block wise randomisation protocol. In ascending
order of the numbers the medication boxes were used for each following
patient included in the study. Participants were randomly assigned to N-
acetylcysteine or placebo administration.
A safety board was installed comprising of a paediatrician, pulmonary
specialist and intensive care specialist, monitoring the safety of the study
medication for both mother and child. After the ﬁrst trial year, maternal
and perinatal morbidity and mortality rates were evaluated by this safety
board. No striking aberrant clinical features were detected.
Effervescent tablets containing 600 mg N-acetylcysteine as well as simi-
lar looking and tasting tablets without N-acetylcysteine (placebo med-
ication) were provided at a dosage schedule of three tablets every eight
hours, starting from time of inclusion until delivery. Placebo tablets 
were ﬂavoured in order to have the same taste as the N-acetylcysteine
tablets.
Clinical follow-up
Depending on their condition, patients were either monitored at the
intensive care unit or at the obstetrical ward. Antihypertensives were
administered either orally as alpha-methyldopa or nifedipin, or intra-
venously as ketanserin or nifedipin, and all participants received intra-
venous magnesium sulphate for seizure prophylaxis. Plasma volume
expansion was not used as a standard procedure. All patients received
corticosteroids for foetal lung maturation.
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All patients underwent venapunction before start of trial medication
and every morning as part of the daily routine. At delivery, arterial and
venous umbilical cord blood was taken in preheparinised syringes imme-
diately after clamping of the cord. Maternal blood was sampled again 24
hours and six weeks after delivery.
In order to promote and assess therapy compliance medication use
was checked daily, whereas after delivery, the tablets remaining in the
medication box were counted.
Biochemical assays
Blood samples were collected into sterile evacuated blood collection
tubes containing ethylenediaminetetra-acetic acid (edta) (Sherwood
Medical, Ballymore, Northern Ireland) and in sterile collection tubes for
serum analyses. Standard blood parameters were determined at the clin-
ical chemistry laboratory of our hospital. 
Venous blood samples were processed within one hour for the deter-
mination of free (sum of reduced and oxidised non-protein bound) and
oxidised thiol levels and stored at –80ºC. Remaining blood was cen-
trifuged (1500x g for 15 minutes) and plasma was stored at –30ºC for
measurement of plasma thiols and ferric reducing ability of plasma
(f r a p). Both whole blood and plasma levels of the thiols cysteine,
homocysteine, cysteinylglycine, glutathione and N-acetylcysteine were
analysed by high performance liquid chromatography (hplc) as
described by Raijmakers et al [10,11]. f r a p levels were measured spec-
trophotometrically essentially as described for plasma by Benzie et al.
and values were expressed as nmol Fe2+ equivalent/ml [23].
Statistical analysis
The analyses were performed on an intention-to-treat basis. The differ-
ence in treatment-to-delivery interval between the nac and the placebo
group has been analysed using Wilcoxon’s two-sample test. Also a 95%
conﬁdence interval for the population difference, using Conover’s
method was computed [23].
The time course of all biochemical parameters were modelled as piece-
wise linear with a breakpoint at one day after start of treatment, since the
largest change due to N-acetylcysteine administration would be expect-
ed during the ﬁrst day. Only values of patients from whom measure-
ments at start and one day after start of treatment were obtained, were
included in the computation of the ﬁrst part of the time course. For the
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second part of the time course only values of patients with at least three
sampling points, after start of the intervention, including day one, were
included. The time courses were computed separately for each patient
using regression analysis. Differences between the nac and placebo
groups for each of the three coefﬁcients involved, e.g. the intercept and
two slopes, were tested using the two-sample t-test. When no signiﬁcant
difference existed between the two treatment groups (all three p > 0.05),
one common time course was estimated for both treatment groups. Oth-
erwise a different time course was estimated for each of the treatments.
Estimation was done within a repeated measurement model, with treat-
ment (if applicable), time (days after start of treatment) and their interac-
tion as ﬁxed factors; the model was completed with random intercepts
and slope(s) for each patient, specifying an unstructured covariance
matrix. The sa s procedure mi x ed was used. 
In addition, for both groups all biochemical parameters measured at
24 hours and six weeks post partum were compared with pre-treatment
values using the Wilcoxon-Signed-Rank test. The differences of bio-
chemical parameters at 24 hours compared to pre-treatment values and
at six weeks compared to pre-treatment values were compared between
the N-acetylcysteine and placebo group using the unpaired Wilcoxon-
Mann-Whitney-U test. Pre-treatment f r a p levels were compared with
those after three study days using the Wilcoxon-Signed-Rank test. 
Secondary parameters of maternal and neonatal outcome were com-
pared using Wilcoxon-Mann-Whitney-U test or Chi-square analysis, as
appropriate. 
All analyses were performed either with sa s version 6.12 statistical
software (sa s Institute, Inc, Cary, nc) or with spss version 9.0 statisti-
cal software and signiﬁcance was assessed at a two-sided level with p <
0.05. All tests with regard to the clinical and biochemical parameters
were explorative in nature.
r e sults
From the 59 women with severe preeclampsia, who were invited to par-
ticipate, 38 women were enrolled in this study. Reasons for not partici-
pating in the trial were emotional distress at admission to the hospital,
fear for the use of extra medication during pregnancy or planned deliv-
ery within a couple of hours after admission.
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All patients were randomly assigned to N-acetylcysteine medication
or a placebo, resulting in 19 patients in each group. 
Clinical characteristics of both study groups were comparable, as
summarised in Table 1. 
Primary outcome measures
Median treatment-to-delivery interval in the N-acetylcysteine and place-
bo groups was 6 (range 0-21) and 5 (range 0-17) days, respectively (p =
0.85). The corresponding 95% conﬁdence interval for the difference
between the two time intervals was –3 to 3 days.
N-acetylcysteine administration resulted in median plasma N-acetyl-
cysteine concentrations of 20.0 µmol/L (range 1.1-65.9) on the ﬁrst treat-
ment day, remaining stable thereafter.
Pre-treatment levels of whole blood and plasma thiols were similar to
those levels in earlier studies from our group in women with severe
preeclampsia and/or hellp syndrome (Table 2a and 2b) [10,11].
During treatment the course of whole blood thiol levels were equal in
both groups. Despite a peak of free and oxidised cysteine levels and of the
ratio of free to oxidised glutathione during the ﬁrst study day, there were
no signiﬁcant ﬂuctuations. 
Plasma homocysteine concentrations signiﬁcantly increased (p <
0.001) during day one in the placebo group, while in the N-acetylcysteine
group plasma homocysteine levels were stable. Other plasma thiol levels
were not inﬂuenced by the N-acetylcysteine administration. In both
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Table 1 Baseline characteristics of the placebo and N-acetylcysteine treatment groups
Placebo group N-acetylcysteine group
n = 19 n = 19
Age (yrs) 30 (23-40) 28.5 (22-34)
Caucasian race 17 (89) 19 (100)
Gestational age at inclusion (weeks) 29+1 (24+4-33) 27+3 (24-32)
Systolic blood pressure (mmHg) 162 (130-220) 160 (120-220)
Diastolic blood pressure (mmHg) 110 (80-140) 110 (85-135)
Complicated by HELLP syndrome 7 (37) 6 (32)
Antihypertensive medication at inclusion 14 (74) 13 (68)
Anticonvulsative therapy at inclusion 11 (58) 8 (42)
Corticosteroid injections at inclusion 8 (42) 5 (26)
Data are presented as medians (min-max) or numbers (%).
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study groups plasma cysteinylglycine levels decreased during the ﬁrst
day and remained stable subsequently.
After two completed days of trial medication f r a p values were com-
pared with baseline levels in seven placebo-treated-patients and twelve
N-acetylcysteine-treated-patients. In the N-acetylcysteine group median
f r a p values were 922 (baseline; range: 583-1408) vs. 1053 (594-1284)
nmol Fe2+ equivalent/ml, and in the placebo group 997 (825-1317) vs. 920
(611-1383) nmol Fe2+ equivalent/ml, respectively. The median differences
in f r a p values were –76 (95% ci –348-196) in the placebo group and 38
(95% ci –104-181) in the N-acetylcysteine group, which was not signiﬁ-
cantly different.
Twenty-four hours and six weeks after delivery, several changes of
thiol concentrations had occurred in both groups as compared to corre-
sponding baseline levels (Tables 2a and 2b).
The only differences found between both groups were decreased plas-
ma glutathione levels 24 hours after delivery in the placebo groups and
increased plasma cysteine concentrations six weeks postpartum in
women who had received N-acetylcysteine administration.
In the N-acetylcysteine group, N-acetylcysteine concentrations were
9.5 µmol/L (range 1.1-19.7) in arterial umbilical cord blood (n = 7) and
15.4 µmol/L (range 2.8-32.8) in venous umbilical cord blood (n = 8). In
the other available arterial (n = 6) and venous (n = 5) umbilical cord blood
samples N-acetylcysteine was not detected. In three arterial and three
venous umbilical cord samples of placebo treated women N-acetylcys-
teine concentrations were found, which were all below 2.2 µmol/L,
except for one value of 9.7 µmol/L. There were twelve umbilical cord
blood samples available in the placebo groups, arterial as well as venous.
Secondary outcome measures
Gestational age at delivery was not signiﬁcantly different between both
groups, indicating there was no prolongation of pregnancy achieved.
The majority of patients in both groups were delivered by caesarean sec-
tion, because of deterioration of the maternal condition (75%) or foetal
distress (Table 3). The incidence of maternal complications, being pul-
monary oedema (n = 4), transient ischemic attack (n = 2), relaparatomy
after caesarean section because of intra-abdominal bleeding (n = 2),
eclamptic seizures (n = 1) and serious psychiatric disorders (n = 1), were
not different between groups.
Data on neonatal outcome are summarised in Table 4. 
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Table 3 Maternal outcome of the placebo and N-acetylcysteine treatment groups
Placebo group N-acetylcysteine group
n = 19 n = 19
Interval treatment and delivery (days) 5 (0-17) 6 (0-21)
Gestational age at delivery (wks) 29+4 (26+1-33+5) 28+2 (25+6-33+2)
Primary caesarean delivery 15 (79) 17 (89)
Antepartum stay at ICU 10 (53) 12 (63)
Postpartum stay at ICU 12 (63) 10 (53)
Hospital stay postpartum (days) 7 (2-18) 8 (3-20)
Data are presented as medians (min-max) or numbers (%). ICU = Intensive Care Unit
Table 4 Neonatal outcome of the placebo and N-acetylcysteine treatment groups
Placebo group N-acetylcysteine group
n = 19 n = 19
Stillbirth 3 1
Early neonatal death 1 (1 hr pp) 3 (1 child 1 hr pp)
Birth weight (g) 1030 (420-1800) 823 (410-1830)
Small-for-gestational-age (< p 10) 9 (47) 7 (37)
n = 16 n = 18
APGAR score after 5 min 8 (3-10) 8.5 (1-10)
pH umbilical arterial blood* 7.23 (7.03-7.37) 7.23 (7.03-7.29)
pH umbilical venous blood* 7.26 (7.05-7.38) 7.26 (7.04-7.31)
n = 15 n = 17
Need of mechanical ventilation 7 (47) 10 (59)
Mechanical ventilation (days) 14 (4-37) 9 (4-21)
Respiratory distress syndrome 7 (47) 10 (59)
Respiratory distress syndrome grade III/IV 7 (47) 9 (53)
Patent ductus arteriosus 4 (27) 3 (23 )
Intraventricular hemorhage grade I/II 3 (20) 4 (25)
Intraventricular hemorhage grade III/IV 0 1 (6)
Necrotising enterocolitis 1 (7) 2 (12)
Retinopathy of the premature** 3 (20) 3 (18)
Sepsis 5 (33) 9 (35)
Data are presented as medians (min-max) or numbers (%).
* missing data in the placebo group: 2; and in the N-acetylcysteine group: 6; ** missing
data in the placebo group: 3; and in the N-acetylcysteine group: 1
Since one neonate in each group died within one hour after delivery the
follow-up data on neonatal morbidity and mortality were analysed for 15
neonates in the placebo group and 17 in the N-acetylcysteine group.
Neonatal morbidity and mortality rates were not different between both
groups.
Compliance and side effects
Two women in the N-acetylcysteine group and four women in the place-
bo group demonstrated suboptimal therapy compliance during the study
period, by taking less than 50% of the study medication. Main reasons
for this were the side effects of N-acetylcysteine, or other problems such
as upper abdominal pain, mental distress, transfer to another tertiary
centre, or refusal at second thought. Side effects were reported by 33% of
the patients in the N-acetylcysteine group and by 32% of the patients in
the placebo group.
discussion
We found no beneﬁt of oral N-acetylcysteine administration on stabilisa-
tion of the disease process in women with severe preeclampsia and/or
hellp syndrome. This is the ﬁrst study reporting on such intervention.
Although the sample size which was computed beforehand could not be
reached within the available study-period, still a power of 75% was
achieved. Furthermore, the difference in treatment-to-delivery interval
found is such small (mean 0.05 days, median 1 day), that doubling of the
number of participants would not have shown a signiﬁcant difference
either. Such a doubling of the results would have resulted in a p-value of
approximately 0.63. In fact, if before the start of the trial a maximum dif-
ference in time intervals of three days would have been accepted as equiv-
alence, our results would have shown equivalence of the two treatments
(using the usual 90% 2-sided conﬁdence interval for the difference). 
The lack of effect of oral N-acetylcysteine could be explained in different
ways. The N-acetylcysteine administration may have been started too
late to exert beneﬁcial effects, namely after initiation of clinical symp-
toms. Other antioxidants, such as vitamins c and e administered to
patients with preeclampsia in randomised controlled study designs dur-
ing established preeclampsia neither had a beneﬁcial effect on maternal
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and neonatal outcome [24,25].In contrast, oral vitamin c and e pre-
scribed to women at risk for preeclampsia from 16-20 weeks throughout
pregnancy, resulted in a signiﬁcant lower incidence compared to placebo
users [26]. Timing of initiation of therapy may be crucial for a beneﬁcial
effect. Another explanation might be the lack of effect of N-acetylcys-
teine administration on plasma and whole blood thiols, especially on glu-
tathione levels. In comparison to uncomplicated pregnant controls we
demonstrated in earlier studies increased plasma cysteine and homocys-
teine levels and decreased ratios of whole blood free to oxidised thiols, as
an indicator of increased oxidative stress during preeclampsia [10,11]. In
the present study we could not demonstrate obvious signs of stabilisa-
tion of the disease process in the pattern of whole blood and plasma thiol
concentrations. However, the increased levels of plasma homocysteine
during the ﬁrst day in the placebo group were probably counteracted in
the N-acetylcysteine group. As reported in earlier studies, oral N-acetyl-
cysteine administration may reduce plasma homocysteine levels [27,28]. 
In this study, free and oxidised cysteine concentrations decreased
gradually after an initial rise in concentrations, but N-acetylcysteine
could not counteract this effect. Since cysteine is an important precursor
of intracellular glutathione [29], a gradual consumption of intracellular
glutathione by oxidative stress might be responsible. Other signs of
oxidative stress were indicated by the decreased ratios of free to oxidised
thiols [30] at initiation and during the course of the disease, not respond-
ing to N-acetylcysteine administration.
Six weeks after delivery, we found a normalisation of whole blood as
well as plasma thiol concentrations in both groups [8,10].
A third explanation could be that an inadequate dose of N-acetylcys-
teine was used. We presume that the dose of N-acetylcysteine used in this
trial was large enough to generate an effect, since we earlier demonstrat-
ed a signiﬁcant increase of whole blood glutathione concentrations in
young, non-pregnant women treated with the same dose of N-acetylcys-
teine [27]. To date, little information is available on the time-response
relationship and optimal duration of N-acetylcysteine therapy [31]. We
presumed that the way of administration did not negatively inﬂuence our
study, since oral N-acetylcysteine treatment has been proven as effective
as intravenous treatment in acetaminophen poisoning [32,33].
Regarding serious neonatal morbidity, such as respiratory distress syn-
drome (r ds), intraventricular haemorrhage grades iii/i v (i v h), and
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necrotising enterocolitis grades 2/3 we found similar rates in both
groups, which were similar to data of a group of neonates born at a gesta-
tional age ≤ 32 weeks [35]. 
N-acetylcysteine is transported across the placenta, though the levels
reached in the foetal circulation are known to be low [35,36]. Pre-term
infants who received N-acetylcysteine infusion with a ﬁnal steady-state
level of 100 µmol/L did not show any adverse effect, though the pharma-
cokinetics of N-acetylcysteine is different from adults and depends
markedly on weight and gestational age [37].
The plasma N-acetylcysteine concentrations reached in our study
were comparable with N-acetylcysteine levels reported in other studies
using oral N-acetylcysteine, ranging between 52 and 66 µmol/L [35].
Surprisingly, we found low concentrations of N-acetylcysteine in the
umbilical cord samples of a few placebo users. These levels most proba-
bly are an indication for other sources of N-acetylcysteine than solely
from our medication [10].
The reported side-effects of the study medication are probably more
related to the disease or to the effervescent properties of the tablets
rather than to N-acetylcysteine itself. The main complaints of the
patients were nausea, vomiting, and gastric discomfort, which all are
known to precede an episode of worsening of the disease, especially in
the case of hellp syndrome. This may have worsened the therapy com-
pliance. 
In conclusion, oral N-acetylcysteine does not seem to be beneﬁcial for
maternal and neonatal outcome in women with severe preeclampsia
and/or hellp syndrome. As N-acetylcysteine was started rather late,
after initiation of the disease, earlier intervention may lead to better
results.
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PART I I I  
Antioxidants: before, 
during and after pregnancy

CHAPTER 7
A longitudinal study of antioxidant status during 
uncomplicated and hypertensive pregnancies
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a bst r act
Background: During normal pregnancy antioxidant capacity increases in
parallel with a rise in free radicals. In contrast, in preeclampsia the oxi-
dant-antioxidant balance seems to be disturbed, which leads to increased
oxidative stress, impairing endothelial function. For a better understand-
ing of this imbalance in preeclampsia, baseline levels throughout normal
pregnancy should be known. 
Material and methods: In uncomplicated pregnancies (n = 19) and
hypertensive pregnancies (n = 6) concentrations of whole blood and
plasma thiols, vitamins e and c , haemoglobin and haematocrite values
were assessed at preconception, 6, 10, 20, 37 weeks of gestational age, and
six weeks postpartum. A repeated mixed model was used for statistical
analysis.
Results: Vitamin c and most whole blood and plasma thiol concentra-
tions decreased during pregnancy, while vitamin e , whole blood oxi-
dised cysteinylglycine and the ratio of free to oxidised homocysteine
revealed a linear increase during pregnancy. Postpartum plasma cysteine
and vitamin c levels and the ratio of free to oxidised levels of cysteine,
cysteinylglycine and glutathione were signiﬁcantly (p < 0.05) lower as
compared to preconceptional levels, whereas whole blood oxidised cys-
teine, cysteinylglycine and glutathione levels and whole blood and plas-
ma homocysteine levels were signiﬁcantly (p < 0.05) higher six weeks
after delivery. Plasma cysteine and homocysteine and whole blood oxi-
dised cysteine and homocysteine levels were signiﬁcantly (p < 0.05) high-
er at 37 weeks gestational age in the hypertensive group compared to
those in the uncomplicated group. There were no other differences
between the hypertensive and uncomplicated group.
Conclusion: In normal pregnancy there seems a balance between
antioxidant and oxidant concentrations despite modest oxidative stress.
In mild hypertensive pregnancies a marginal imbalance of these concen-
trations may occur.
i n t roduct ion
During normal pregnancy antioxidant capacity increases in parallel with
a rise in free radical products, such as in lipid peroxides [1]. Under physi-
ological conditions reactive oxygen species are continuously produced
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within the cell as a result of mitochondrial electron transfer processes, as
a by-product of the enzymes xanthine oxidase, lipoxygenase and
cyclooxygenase or formed from L-arginine by no synthase [2]. Oxygen
radicals exert critical actions such as signal transduction, gene transcrip-
tion, and regulation of soluble guanylate cyclase activity in cells [3,4].
Under healthy conditions reactive oxygen species (ros) and lipid perox-
idation are adequately controlled by antioxidants [2].
The thiol system plays an important role in maintaining the redox bal-
ance of cells, thereby preventing oxidative damage [5]. In preeclampsia
the oxidant-antioxidant balance seems to be disturbed [6,7]. Total
antioxidant capacity as well as the levels of individual antioxidants, such
as superoxide dismutase, glutathione peroxidase, glutathione, cysteine,
ceruloplasmin, α-tocopherol (vitamin e), and ascorbic acid (vitamin c),
have been demonstrated to be lowered in women with preeclampsia [8-
11]. Endothelial dysfunction is a pivotal feature of preeclampsia and is
possibly enhanced by direct and indirect damage of ros , such as lipid
peroxides [12].
For a better understanding of the imbalance between oxidants and
antioxidants in preeclampsia, baseline levels throughout normal preg-
nancy should be known. 
Therefore, we evaluated the concentrations of vitamin e , vitamin c ,
and whole blood and plasma thiols preconceptionally, throughout preg-
nancy and 6 weeks after delivery, in women with uncomplicated preg-
nancies as well as in women with pregnancies complicated by gestational
hypertension or preeclampsia.
m at er i a l a nd methods
The study was performed between October 2000 and September 2001
at the University Medical Center Nijmegen, the Netherlands. The exper-
imental protocol was approved by the Medical Ethical Review Commit-
tee. All women gave written informed consent. Healthy nulliparous and
multiparous women were recruited by advertisements in local newspa-
pers and pamphlets at general practitioners’ ofﬁces, pharmacies, and
children nursery homes in Nijmegen. Women with a history of pre-
eclampsia and/or hellp syndrome were recruited from the outpatient
clinic.
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Preconceptionally 28 nulliparous women, 18 multiparous women with
a history of uneventful pregnancies and 3 women with a history of
preeclampsia and/or hellp syndrome were included. During the fol-
low up of the study 9 nulliparous women, 6 multiparous women and 1
woman with pre-existing hypertension did not become pregnant. More-
over, 7 women experienced a miscarriage and one nulliparous women
had a twin pregnancy. These 24 women were excluded for further evalua-
tion. Thus, the ﬁnal analysis consisted of the data of 9 primiparous
women and 10 multiparous women with uneventful pregnancies form-
ing the uncomplicated group (n = 19). The hypertensive group comprised
three primiparous, one multiparous women and two women with a his-
tory of preeclampsia, who developed gestational hypertension and/or
preeclampsia (n = 6) (Table 1). None of the women used chronical med-
ication.
Gestational hypertension was deﬁned as blood pressure of 140/90
mmHg or higher, measured with an interval of at least four hours accord-
ing to the deﬁnitions of the International Society for the Study of Hyper-
tension in Pregnancy (isshp). Preeclampsia was deﬁned as gestational
hypertension accompanied by a proteinuria of at least 0.3 g/L.
All women were invited at our outpatient clinic for investigation at
seven moments, preconceptionally and at 6, 10, 20, 30, 37 weeks gesta-
tional age, as well as at 6 weeks post partum. 
Blood pressure reading was performed at the right upper arm of the
women, in a sitting position. Blood samples were collected by venapunc-
ture into sterile evacuated blood collection tubes containing ethylenedi-
aminetetra-acetic acid (edta) (Sherwood Medical, Ballymore, North-
ern Ireland) and were processed within half-an-hour. Whole blood, for
measurement of free and oxidised thiols, was prepared for analysis and
stored at –80°C until analysis. The remaining whole blood was cen-
trifuged at 1500 g for 15 minutes and the blood plasma was used for
measurement of plasma (total) thiols, vitamin c (ascorbic acid), and vita-
min e (α-tocopherol) after storage until analysis either at –80ºC (vita-
min c and vitamin e) or at –30ºC (plasma thiols). 
Processed plasma and whole blood samples were analysed for the con-
centration of cysteine, homocysteine, glutathione, and cysteinylglycine
by high performance liquid chromatography (hplc) as described previ-
ously [11,13].
For the analysis of vitamins c and e a hplc method was used, as
described in detail by Zusterzeel et al. [14].
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Statistical analysis
A. Course of concentrations from preconception throughout
pregnancy
Before designing the study protocol, we expected a gradual decrease or
increase of the biochemical variables, with a drop of the concentrations
around the twentieth week of pregnancy due to hemodilution. There-
fore, we used a repeated mixed model on each parameter separately,
while accounting for the type of pregnancy (uncomplicated or hyperten-
sive). 
At ﬁrst, we found that for nearly all biochemical variables the model
was statistical signiﬁcantly improved when a quadratic term in time was
included in the linear part of the model (Likelihood-Ratio test). This
might suite well with the drop of the concentrations found around the
twentieth gestational week for most of the variables.
Furthermore, no signiﬁcant improvement was reached when the best
model found above was extended with either a higher-order-time term.
Inspection of the residuals, using a saturated model, did not show devia-
tion from normality of any of the variables, which would have motivated
to use a quadratic or log-transformation. 
Finally, the following repeated mixed model was used for each labora-
tory parameter, separately. The dependent variable was the biochemical
variable. The independent random variable was ‘women’ and the inde-
pendent continuous variable was linear time (and quadratic time, respec-
tively) and the independent class variable was type of pregnancy. Also
the interaction term between the type of pregnancy and the time vari-
able(s) were included in the model, allowing for differences in the course
between uncomplicated and hypertensive pregnancies.
The initial model we used is as follows:
Yi(tij) = β1 Ci + β2 nCi + (β3 Ci + β4 nCi ) * tij + (β5 Ci + β6 nCi ) * t2ij + β1i +
β2i * tij + β3i * t2ij + εij
Where i refers to subject and j to the timing of investigation, i.e. pre-
conceptional or during pregnancy, with the ﬁxed effect β, the random
effect b, C and nC as indicator variables for complicated (hypertensive)
and uncomplicated pregnancies and εij as the normal distributed residual
with mean zero. Note that this implies that differences between women
may vary over time.
All regression variables with standard errors of each biochemical vari-
able are presented. The regression coefﬁcient of the quadratic term is of
particular interest; a negative value indicates a top level and a positive
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value indicates a bottom level. Furthermore, the larger this coefﬁcient in
absolute terms the steeper the course.
B. Six weeks postpartum vs. preconceptional levels
The difference in mean levels of the biochemical parameters at six weeks
postpartum compared to the mean preconceptional level was analysed
using a repeated mixed model, somewhat different from the one
described above. 
The dependent variable was the biochemical parameter. The indepen-
dent random variable was ‘women’ and the independent class variables
were type of pregnancy and point of measurement (preconceptional and
six weeks postpartum). Also the interaction term between uncomplicat-
ed and hypertensive pregnancy and the point of measurement were
included in the model. The appropriate, adjusted Tukey-Kramer contrast
test was used to test for speciﬁc differences in mean levels at the two
points of measurement.
The estimated mean levels of the biochemical variables with 95% con-
ﬁdence intervals are presented by each group and by each point of mea-
surement. 
Clinical and demographic characteristics were compared using
Mann-Whitney-U tests. A p-value below 0.05 was considered statistical-
ly signiﬁcant.
r e sults
Baseline characteristics of the women in each group are presented in
Table 1. No clinical and statistical signiﬁcant differences at baseline
between women with uncomplicated pregnancies compared to women
who developed hypertension during the course of pregnancy were
found. The women in the hypertension group developed mild hyperten-
sion only.
Longitudinal biochemical changes during uncomplicated 
pregnancy 
Whole blood levels of free and oxidised cysteine, homocysteine and glu-
tathione and plasma levels of cysteine, homocysteine and cysteinyl-
glycine demonstrated parabolic courses of concentrations with the low-
est levels around 20 weeks of gestation (Figure 1).
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Concentrations of vitamin c (Figure 2), whole blood free cysteinyl-
glycine, plasma glutathione as well as the ratios of free to oxidised levels
of cysteine, cysteinylglycine and glutathione (Figure 1) showed a linear
decrease during the course of pregnancy. A linear increase was observed
for vitamin e (Figure 2), whole blood oxidised cysteinylglycine as well as
the ratio of free to oxidised homocysteine (Figure 1).
The comparison between postpartum and preconceptional levels
revealed several signiﬁcantly lower variables six weeks postpartum,
namely plasma cysteine levels (p < 0.001) and vitamin c levels (p < 0.01)
and the ratios of free to oxidised levels of cysteine, cysteinylglycine and
glutathione (p < 0.05).
Whole blood as well as plasma levels of homocysteine were all signiﬁ-
cantly higher six weeks after delivery compared to the preconceptional
levels (p < 0.001); except for the ratio free to oxidised homocysteine (p <
0.05). Besides, there were signiﬁcant higher whole blood oxidised cys-
teine (p < 0.05), cysteinylglycine (p < 0.05) and glutathione (p < 0.01) lev-
els found six weeks postpartum. Plasma vitamin e , cysteinylglycine and
glutathione levels and whole blood free cysteine and glutathione levels
were not changed postpartum as compared to the preconceptional situa-
tion (Tables 2a and 2b).
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Table 1 Characteristics of women with uncomplicated and hypertensive pregnancies
Control pregnancies Hypertensive pregnancies
n = 19 n = 6
Age (yrs) 31 (25-38) 30 (28-33)
Primiparity (n) 9 (47) 4 (67)
Diastolic blood pressure* (mmHg) 74 (70-80) 80 (70-100)
Body Mass Index* (kg/m2) 22.2 (20.5-31.3) 25.6 (21.3-31.6)
Smoking* (n) 1(5) 0 (0)
Folic acid* (n) 19 (100) 6 (100)
Multivitamins (n)** 7 (37) 1 (17)
Iron supplementation (n)*** 6 (32) 0 (0)
Gestational age at delivery (wks) 40+4 (35+5-41+6) 39+4 (37+2-40+5)
Birth weight (g) 3420 (2670-4690) 3170 (2600-3995)
Data are presented as medians and numbers (%). 
* preconceptional; ** incidental; ***started after 30 weeks
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Table 2B The estimated mean levels (95% CI) of haematological parameters and vita-
mins (mmol/L) preconceptional and six weeks postpartum.
Type of pregnancy Preconceptional 6 wks postpartum
Vitamin C (µmol/L) uncomplicated 67.2 (56.9 - 77.5) 43.7 (32.2 - 55.3)
hypertensive 65.6 (47.1 - 84.0) 42.1 (24.5 - 59.6)a
Vitamin E (µmol/L) uncomplicated 24.7 (21.2 - 28.2) 26.7 (23.3 - 30.1)
hypertensive 26.3 (20.3 - 32.2) 28.2 (22.8 - 33.6)
Haemoglobin (mmol/L) uncomplicated 8.10 (7.94 - 8.25) 7.83 (7.56 - 8.10)
hypertensive 8.23 (7.94 - 8.53) 7.1 (6.61 - 7.59)a
Haematocrite (L/L) uncomplicated 0.38 (0.38 - 0.39) 0.38 (0.37 - 0.39)
hypertensive 0.39 (0.37 - 0.40) 0.35 (0.33 - 0.37)a
a: statistical signiﬁcant difference between the estimated mean level preconceptional
compared to 6 weeks postpartum, using the repeated mixed model with appropriate
contrast test according to Tukey-Kramer, p < 0.05.
The mean levels of haemoglobin (mmol/L), haematocrite (L/L), vitamin C (µmol/L) and
vitamin E (µmol/L) from preconceptional upto 6 weeks postpartum by group. The sym-
bols indicate the observed mean and the vertical bars indicate ± one standard deviation
(SD). The thick lines indicate the estimated mean proﬁles, using a second-degree poly-
nomial in a linear mixed model and also the appropriate 95% conﬁdence bands are
shown (thin, short dashed line). Women with uncomplicated pregnancy: dot, solid line.
Women with hypertension during pregnancy: diamond, long dashed line.
Figure 2 Mean levels of haemoglobin, haematocrite, vitamin C and vitamin E from 
preconceptional upto 6 weeks postpartum
Course of the biochemical concentrations during hypertensive
and uncomplicated pregnancy
The concentrations and ratios of almost all biochemical variables of the
hypertensive group followed a comparable course as in the uncomplicat-
ed group. However, plasma cysteine (p < 0.01) and homocysteine (p <
0.05) levels as well as whole blood oxidised cysteine and homocysteine
concentrations (p < 0.01) were statistical signiﬁcantly higher at 37 weeks
gestational age as compared to the uncomplicated group (Figure 1).
At six weeks postpartum there were no signiﬁcant differences
between the levels of the hypertensive group and the uncomplicated
group. In contrast, haemoglobin and haematocrite values were signiﬁ-
cantly lower (p < 0.001) six weeks postpartum in the hypertensive group
compared to the uncomplicated group (Table 2b).
Whole blood and plasma cysteinylglycine levels are not depicted in the
Figures 1 and 2; the different variables follow the course as described in
this section.
discussion
This is one of the ﬁrst longitudinal studies on whole blood and plasma
thiol levels before and during pregnancy. Cikot et al. have described earli-
er the course of vitamin and homocysteine levels in uncomplicated preg-
nancies [15].
Resuming, for most thiol concentrations we found lower levels around
20 weeks gestational age. Vitamin c levels decreased gradually during
pregnancy, while vitamin e concentrations gradually increased. There
were no striking differences in the hypertensive group vs. the uncompli-
cated group, only higher plasma cysteine and homocysteine levels and
whole blood oxidised cysteine and homocysteine levels were found in the
hypertensive group at 37 weeks of gestational age. 
Longitudinal biochemical changes during uncomplicated 
pregnancy 
In general we have found three different patterns during uncomplicated
pregnancy. At ﬁrst, most thiols showed the lowest levels between 20 and
30 weeks of gestational age. For most of these thiols the most probable
explanation is the physiological hemodilution of pregnancy at a maxi-
mum at 20 weeks [16]. In addition, trophoblast invasion during the ﬁrst
98 pa rt iii
half of pregnancy has been associated with the generation of free radi-
cals [17], which may lead to an increased consumption of antioxidants. In
our earlier cross-sectional studies, plasma thiol concentrations were sig-
niﬁcantly lower in uncomplicated pregnancies around 30 weeks of gesta-
tional age compared to non-pregnant levels [11]. The present results
seem to be in line with that ﬁnding, because in the current study after the
twentieth week gestational age the levels of plasma thiols in normal preg-
nancy are at their deepest point until 30 weeks of gestation, possibly in
response to increasing oxidative stress. Other indicators of increased
oxidative stress are the decreased ratios of free to oxidised levels of cys-
teine, cysteinylglycine and glutathione following a linear decrease during
the course of pregnancy, as demonstrated in this study. Whether
increased oxidative stress is caused by a net increase of lipid peroxidation
is not clear, since reports on this subject are conﬂicting [6,18]. In general,
it is believed that in physiologic, uncomplicated pregnancies increased
oxidative stress or lipid peroxidation is counteracted by increasing
antioxidant capacity [18,19].
We found a modest, though signiﬁcant, linear decrease of vitamin c
levels. We consider this as a sign of imbalance between vitamin c con-
sumption and expenditure during pregnancy. Other studies on vitamin c
levels in pregnancy have been focussed mainly on the last trimester of
gestation and found stable concentrations [20,21]. Since in our study pre-
conceptional and early ﬁrst trimester levels were also measured, we were
able to detect a decreasing trend while other groups did not. Vitamin c is
an important dietary antioxidant, acting synergistically with vitamin e in
the defence against lipid peroxidation due to its ability to regenerate vita-
min e (α-tocopherol) by reducing α-tocopherol radicals to α-tocopherol
[22].
During gestation the lipophilic vitamin e is one of the most important
antioxidants, protecting against lipid peroxidation [18]. In accordance
with other reports we also found a linear increase in the plasma vitamin e
levels [21,23,24], partly caused by a major increase of cholesterol and
triglycerides levels during pregnancy [25].
We demonstrated that whole blood and plasma homocysteine levels
are signiﬁcantly increased six weeks postpartum as compared to precon-
ceptional levels, an effect of pregnancy described earlier [15]. Postpar-
tum hyperhomocysteinemia is associated with an approximately 2-fold
to 3-fold increased risk for pregnancy-induced hypertension, abruptio
placentae, and intrauterine growth restriction, as recently published by
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Steegers-Theunissen et al. [26]. Interestingly they demonstrated that
these associations lost their signiﬁcance after adjustment for maternal
age and for the time interval between pregnancy and testing [26].
Decreased ratios of free to oxidised levels of cysteine, cysteinylglycine
and glutathione six weeks postpartum might be an expression of an
ongoing effect of oxidative stress. A recent study on lowered ratios of
free to oxidised levels of glutathione and other thiols indicate a shift in
redox balance towards more oxidised levels, which is interpreted as a
direct marker of oxidative stress [27]. In our previous study on thiol levels
after uncomplicated pregnancies we also found lowered ratios of free to
oxidised glutathione and cysteinylglycine three months postpartum
(unpublished results). The high number of women on lactation at six
weeks after delivery might contribute partly to the ongoing oxidative
stress. A possible explanation could be lactation, which was given by 10
women in the uncomplicated and 5 women in the hypertensive group,
respectively. Dostolova demonstrated an inadequate biochemical vita-
min status during puerperium and lactation [28].
In general, the number of women taking iron supplementation and
multivitamins was quite small. Moreover, due to the limited numbers
stratiﬁed analysis was not feasible. Nevertheless, we did not expect a sig-
niﬁcant effect, either negative or positive, on antioxidant levels of iron
supplementation and multivitamins.
Course of the biochemical concentrations during hypertensive
and uncomplicated pregnancy
Despite the mild form of hypertension or preeclampsia in the hyperten-
sive group, in which almost all variables followed a similar course as in
the uncomplicated group, plasma cysteine and homocysteine and whole
blood oxidised cysteine and homocysteine levels at 37 weeks of gestation
were signiﬁcantly higher compared to those levels in the uncomplicated
group. In previous studies from our research group we also demonstrat-
ed higher plasma thiol levels in women with severe preeclampsia vs. nor-
motensive women at a mean gestational age of 32 weeks [11,13]. Gesta-
tional hypertension and preeclampsia cause hemoconcentration, which
might explain the higher plasma cysteine and homocysteine levels in the
present study [29]. The increased oxidised levels of cysteine and homo-
cysteine are not correlating with increased oxidative stress since the
ratios of free vs. oxidised thiols are not different compared to those in
uncomplicated pregnancies.
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Plasma vitamin c and e levels were not different between the two
groups. Since hypertensive disorders of pregnancy are thought to be
associated with a disturbance of the oxidant-antioxidant balance, one
would expect different patterns, especially for vitamin c and e levels. We
studied a mixed group of women with either mild preeclampsia or gesta-
tional hypertension, which may have inﬂuenced the results. Several stud-
ies reported lower vitamin e concentrations in preeclamptic women vs.
normotensive pregnant women [8,22,30], though increased vitamin e
levels have been reported as well [24]. 
Probably due to the mild form of preeclampsia and hypertension we
found no major deviations of antioxidants, neither we found signs of
increased oxidative stress in women who developed hypertension during
pregnancy.
In conclusion, in uncomplicated pregnancies the oxidant-antioxidant
status seems to be in balance. In mild hypertensive pregnancies modest
oxidative stress may be present.
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a bst r act
Aim: To analyse the postpartum concentrations of intra- and extra cellu-
lar blood antioxidants in women with uncomplicated pregnancies.
Material and methods: Whole blood and plasma thiols, plasma vita-
mins e and c , serum cholesterol and triglyceride, Ferric Reducing Abili-
ty of Plasma (f r a p) concentrations were compared between women
delivered by caesarean section (n = 17) or spontaneous delivery (n = 10). A
repeated mixed model was used for statistical analysis.
Results: The majority of whole blood thiols increased signiﬁcantly in
both groups the ﬁrst days postpartum. However, within the caesarean
group whole blood free cysteine, oxidised cysteine, homocysteine and
glutathione and plasma cysteine and homocysteine levels dropped signif-
icantly after 24 hours, while f r a p levels peaked signiﬁcantly in this
group. Plasma vitamin e levels decreased signiﬁcantly in both groups
within 24 to 48 hours after delivery. Independent of the way of delivery
whole blood and plasma thiols were signiﬁcantly increased and vitamin e
levels were signiﬁcantly decreased three months postpartum while plas-
ma vitamin c levels and f r a p were unchanged compared to antepartum
levels. 
Conclusion: Decreased plasma vitamin e levels shortly after delivery
are associated with decreased lipid peroxidation. The 24 hours postpar-
tum drop of some plasma and whole blood thiols in the caesarean group
may be due to prolonged fasting.
i n t roduct ion
In uncomplicated pregnancies lipid peroxide concentrations increase
with advancing gestational age, possibly caused by a pronounced physio-
logical hyperlipidemia and production of lipid peroxides in the placenta
[1]. In addition, increased levels of reactive oxygen species (ros),
released by respiratory burst of neutrophiles are found in uncomplicated
pregnancies [2], although also decreased levels compared to the non-
pregnant state are reported [3]. In parallel with the rise in lipid peroxida-
tion various antioxidants increase during uncomplicated pregnancy,
such as vitamin e , vitamin c , glutathione peroxidase, ceruloplasmin, red
blood cell amino thiols, and net antioxidant activity [4-6]. One of the
most important intracellular antioxidants is glutathione, which can
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maintain the redox balance of cells by inhibition of lipid peroxidation,
either acting alone or in combination with glutathione peroxidases and
glutathione S-transferases [4]. In healthy people the formation of ros is
effectively counteracted by the antioxidant defence. Unless properly
counteracted an excess of ros causes oxidative stress, which may result
in glutathione depletion, lipid peroxidation, or membrane damage [7].
Labour is associated with generation of ros and lipid peroxidation
[8], possibly due to repetitive ischemia and reperfusion [9]. Within 24 to
48 hours after normal pregnancy a decrease is reported of lipid peroxides
and antioxidant activity [10]. However, Nakai et al. [11] found a signiﬁ-
cant increase of the antioxidants superoxide dismutase and catalase in
the ﬁrst 24 hours after delivery, which was ascribed to the physical stress
and pain of labour. 
In general, data on the postpartum course of the different antioxidant
levels are scarce. Vitamin e concentrations are decreased at three
months postpartum, though the time of onset of this decrease is
unknown [6]. The postpartum courses of other antioxidants, such as vi-
tamin c and plasma and whole blood glutathione levels as well as other
thiols have never been studied before. Therefore we studied the concen-
trations of the antioxidants vitamin e , vitamin c , plasma and whole
blood thiols, as well as antioxidant capacity, by measuring the f r a p , in
the peripartum period and throughout the puerperium of women with
uncomplicated pregnancies. 
m at er i a l a nd methods
Subjects
The study was performed between October 2000 and September 2001
at the University Medical Center Nijmegen, the Netherlands. The exper-
imental protocol was approved by the Medical Ethical Review Commit-
tee and each subject gave written informed consent. Seventeen healthy
women with uncomplicated, normotensive pregnancies, who delivered
by elective caesarean section, either in case of breech presentation or in
case of repeat caesarean section, and ten healthy, pregnant women with
uncomplicated, normotensive pregnancies, who all delivered vaginally
and spontaneously, were included before onset of labour. All caesarean
sections were performed under spinal anaesthesia.
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Blood samples
Women were studied longitudinally and blood was sampled within one
week before delivery and at seven occasions after delivery; e.g. 6 hours, 12
hours, 24 hours, 48 hours, 72 hours, 6 weeks, and 3 months postpartum.
Blood was collected into sterile evacuated blood collection tubes con-
taining ethylenediaminetetra-acetic acid (edta) or into dry collection
tubes for serum. Blood was sampled after fasting of at least 8 hours,
except for the samples 6, 12 and 24 hours postpartum of the vaginal
group. Whole edta blood was processed within half-an-hour for the
measurement of free and oxidised thiols as described before [12,13] and
stored at –80°C until analysis. The remaining whole blood was cen-
trifuged at 1500 x g for 15 minutes and the obtained plasma was used for
measurement of (total) plasma thiols, ferric reducing ability of plasma
(f r a p), vitamin c (ascorbic acid), and vitamin e (α-tocopherol), and
was stored either at –80ºC (vitamin c , vitamin e and f r a p) or at –30ºC
until analysis (plasma thiols). 
Processed plasma and whole blood samples were analysed for the con-
centrations of cysteine, homocysteine, glutathione, and cysteinylglycine
by high performance liquid chromatography (hplc) as described previ-
ously [12,13].
f r a p levels were measured spectrophotometrically and were
expressed as nmol Fe2+ equivalent/ml [14]. For the analysis of vitamins c
and e a hplc method was used, as described earlier [15].
Since vitamin e has the same carrier system in plasma as cholesterol
and triglycerides, which increases substantially during pregnancy [16],
vitamin e levels were also calculated as the ratio vitamin e to cholesterol
and the ratio vitamin e to triglycerides. Some investigators consider the
ratio vitamin e to cholesterol a more relevant marker than vitamin e
alone [17]. Haemoglobin, haematocrite, serum cholesterol and triglyc-
eride concentrations were measured at the routine clinical chemistry lab-
oratory of our hospital using standardised methods.
Statistical analysis
A. Concentration course during the ﬁrst three days after delivery
At forehand we expected these laboratory parameters to exert a fast
decline, followed by a slower recovery. Therefore we used a repeated
mixed model on each parameter separately, while accounting for the way
of delivery (being either vaginal delivery or caesarean section). 
At ﬁrst, we found that for nearly all laboratory parameters the model
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was statistical signiﬁcantly improved when a quadratic term in time was
included in the linear part of the model (Likelihood-Ratio test). This
indicates that the recovery of this parameter after stress, e.g. increase or
decrease, was reached already within three days postpartum. Further-
more, no signiﬁcant improvement was reached when the best model
found above was extended with either a higher-order-time term, or an
exponential term in time or a broken linear term in time. Inspection of
the residuals, using a saturated model, did not show deviation from nor-
mality of any of the parameters, which would have motivated to use a
quadratic or logarithmic transformation. After all, the following ﬁnal
mixed model was used for each laboratory parameter, separately. The
dependent variable was the laboratory parameter. The independent ran-
dom variable was ‘women’ and the independent continuous variable was
linear time (and quadratic time, respectively) and the independent class
variable was the way of delivery (vaginal, caesarean). Also the interaction
term between way of delivery and the time variable(s) was (were) includ-
ed in the model, allowing for differences in the course between the ways
of delivery.
The initial model we used is as follows:
Yi(tij) = β1 Ci + β2 nCi + (β3 Ci + β4 nCi ) * tij + (β5 Ci + β6 nCi ) * t2ij + b1i +
b2i * tij + b3i * t2ij + εij
Where i refers to subject and j to the time after partus, with the ﬁxed
effects β, the random effects b, C and nC are indicator variables for cae-
sarean and non-caesarean and εij is the normal distributed residual with
mean zero. Note that this implies that differences between women may
vary over time.
All regression parameters with standard errors of each laboratory
parameter are presented. The regression coefﬁcient of the quadratic
term is of particular interest. For instance, ﬁrst, a negative value indicates
a top level within three days postpartum and a positive value indicates a
bottom level within three days postpartum. Furthermore, the larger this
coefﬁcient in absolute terms, the steeper the course.
B. Concentration course six weeks and three months after delivery
The difference in mean levels of the laboratory parameter at six weeks
and three months postpartum compared to the mean level at the time of
delivery was analysed using a repeated mixed model, somewhat different
from the one described above. The dependent variable was the laborato-
ry parameter. The independent random variable was ‘women’ and the
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independent class variables were way of delivery (vaginal, caesarean) and
time (three levels: at delivery, six weeks after delivery and three months
after delivery). Also the interaction term between way of delivery and the
time variable was included in the model. The appropriate, adjusted
Tukey-Kramer contrast test were used to test for speciﬁc differences in
mean levels.
The estimated mean levels of the laboratory parameters with 95%
conﬁdence intervals are presented by each group and by each point of
measurement. 
Clinical and demographic characteristics were compared using
Mann-Whitney-U tests. A p-value below 0.05 was considered statistical-
ly signiﬁcant.
r e sults
The patient characteristics are presented in Table 1. Of all these, only ges-
tational age at delivery was slightly, but signiﬁcantly lower in the caesare-
an group than in the vaginal group. During pregnancy none of the
women smoked, but one woman of the caesarean group restarted smok-
ing two months after delivery. No signiﬁcant differences between base-
line levels of the two groups were found in any of the biochemical para-
meters. The calculated means at delivery are presented in Tables 2a and
2b .
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Table 1 Clinical and demographic characteristics of the study groups
Caesarean group Vaginal group
n = 17 n = 10
Age (yrs) 32 (27-38) 33 (26-41)
Primiparity 3 (18%) 4 (40%)
Gestational age at delivery (wks) 38+6 (37+6-41+2)a 40 (38-42+3)
Lactation
ﬁrst days postpartum 15 (88%) 7 (70%)
6 weeks postpartum 12 (71%) 5 (70%)
3 months postpartum 9 (53%) 5 (50%)
Diastolic blood pressure (mmHg) 70 (60-80) 63 (55-80)
Smoking before pregnancy 2 (12%) 2 (20%)
Data are presented as medians (min-max) or numbers (%). a p < 0.05
a n tiox ida n ts: befor e , dur ing a nd a f t er pr egna ncy 111
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A. Concentration course during the ﬁrst three days after delivery
The analysis of whole blood levels of free cysteine showed that none of
the parameterisations of time adequately ﬁtted to the data. A further
inspection showed that this was due to the mean level of free cysteine at
24 hours, being remarkable low in women who were delivered by cae-
sarean section. This time pattern is visualised in Figure 1 showing the
estimated and observed mean values of whole blood cysteine.
A similar pattern was observed in the mean whole blood levels of oxi-
dised cysteine, homocysteine and glutathione, although to a far lesser
extent, since these parameters ﬁtted adequately to the quadratic model.
During the ﬁrst 72 hours following delivery a signiﬁcant increase of
whole blood levels of free cysteine, oxidised cysteine, and oxidised
homocysteine was observed in women who were delivered vaginally,
whereas in the caesarean group mean whole blood levels of free cysteine
and oxidised cysteine, oxidised homocysteine and oxidised glutathione
increased after an initial signiﬁcant drop of levels (Table 2a).
Furthermore, statistical signiﬁcant differences in the time pattern, as
well in rise as in decline, between both groups were observed for the plas-
ma thiols (cysteine, homocysteine, cysteinylglycine and glutathione),
f r a p , cholesterol and ratio of vitamin e to cholesterol.
During the ﬁrst three days the mean levels of plasma thiols, f r a p and
ratio of vitamin e to cholesterol remained unchanged in the group of
vaginal delivery. However, among women who were delivered by cae-
sarean section the ﬁrst three days after delivery were characterised by a
temporary fall in concentrations of plasma cysteine and homocysteine
(Figures 2 and 3), a temporary increase of f r a p and the ratio of vitamin
e to cholesterol, whereas plasma cysteinylglycine and glutathione con-
centrations increased linearly during this time period. 
In both groups the mean cholesterol levels reached their lowest point
within three days after delivery, although in the caesarean group levels
are somewhat lower as compared to the vaginal group. All other parame-
ters, except those mentioned above, showed no difference in the time
patterns between both delivery groups. As a result, irrespective of way of
delivery, vitamin e (Figure 4), ratio of vitamin e to triglycerides, haemo-
globin and haematocrite decreased quadratically during the ﬁrst 72
hours after delivery, resulting in a bottom level near 36 hours after deliv-
ery. Furthermore, a statistically signiﬁcant linear increase in the mean
whole blood levels of free homocysteine and cysteinylglycine was
observed, whereas whole blood levels of free glutathione and serum
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Figure 1 Whole blood cysteine levels in both study groups
The lines represent the estimated course of concentrations. The vertical bars indicate 
± one standard error (SE). Vaginal group (◊; long dashes); caesarean group (x; solid line).
Note: In contrast to other parameters, for whole blood cysteine levels none of the para-
meterisations of time adequately fitted to the data. More data points would be needed
to obtain a satisfying model.
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Figure 2 Plasma cysteine levels in both study groups
The lines represent the estimated course of concentrations. The vertical bars indicate 
± one standard error (SE). Vaginal group (◊; long dashes); caesarean group (x; solid line)
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Figure 3 Plasma homocysteine levels in both study groups
The lines represent the estimated course of concentrations. The vertical bars indicate 
± one standard error (SE). Vaginal group (◊; long dashes); caesarean group (x; solid line)
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Figure 4 Plasma vitamin E levels in both study groups
The lines represent the estimated course of concentrations. The vertical bars indicate 
± one standard error (SE). Vaginal group (◊; long dashes); caesarean group (x; solid line)
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Table 3A The estimated mean levels (95% CI) of haematological parameters, vitamins, cholesterol and
triglycerides antepartum, six weeks and three months postpartum
antepartum 6 wks pp 3 mnths pp
Haemoglobin (mmol/L) 7.23 (7.02 - 7.45) 7.69 (7.48 - 7.89) 7.93 (7.75 - 8.12)
Haematocrite (L/L) 0.34 (0.33 - 0.35) 0.37 (0.36 - 0.38) 0.39 (0.38 - 0.40)
Cholesterol (mmol/L) 6.38 (5.87 - 6.89) 5.18 (4.69 - 5.67)a 4.94 (4.56 - 5.31)a
Triglycerides (µmol/L) 2.56 (2.29 - 2.83) 1.14 (0.85 - 1.42)a 1.02 (0.79 - 1.25)a
Vitamin E (µmol/L) 35.88 (33.09 - 38.) 26.7 (24.2 - 29.1) 23.8 (21.8 - 25.9)
Ratio vitamin E/cholesterol 5.64 (5.26 - 6.03) 5.18 (4.90 - 5.46) 4.85 (4.59 - 5.11)
Ratio vitamin E/triglycerides 14.6 (13.3 - 15.9) 29.3 (23.8 - 34.8)a 27.9 (23.3 - 32.4)a
Vitamin C (µmol/L) 45.5 (36.6 - 54.5)a 44.9 (30.8 - 59.1)a 43.1 (31.6 - 54.6)a
FRAP (nmol Fe2+ eq/mL) 352.1 (328.0 - 376.7)a 358.0 (334.7 - 381.3)a 357.5 (326.7 - 388.2)a
A, b, c: same letters, horizontally, indicate no statistical signiﬁcant difference between the points of
measurement.
FRAP = ferric reducing ability of plasma
triglyceride concentrations were characterised by a signiﬁcant linear
decrease. 
Oxidised cysteinylglycine and plasma vitamin c did not show signiﬁ-
cant differences in time, independent of the way of delivery. The ratios of
free to oxidised whole blood cysteine, homocysteine, glutathione, and
cysteinylglycine did not change during the ﬁrst three days, except for a
slight, signiﬁcant, increase in the ratios of cysteinylglycine and glu-
tathione among women in the caesarean group. 
B. Concentration course six weeks and three months after delivery
The repeated measurement analysis showed no statistical signiﬁcant dif-
ferences in concentration courses of any of the variables between the two
delivery groups. This is demonstrated in the examples presented in the
Figures 1 to 4, where the observed mean values (95% conﬁdence inter-
vals) in both groups at the three time points (antepartum, 6 weeks and 3
months postpartum) are compared. Therefore the long-term postpar-
tum course can be described irrespective of the way of delivery. 
In Tables 3a and 3b the estimated mean values at each of the three time
points are shown. 
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In general there were no statistical signiﬁcant differences between the
mean values of the thiols at six weeks and three months postpartum,
whereas both postpartum values are signiﬁcantly higher compared to
the antepartum value. The mean values of free cysteinylglycine, the ratio
of free to oxidised cysteine, vitamin c and f r a p were not signiﬁcantly
different between these three points of measurement, indicating a fairly
constant level. The concentration course of plasma glutathione showed a
pattern different from any of the other variables, namely the mean level
of glutathione increased signiﬁcantly at six weeks compared to antepar-
tum levels followed by a drop three months postpartum to a level that
was still signiﬁcantly higher than that antepartum. Furthermore, not
until three months postpartum, the mean ratios of free to oxidised of
both cysteinylglycine and glutathione were signiﬁcant lower compared
to corresponding antepartum ratios. This was also observed for vitamin
e and the ratio of vitamin e to cholesterol. Three months postpartum
only the mean values of haemoglobin and haematocrite were signiﬁcant-
ly increased. 
The mean values of the ratio of vitamin e to triglycerides followed a
recovery pattern similar to that of most of the thiols, a full recovery at
three months after child birth with the increase starting six weeks post-
partum. This also holds for the mean values of the cholesterol and
triglycerides, although decreasing in time. 
discussion
Despite the current interest for the oxidant-antioxidant system during
normal and compromised pregnancies, there are only a few studies on
antioxidant behaviour in the puerperium. This is the ﬁrst report in which
the exact time of onset of postpartum decrease of vitamin e is demon-
strated. We found decreased vitamin e levels between 24 and 48 hours
after delivery, which corresponds well with the decrease of lipid peroxi-
dation within 24 hours postpartum as reported by others [6]. Oosten-
brug et al. (1998) sampled maternal blood directly after delivery and
found no decrease of α-tocopherol levels, though two other forms of
tocopherol, e.g. δ and β + γ tocopherol, which are very potent antioxi-
dants as well, were decreased shortly after delivery as compared to levels
found at 32 weeks of gestation [18]. During pregnancy the lipophilic vita-
min e is one of the most important antioxidants, protecting against lipid
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peroxidation [19]. When the burden of free radical damage and lipid per-
oxidation disappears after delivery, vitamin e levels will gradually
decrease to non-pregnant levels, as found in our study where the decline
of concentrations continued until three months postpartum. During
pregnancy there is a major increase of cholesterol and triglycerides lev-
els, whereas these levels gradually decrease after delivery to non-preg-
nant levels [20]. Triglycerides declined faster than vitamin e concentra-
tions, resulting in an increased ratio of vitamin e to triglycerides after an
initial decrease during the ﬁrst three days. The ratio of vitamin e to cho-
lesterol acted in the opposite way, e.g. a decrease after an initial increase.
The courses of these ratios illustrate that vitamin e itself is diminished
after delivery and cannot only be explained by decreased concentrations
of triglyceride and cholesterol. Since only cholesterol and not triglyc-
eride levels are directly related to vitamin e levels , the vitamin e to cho-
lesterol ratio is probably the most important ratio [16].
Vitamin c exhibits multiple antioxidant properties and is one of the
most important extra-cellular antioxidants in humans [21]. It contributes
in the defence against lipid peroxidation due to its ability to regenerate
vitamin e by reducing α-tocopherol radicals to α-tocopherol [22]. In our
study the antepartum levels of vitamin c were not higher as compared to
non-pregnant levels in healthy individuals (normal range 50-200 mM)
[21]. Furthermore, we found no change of vitamin c levels in the puer-
perium. Various studies on vitamin c levels during normal pregnancy
reported a fairly constant level of vitamin c throughout pregnancy
despite a seasonal variation of vitamin c in some regions, and a rise in
concentrations up to 6 months postpartum as represented by Dostolova
[23]. Nevertheless, Woods et al. reported that vitamin c concentrations
were signiﬁcantly lower in women during delivery as compared to
women who underwent an elective caesarean section [9]. They postulat-
ed that this was due to generation of ros , caused by repetitive ischemia
and reperfusion of uterine tissue after each contraction. 
Remarkably we did not ﬁnd an effect of labour, neither for plasma vi-
tamin c and e , nor for plasma and whole blood thiols. Since in our study
the ﬁrst blood sample was obtained six hours after delivery, a possible
effect of labour might already have been disappeared. Moreover, the
ratios of free to oxidised thiols, a measure of oxidative stress [24], were
not changed, indicating that there was no signiﬁcant increase of oxida-
tive stress.
A second intriguing ﬁnding was the drop of the whole blood levels of
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free and oxidised cysteine, oxidised homocysteine, free and oxidised glu-
tathione, and plasma cysteine and homocysteine 24 hours after caesare-
an section, which most likely might be explained by the prolonged fast-
ing of 24 hours after caesarean section. Impairment of the nutritional
status, by fasting may result in lower levels of sulphur containing amino
acids, such as cysteine [25]. Since cysteine is the rate limiting amino acid
for synthesis of glutathione, fasting might result in a signiﬁcant decrease
of hepatic glutathione synthesis [26]. Inadequate intracellular concentra-
tions of glutathione are associated with a compromised antioxidant
defence system and an insufﬁcient capacity to combat free radicals [27].
In animal studies, general anaesthesia or hypoxia are associated with
increased formation of lipid peroxides and simultaneous depletion of
plasma vitamin E and glutathione levels [28]. Since all women in the cae-
sarean group received spinal anaesthesia, this probably did not affect our
study results. Increased f r a p concentrations 24 hours after delivery in
the caesarean group might be a reaction on the decreased levels of free
cysteine and glutathione. 
The third important ﬁnding of this study are the changes noted in the
late puerperium; i.e. three months after delivery plasma levels of cys-
teine, homocysteine, cysteinylglycine, and glutathione are increased,
which most likely is due to the diminished plasma volume as compared to
the pregnant values [29]. This is in line with a previous report from our
group, demonstrating lower plasma thiol levels during uncomplicated
pregnancies compared to levels in non-pregnant women [13]. Plasma glu-
tathione showed a peak level at six weeks postpartum, which was not due
to outliners as can be seen from the conﬁdence intervals, being as wide at
all three points of measurement, being antepartum, six weeks postpar-
tum and three months postpartum respectively. Lowered ratios of free to
oxidised levels of glutathione and other thiols indicate a shift in redox
balance toward more oxidised levels, and are interpreted as a direct
marker of oxidative stress [24]. Reduced glutathione is a very potential
scavenger of free radicals and peroxides [30]. Three months postpartum
lowered ratios of free to oxidised glutathione and cysteinylglycine were
demonstrated which might indicate the presence of oxidative stress. The
source of oxidative stress is unclear, and is not caused by re-start of
smoking since this involves only one woman in the caesarean group.
Multivitamin supplementation was only taken by four women (15%) in
the caesarean group and probably also did not affect our results. Since
the majority of the study population (n = 22) were breastfeeding we can-
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not draw any conclusion on the effect of lactation on parameters of
oxidative stress. Haemoglobin and haematocrite values dropped signiﬁ-
cantly shortly after delivery, most probably due to postpartum haemor-
rhage and by shift of extra vascular body water into the circulation [31].
From previous studies these concentrations are known to normalise to
non-pregnant levels four to six months after delivery [31], as was con-
ﬁrmed in our study. 
In conclusion, plasma vitamin e levels are lowered between 24 to 48
hours after delivery. Antioxidant capacity does not seem to decrease
within 24 hours postpartum. However, fasting after caesarean section
may negatively inﬂuence concentrations of some important plasma and
whole blood thiols. 
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PART IV 
Biochemical parameters of preeclampsia

CHAPTER 9
Levels of plasminogen activators and their inhibitors 
in maternal and umbilical cord plasma 
in severe preeclampsia
Eva Maria Roes, C.G. Fred Sweep, Chris M.G. Thomas, 
Petra L.M. Zusterzeel, Anneke Geurts-Moespot, 
Wilbert H.M. Peters, Eric A.P. Steegers
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a bst r act
Aim: The purpose of this study was to evaluate the plasminogen activator
system in maternal and umbilical cord plasma in patients with severe
preeclampsia compared with control subjects with normotensive preg-
nancies.
Material and methods: Maternal blood was sampled from 42 patients at
a median gestational age of 32 weeks. After delivery, arterial and venous
umbilical cord blood was sampled from 37 and 36 of these patients,
respectively. Maternal blood from women with uncomplicated pregnan-
cies was sampled at the gestational age of 32 weeks (n = 18, group i), and
umbilical cord blood was sampled after premature deliveries of nor-
motensive pregnancies (n = 5, group ii). Data were analysed with the use
of Mann-Whitney-U tests.
Results: Patients had signiﬁcantly higher tissue plasminogen activator
(p < 0.01) and unchanged urokinase plasminogen activator plasma levels
compared with control subjects at 32 weeks of gestation; lower plasmino-
gen activator inhibitor type 2 (p < 0.01) and no different plasminogen
activator inhibitor type 1 concentrations were observed compared to
control subjects at 32 weeks of gestation. In the arterial and venous
umbilical cord plasma of patients plasminogen activator inhibitor type 1
levels were signiﬁcantly higher (p < 0.01) compared with control subjects
at 32 weeks of gestation, although urokinase plasminogen activator levels
in arterial and venous umbilical cord plasma (p < 0.01) were signiﬁcantly
lower.
Conclusion: Lower plasminogen activator inhibitor type 2 levels are
associated with placental insufﬁciency, and higher tissue plasminogen
activator levels with endothelial dysfunction in patients with severe
preeclampsia. The higher plasminogen activator inhibitor type 1 levels
and lower urokinase plasminogen activator levels in umbilical cord of
these patients are suggestive of decreased ﬁbrinolysis in the foetal circu-
lation.
i n t roduct ion
The serine proteases, urokinase-type and tissue-type plasminogen acti-
vators (upa and tpa) convert the proenzyme plasminogen into plasmin.
upa is produced in the kidney, macrophages, and placenta [1]. Apart
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from its function in urinary ﬁbrinolysis, upa is important for the growth
and remodelling of tissues and in tissue repair [2]. The plasminogen acti-
vator inhibitor type-2 (pa i-2), which is produced mainly by trophoblasts
[3], plays an important role in counteracting upa . tpa is produced by
endothelial cells and is mainly kept in balance by the plasminogen activa-
tor inhibitor type-1 (pa i-1), which is produced not only by endothelial
cells, but also by activated platelets, placental vasculature, and tro-
phoblasts [2]. During pregnancy, decidual tissue is another site of tpa
production [4]. 
The plasminogen activator (pa) system in pregnancy may have different
functions. upa , pa i-1, and pa i-2 have important roles in the degradation
and proteolysis of the decidua to secure adequate trophoblast invasion [5].
Furthermore, after placental separation adequate haemostasis necessi-
tates decreased ﬁbrinolysis and increased coagulation [6]. pa i concen-
trations rise signiﬁcantly throughout uncomplicated pregnancy, con-
comitantly with small increases of the plasminogen activators tpa and
upa plasma levels [7-12]. 
Preeclampsia occurs with extensive changes in the plasminogen acti-
vator system, indicating a further reduction in ﬁbrinolysis compared to
uncomplicated pregnancies [1,9,13-23]. Extensive placental infarction in
patients with preeclampsia is characterised by higher plasma pa i-1 levels
and lower plasma pa i-2 levels than in uncomplicated pregnancies [14]. In
general, pa i-2 is considered a good marker of placental function,
because of its selective production by trophoblasts [24].
In contrast to adults, neonates have increased ﬁbrinolytic activity,
mainly because of increased production of pa ’s and reduced levels of the
ﬁbrinolysis inhibitors α2-antiplasmin and histidine-rich glycoproteins
[25-27]. This might protect against the possible occurrence of intravas-
cular ﬁbrin deposits after placental separation. We hypothesise that
apart from an effect on maternal levels in preeclampsia, the offspring of
these mothers are inﬂuenced by altered activities in the foetal pa system
as well.
To test this hypothesis, we investigated the maternal and foetal plasma
concentrations of upa , tpa , pa i-1, and pa i-2 in severely preeclamptic
women with or without hellp (haemolysis – elevated liver enzymes –
low platelets) syndrome compared with normotensive pregnant control
subjects.
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m at er i a l a nd methods
Subjects
The study group comprised 21 patients with severe preeclampsia and 21
patients with preeclampsia and concurrent hellp syndrome
(pe/hellp). Maternal blood was sampled at admission to the hospital
at the mean gestational age of 32 weeks and after delivery; 37 samples of
arterial umbilical cord plasma (preeclampsia [n = 20], pe/hellp [n =
17]) and 36 samples of venous umbilical plasma (preeclampsia [n = 19],
pe/hellp [n = 17]) of these patients were obtained. Among the group of
patients, the median time lapse between admission and delivery was 1
day (range, 0-21 days). All women of the term control group were deliv-
ered at the day of admittance. The 32-weeks maternal plasma and umbili-
cal cord samples were from two different control groups.
The following controls were used in the present study: At the mean
gestational age of 32 weeks, maternal blood was drawn from 18 women
with uncomplicated pregnancies (group i). The second control group
comprised 5 women with normotensive pregnancies who delivered pre-
maturely at a mean gestational age of 32 weeks and provided arterial
(except in one case) and venous umbilical cord blood specimens (group
ii). The maternal plasma and umbilical cord samples at 32 weeks of ges-
tation were from two different control groups. To assess the effect of
increased gestational age on the plasma concentration of the analytes
that were tested, we also collected blood samples (both maternal and
umbilical cord blood) from 15 women with uncomplicated pregnancies
at a mean gestational age of 38 weeks (group iii). 
All the women gave informed consent. The study protocol was
approved by the local Ethics Committee. 
Severe preeclampsia was deﬁned as a diastolic blood pressure ≥ 110
mmHg measured at least two times with an interval of four hours, and
proteinuria of at least 300 mg/L, according the criteria of the Interna-
tional Society for the Study of Hypertension in Pregnancy (isshp). The
hellp syndrome was biochemically characterised as featuring a lactate
dehydrogenase concentration ≥ 600 iu/l , alanine transferase (a lt) and
aspartate transferase (a st) ≥ 70 iu/l and thrombocytopenia with
thrombocyte count rates < 100 x 109/L . Small-for-gestational-age was
deﬁned as a birth weight below the 2.3th percentile [28].
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Methods
All pregnant women underwent punction of their brachial vein, and
blood was drawn into sterile tubes containing ethylene diaminetetracetic
acid (edta) (Sherwood Medical, Ballymore, Northern Ireland). Within
1 hour after collection whole blood was centrifuged at 1500 x g for 10
minutes and plasma was stored in small aliquots at –30 °C until analysis.
Arterial and venous umbilical cord blood samples were drawn in prehep-
arinised tubes immediately after delivery and after the cord was
clamped.
The plasma concentrations of upa , tpa , pa i-1, and pa i-2 were assayed
with el isa procedures, as developed and described by Grebenschikov
et al. [29].
Statistical analyses
Clinical and demographic characteristics were compared with Chi-
square test and Student’s t-tests, as appropriate. 
Maternal plasma levels of the components of the pa system were com-
pared between patients and control subjects at the gestational age of 32
weeks (group i). Likewise, arterial and venous umbilical cord plasma lev-
els of the components of the pa system were compared between patients
and the 32-week control subjects (group ii). Maternal and umbilical cord
blood at the gestational age of 32 weeks was taken from two different
control groups and, for this reason, could not be analysed by paired tests.
To assess the effect of increasing gestational age on the components of
the pa system, maternal and umbilical cord plasma levels at 32 weeks of
pregnancy (group i and ii) were compared with the results that were
obtained at 38 weeks of pregnancy (group iii). All tests were performed
using the non-parametric Mann-Whitney-U test. In view of the multiple
testing, a probability value of < 0.01 was considered to indicate statistical
signiﬁcance.
r e sults
Clinical and demographic data are depicted in Table 1. In the control
groups, there were no infants with birth weights below the 2.3th per-
centile compared with 5% in the patients group. Mean placental weight
within the preeclamptic group was signiﬁcantly lower compared with
the control group i (p < 0.001), although not compared with control
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Table 1 Characteristics of control groups and patients
32-weeks 32-weeks term controls patients
controls controls
(group I) (group II) (group III)
n = 18 n = 5 n = 15 n = 42
Primiparous 9 (50) 3 (60) 6 (40) 34 (81)
Diastolic blood pressure (mmHg) 70 ± 6** 74 ± 4** 75 ± 8** 109 ± 9
Gestational age at sampling (wks) 32.1 ± 1.9 32.9 ± 0.6 38.5 ± 1 31.9 ± 3.3
Gestational age at delivery (wks) 38.7 ± 2.1 32.9 ± 0.6 38.5 ± 1 32.3 ± 3.2
Primary cesarean delivery 0 0 15 (100) 37 (88)
General anaesthesia - - 0 24 (65)
Birth weight (g) 3281 ± 581** 2011 ± 412 3512 ± 610** 1460 ± 660
Small for gestational age (< p 2.3) 0 0 0 2 (5)
Placental weight (g) 549 ± 121*** 444 ± 75 652 ± 126*** 320 ± 136
Data are presented as means ± SD and numbers (%).
Control group vs. patients: * p < 0.05; ** p < 0.01; ***p < 0.001
0
10
20
30
40
50
60
70
80
90
100
*
*
controls (group I)
patients
(n
g
/m
l)
uPA tPA PAI-1 PAI-2
Figure 1 Median concentrations of uPA, tPA, PAI-1 and PAI-2 in maternal plasma
uPA tPA PAI-1 PAI-2
controls 2.5 (1.0 - 4.5) 5.4 (2.5 - 9.0) 81 (36 - 134) 80 (43 - 99)
patients 1.7 (0.3 - 5.3) 11.3 (1.2 - 26) 100 (36 - 200) 51 (1 - 100)
Data are presented as medians and ranges (ng/ml); * p < 0.01
group ii . Most of the patients received magnesium sulphate (70%) and
some kind of antihypertensive medication (64%). Twenty-one of the
patients (50%) and one woman in control group ii received intramuscu-
lar corticosteroid injections for foetal lung maturation.
The initial analysis of the data did not reveal differences in maternal
and in umbilical cord plasma levels between preeclamptic patients with
or without hellp syndrome; therefore all data were analysed for the
combined group of patients.
Maternal levels in patients and 32-weeks controls (group i)
Maternal plasma upa levels were not different between patients and con-
trol subjects at 32 weeks of gestation, whereas tpa levels were signiﬁcant-
ly higher (p < 0.01, Figure 1). There was no signiﬁcant difference in
maternal pa i-1 levels between patients and control subjects at 32 weeks
of gestation, although the pa i-2 concentrations were signiﬁcantly lower
(p < 0.01) in the patients (Figure 1).
Arterial and venous umbilical cord plasma levels in patients and
32-weeks controls (group i i)
Arterial and venous umbilical cord levels of upa were signiﬁcantly lower
in patients compared to control subjects at 32 weeks of gestation (Figure
2a). Arterial and venous umbilical upa and tpa concentrations were not
different from each other, neither in patients nor in control subjects. Fur-
thermore, patients have dramatically signiﬁcantly higher pa i-1 levels in
arterial and venous umbilical cord plasma compared with control sub-
jects at 32 weeks of gestation. pa i-2 concentrations in umbilical cord
plasma were not different between patients and the control subjects at 32
weeks of gestation. Arterial and venous umbilical cord plasma levels of
pa i-1 were not signiﬁcantly different, neither in patients nor in control
subjects (Figure 2b). 
Effect of gestational age on maternal levels
Median maternal plasma levels of upa and tpa in term controls were 2.5
ng/ml and 5.1 ng/ml, respectively, and were not signiﬁcantly different
from those determined at 32 weeks of pregnancy (2.5 ng/ml and 5.4
ng/ml, respectively). Median pa i-1 and pa i-2 levels in maternal blood of
term controls were 85 ng/ml and 84 ng/ml, respectively, and were not sig-
niﬁcantly different from those sampled at gestational age of 32 weeks (81
ng/ml and 80 ng/ml, respectively) (Table 2, Figure 1).
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Figure 2A Median concentrations of uPA and tPA in umbilical cord plasma
uPA _ art uPA _ven tPA _art tPA _ven
controls 1.3 (0.9 - 1.7) 1.2 (0.6 - 1.8) 3.0 (1.7 - 7.5) 2.0 (0.6 - 3.8)
patients 0.7 (0.3 - 1.1) 0.6 (0.3 - 1.3) 1.4 (0.2 - 9.1) 1.4 (0.2 - 4.3)
Data are presented as medians and ranges (ng/ml); * p < 0.01
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Figure 2B Median concentrations of PAI-1 and PAI-2 in umbilical cord plasma
PAI-1_art PAI-1_ven PAI-2_art PAI-2_ven
controls 4.4 (3.6 - 9) 4.1 (2.2 - 23) 2.2 (1.5 - 12) 2.0 (1.7 - 2.3)
patients 35 (5.9 - 213) 23.5 (6.3 - 220) 2.0 (1.2 - 46) 2.1 (0.9 - 56)
Data are presented as medians and ranges (ng/ml); * p < 0.01
Effect of gestational age on arterial and venous umbilical cord
levels
Arterial and venous umbilical cord concentrations of upa after term
pregnancies were lower (p < 0.01) compared to those after 32 weeks of
gestation (0.7 ng/ml vs. 1.3 ng/ml and 0.9 ng/ml vs. 1.2 ng/ml, respective-
ly). Arterial tpa concentrations in arterial umbilical cord plasma were
lower (p < 0.01) after term pregnancies (1.0 ng/ml) compared with 32
weeks of gestation (3.0 ng/ml). Venous umbilical cord concentrations
were also lower (p < 0.01) at term compared with 32 weeks of gestation
(0.6 ng/ml vs. 2.0 ng/ml, respectively; Table 2, Figure 2a). Opposed to
this, arterial and venous pa i-1 umbilical cord concentrations after term
pregnancies were higher (p < 0.01) compared with control subjects at 32
weeks of gestation (18.8 ng/ml vs. 4.4 ng/ml and 14.4 ng/ml vs. 4.1 ng/ml,
respectively). pa i-2 plasma concentrations in arterial and venous umbil-
ical cord plasma were not different (2.3 ng/ml vs. 2.5 ng/ml and 2.2 ng/ml
vs. 2.0 ng/ml, respectively; Table 2, Figure 2b).
discussion
This study showed that patients with preeclampsia have lower pa i-2
maternal plasma concentrations, whereas tpa concentrations were high-
er and pa i-1 and upa concentrations were not different, as compared
with those of control subjects. The most intriguing ﬁndings of our study
were the markedly higher pa i-1 concentrations in arterial and venous
umbilical cord plasma and the lower concentrations of upa in arterial
and venous umbilical cord plasma. Because of the possible effects of
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Table 2 Median concentrations of uPA, tPA, PAI-1 and PAI-2 in plasma and umbilical cord plasma from 
term controls (group III)
uPA tPA PAI-1 PAI-2
(ng/ml) (ng/ml) (ng/ml) (ng/ml)
Maternal plasma 2.5 (1.4 - 3.2) 5.1 (2.9 - 21) 85 (50 - 165) 84 (50 - 125)
Arterial umbilical cord plasma 0.7 (0.6 - 1.3) 0.95 (0.4 - 6.4) 18.8 (6.8 - 54) 2.3 (1.6 - 3.8)
Venous umbilical cord plasma 0.9 (0.6 - 1.9) 0.6 (0.2 - 1.1) 14.4 (6.4 - 49) 2.2 (1.3 - 3.5)
Data are presented as medians and ranges (ng/ml).
increasing gestational age on the components of the pa system, we com-
pared maternal and umbilical cord plasma samples of pregnant control
subjects at 32 weeks of gestation instead of controls who delivered after
term pregnancies. 
Despite the lack of differences between maternal blood concentra-
tions at 32 weeks of gestation and at-term levels, there was a signiﬁcant
effect of increasing gestational age on umbilical cord blood concentra-
tions. Åstedt and Lindoff found higher levels of tpa , pa i-1, and pa i-2
after term deliveries compared to premature deliveries and no difference
in upa levels [30]. However, Ekelund and Finnström reported no signiﬁ-
cant differences in overall ﬁbrinolytic activity between preterm infants,
small-for-gestational-age infants, and healthy full-term infants [31]. This
discrepancy in results may be partly due to differences in blood sam-
pling. Åstedt and Lindoff sampled blood before clamping of the umbili-
cal cord; Ekelund and Finnström sampled more than one hour after
delivery; we sampled directly after the delivery after clamping the cord.
Because in our study there were signiﬁcant effects of gestational age on
levels of the components of the pa system, this stresses the need to use
control subjects who are matched for gestational age in studies on the pa
system in pregnancy. Moreover, to rule out possible inﬂuences of prema-
ture labour we used maternal plasma of women with uncomplicated
pregnancies, who subsequently delivered at term.
We did not ﬁnd differences in maternal upa concentrations between
patients and control subjects, matched for gestational age. Results of ear-
lier reports present conﬂicting results concerning this issue. Overall,
during preeclampsia, upa plasma levels are lower as compared with con-
trols of the same gestational age, and particularly, if preeclampsia is com-
plicated by intrauterine growth restriction [9,16]. Among most of our
patients with severe preeclampsia, intrauterine-growth-restriction was
not present, which might explain why we did not ﬁnd lower upa levels.
Higher tpa levels in maternal plasma of preeclamptic patients compared
to controls are in accordance with other reports [1,9,15]. Higher tpa
maternal plasma concentrations may be due to vascular alterations and
endothelial activation [1].
We found no signiﬁcant difference in plasma levels of pa i-1 in pre-
eclamptic patients compared with control subjects, which is in accord-
ance with results of Nakashima et al. [9]. However, other reports dealing
with the pa system in patients with preeclampsia presented signiﬁcantly
higher pa i-1 concentrations in preeclampsia compared with uncompli-
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cated pregnancies. Halligan et al. [15] and Gilabert et al. [17] did not
speciﬁcally mention separate analyses of patients who also had hellp
syndrome in their study groups [15,17]. We performed a separate analysis
between patients with preeclampsia and patients with preeclampsia and
hellp syndrome and did not ﬁnd differences in maternal pa i-1 levels
between these two groups. This suggests that the heterogeneity of our
study population most likely does not explain the discrepancy between
our results and these reports [15,17]. Because of the involvement of pa i-1
in various pathophysiologic processes, such as impaired endothelial and
placental function and platelet activation [2], pa i-1 might be a non-spe-
ciﬁc marker of preeclampsia. In our study, patients have signiﬁcantly
lower maternal levels of pa i-2 than control subjects, which is in line with
earlier reports [9,15,17]. This is suggestive for impaired placental func-
tion. 
Because preeclampsia has been associated with development of car-
diovascular disease at a later age and an association of reduced ﬁbrinolyt-
ic activity with cardiovascular disease was demonstrated [32], the distur-
bance of the pa system in preeclampsia might be seen as a predisposing
factor. The 4g/4g mutation of the pa i-1 gene has been associated with
preeclampsia [33], and involvement of this mutation in cardiovascular
disease has been reported [34].
Another important effect of impairment of the pa system in pre-
eclampsia may be found in the foetal ﬁbrinolytic system. In general, ﬁbri-
nolytic activity in neonates is higher as compared with adult levels [27]
and in particular to maternal levels [26,35]. This may protect the neonate
against intravascular ﬁbrin deposits, which may be generated after pla-
cental separation. 
We did not observe differences between arterial and venous concen-
trations for upa , tpa , pa i-1, and pa i-2 in umbilical cord plasma in
patients and control subjects, therefore no assumption can be made
about production or breakdown of these components of the pa system
by the foetus itself. 
Previous reports that speciﬁcally dealt with the pa system in neonates
who were born after preeclamptic pregnancies, are scarce. Condie
reported depressed ﬁbrinolytic activity in umbilical vein blood of pre-
eclamptic pregnancies compared with uncomplicated pregnancies [36].
Bonnar et al. mentioned higher levels of plasminogen activator and pa i-1
in preeclampsia than in normal pregnancy [10]. We found lower levels of
upa in venous and arterial umbilical cord plasma of patients compared
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with gestational-age-matched control subjects. Lower levels of the uroki-
nase plasminogen activator implicate decreased ﬁbrinolysis and are pos-
sibly due to placental insufﬁciency. Another sign of decreased ﬁbrinoly-
sis in these children can be found in the higher pa i-1 levels in arterial and
venous umbilical cord plasma of patients compared with our gestational-
age-matched control subjects. pa i-2 levels in umbilical cord plasma are
not different between patients and 32-week-control subjects nor when
compared with term control subject levels. Because there is no difference
in placental weight between control group ii and patients, this probably
does not explain the differences in pa system. Intrauterine growth
restriction is a factor resulting in decreased ﬁbrinolysis [10]. The preva-
lence of small-for-gestational-age infants among our patients, however,
was only 5%, and therefore probably does not exclusively explain our
results. 
Many of our patients received antihypertensives. A direct association
between methyldopa, ketanserine, and magnesium sulphate and the lev-
els of the pa system is not known [37,38]. Corticosteroid administration,
however, might be involved in increased pa i-1 and tpa concentrations.
Since 50% of our patients group received corticosteroid injections, we
cannot rule out this effect entirely.
A difference between patients and control subjects at 32 weeks of ges-
tation, who were delivered prematurely, is the absence of labour among
patients. During labour tpa and pa i-1 concentrations increase markedly
[39]. Nevertheless, in our study pa i-1 concentrations are signiﬁcantly
higher among patients, most of whom delivered by caesarean section
without labour, as compared with the control subjects at 32 weeks of ges-
tation, who all delivered vaginally. General anaesthesia is known to
slightly increase pa i-1 levels during the ﬁrst 24 hours after surgery [40].
There are no reports on its effects on umbilical plasma levels. Because
most of the patients underwent caesarean delivery with general anaes-
thesia, some association of the general anaesthesia and increased pa i-1
concentrations in umbilical cord blood cannot be ruled out. 
The disturbance of the pa system in umbilical cord plasma may enhance
the risk for thrombo-embolic complications in the foetus of preeclamp-
tic mothers. Established risk factors for neonatal thromboembolism are
asphyxia, septicaemia and placement of an arterial central line [41],
which are probably more common in preterm and small-for-gestational-
age infants than in children who were born after uncomplicated term
138 pa rt i v
pregnancies. However, there are no speciﬁc reports of a higher incidence
of neonatal thrombo-embolic complications born to mothers with pre-
eclampsia with or without the hellp syndrome. 
However, Impey et al. reported a clear association between pre-
eclampsia at term and the occurrence of neonatal encephalopathy [42].
We hypothesise that this might be related to the decreased ﬁbrinolysis,
present in umbilical cord plasma of women with preeclampsia.
In conclusion, the pa system is disturbed in maternal and in umbilical
cord blood in preeclampsia and the hellp syndrome. Signiﬁcant differ-
ences in pa and inhibitor concentrations in maternal plasma of patients
with preeclampsia reﬂect important underlying processes involved in
this disease, such as endothelial dysfunction and malplacentation. High-
er pa i-1 levels and lower upa levels in umbilical cord plasma of the
patients, both arterial and venous, point to decreased ﬁbrinolysis in
neonates born to mothers with preeclampsia. It remains to be investigat-
ed whether this actually leads to a higher risk for thrombo-embolic com-
plications in these children.
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Increased plasma v egf concentrations are found in preeclampsia, pos-
sibly linked with local placental ischemia or endothelial dysfunction
i n t roduct ion
Vascular endothelial growth factor (v egf) is one of the angiogenic
growth factors important for placental growth and differentiation [1]. At
the end of the ﬁrst trimester of pregnancy, v egf concentrations in
serum are 4 to 5 times higher as compared to non-pregnant values, inde-
pendent of later development of preeclampsia [2]. In women with
preeclampsia, v egf concentrations further increase until the end of
pregnancy, whereas these concentrations remain stable throughout
pregnancy in uncomplicated pregnancies [2]. Possible explanations for
the increased v egf concentrations are up-regulation of v egf produc-
tion due to local placental ischemia [3] or increased production by dam-
aged endothelium as a mechanism of endothelial repair [4].
Vascular permeability and increased coagulation, characteristic fea-
tures of preeclampsia, strengthen the evidence for a role of v egf in
preeclampsia [5]. Bosio et al. demonstrated an association between ele-
vated plasma v egf concentrations and increased total peripheral vascu-
lar resistance in women with preeclampsia [2]. v egf is highly expressed
in the adrenal glands, lung epithelia and kidney glomeruli [6]. Glomeru-
lar endothelial cells secrete v egf , possibly in order to protect the
integrity of the local vascular endothelium. Overexpression of v egf
within the glomeruli may result in increased glomerular permeability for
macromolecules leading to proteinuria [7]. Many proteinuric renal dis-
eases are accompanied by increased urinary v egf excretions [8]. As
proteinuria is a key feature of preeclampsia, one could hypothesise that
this disease is also associated with increased urinary v egf excretion. 
During pregnancy a substantial part of v egf is bound to plasma pro-
teins such as the soluble form of the fms-like tyrosine receptor (sFlt-1)
[9,10]. As a consequence, this bound v egf might only partly or not at
all, be detected by highly speciﬁc sandwich-type assays (el isa). There-
fore, we suggest that urinary and plasma v egf concentrations, as meas-
ured by el isa both reﬂect the unbound proportion of systemic v egf
production in pregnant women. In the present study we investigated uri-
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nary v egf excretion in women with severe preeclampsia and its relation
with proteinuria, compared to that in healthy pregnant and non-preg-
nant women.
m at er i a l a nd methods
The Medical Ethical Review Committee of the University Medical Cen-
ter Nijmegen, the Netherlands approved the experimental protocol and
all subjects gave written informed consent. Urine samples were collected
from 37 women with severe preeclampsia and/or hellp syndrome (pe),
32 pregnant controls (pc) during uncomplicated pregnancies and 30
non-pregnant women (np) with previous uncomplicated pregnancies
only. Severe preeclampsia was deﬁned as a diastolic blood pressure of 110
mmHg or higher, measured at least twice with an interval of four hours,
and proteinuria of at least 300 mg/l . The hellp syndrome was bio-
chemically characterised as featuring a lactate dehydrogenase concen-
tration of at least 600 iu/l , alanine aminotransferase and aspartate
aminotransferase of at least 70 iu/l and thrombocytopenia of below 100
x 109/L .
Urine samples were collected randomly during the day. The collected
samples were centrifuged for 10 minutes at 3,000 g and the supernatant
was mixed with a storage buffer to ascertain a stable pH and to prevent
bacterial growth. This storage buffer was a solution of 1 m hepe s (pH
7.5), containing 5% (w/v) bovine serum albumin, 1% (w/v) sodium azide,
1% (v/v) Tween 20, and 10% (v/v) glycerol.
Antigen levels of v egf in urine were measured by a speciﬁc el isa as
described by Span et al. [11]. The assay applies a combination of four
polyclonal antibodies (raised in four different animal species) employed
in a sandwich assay format to exclude heterophilic antibody interference
[12]. To increase the sensitivity of the v egf assay, the hr p labelled goat
anti-rabbit detection antibody was replaced by a goat anti-rabbit IgG
Biotin conjugate (#B-9642, Sigma, Chemical Co, St. Louis, mo), strep-
tavidin-labeled ∃-Galactosidase (#1112481, Boehringer Mannheim, Ger-
many) was used as enzyme and 4-methylumbelliferyl-∃-D-galactopyra-
noside (mug , Sigma Chemical, St. Louis, mo) as substrate. In this assay
distinct molecular forms of v egf , like v egf-165 and v egf-121 are
measured. No cross-reactivity could be demonstrated with several other
growth factors [11]. The analytical sensitivity of the v egf assay is 0.005
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ng/ml. The within-assay and between-assay coefﬁcients of variation are
8.7% and 13.4%, respectively.
In each urine sample the creatinine concentration was measured and
v egf concentrations were expressed as nanograms per mmol creati-
nine. v egf/mmol creatinine concentrations were compared between
the groups using Mann-Whitney-U tests and correlations were assessed
with Spearman rank coefﬁcient of correlation using spss 9.0 for Win-
dows. A p-value < 0.05 was considered signiﬁcant.
r e sults
The clinical characteristics of the three study groups (pe , pc , np),
expressed as median (range), were as follows: maternal age was signiﬁ-
cantly lower (p < 0.001) in pe (28, 21-41 years) as compared to pc (32, 25-
39 years) and np (34, 29-42 years); diastolic blood pressure (Korotkoff V)
was signiﬁcantly higher (p < 0.001) in pe (115, 100-120 mmHg) as com-
pared to pc (68, 58-80 mmHg) and np (78, 62-88 mmHg); proteinuria
was signiﬁcantly higher (p < 0.001) in pe (3.63, 0.1-27.4 g/10 mmol crea-
tinine) compared to np (0.05, 0.01-0.09 g/10 mmol creatinine) whereas
urine of pregnant controls was tested negative for protein with the 
urinary dipstick test; gestational age at sampling was similar in pe (29+3,
22+4-390 weeks) and in pc (30, 29+5-39+2 weeks); gestational age at 
delivery was signiﬁcantly lower (p < 0.001) in pe (36+5, 24+6-41+6 weeks)
compared to pc (400, 35+7-41+6 weeks); and birth weight was signiﬁcant-
ly lower (p < 0.001) in pe (2670, 330-4690 g) compared to 3410 (2595-
4690 g) in pc .
The urinary v egf/creatinine ratios are depicted in Table 1. In women
with severe preeclampsia, v egf excretion was signiﬁcantly (p < 0.0001)
higher compared to pregnant and non-pregnant controls. v egf excre-
tion was not signiﬁcantly different between women with severe
preeclampsia only (63.8, 35.5-148.0 ng/ mmol creatinine) and those with
additional hellp syndrome, (44.1, 21.1-134.7 ng/mmol creatinine).
There were neither signiﬁcant correlations between v egf excretion and
proteinuria (r = 0.072; p = 0.68), nor between v egf excretion and dia-
stolic blood pressure (r = 0.253; p = 0.13), both assessed within the group
of patients with preeclampsia. The correlation of v egf with gestational
age was assessed with the overall group but there was no signiﬁcant cor-
relation (r = –0.101; p = 0.41). 
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discussion
This is the ﬁrst study evaluating urinary v egf concentrations in women
with severe preeclampsia. In our study healthy, non-pregnant and preg-
nant controls had similar urinary v egf concentrations, which can be
explained by concomitant increases of the concentration of v egf and its
binding proteins in plasma during pregnancy. The substantial increases
of urinary v egf concentrations in severe preeclampsia may be ex-
plained by an even more dramatic increase of systemic v egf than its
binding proteins, leading to a net increase of unbound v egf detected in
the urine specimens. Another more feasible explanation may be that the
elevated urinary v egf concentrations in severe preeclampsia reﬂect
local renal v egf production.
In normal kidneys, v egf is mainly present in glomerular epithelial
cells and to a lesser extent in distal tubular and connecting duct cells as
well as in the juxtaglomerular areas [13-15]. We presume that endothelial
damage of the glomeruli, as found in preeclampsia, may result in
increased v egf excretion due to local endothelial damage [16].
Additionally, during preeclampsia the renal vascular system is hypo-
perfused, probably resulting in local hypoxia and subsequent increased
v egf production, a mechanism similar to that in patients with chronic
renal failure. This may result in increased vascular permeability of the
glomerular endothelium [17]. Proteinuria was not signiﬁcantly correlat-
ed with urinary v egf levels, indicating that v egf is not a marker of pro-
teinuria, but rather a pathophysiological sign of renal damage. In oncolo-
gy research v egf is recognised as one of the most important angiogenic
cytokines, overexpressed in human cancer cells [18]. Except for bladder
cancer, in which urinary v egf levels are very useful in diagnosing pri-
mary or recurrent cancer [19], its role as a non-invasive marker is still
unknown.
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Table 1 Urinary VEGF excretion 
PE PC NP
n = 37 n = 32 n = 30
VEGF 
(ng/mmol creatinine) 54.0 (19.9-192.4)* 28.2 (6.7-63.0) 29.5 (10.1-59.1)
Data are presented as medians (ranges). * p < 0.0001
In conclusion, high urinary v egf concentrations in severe pre-
eclampsia might rather reﬂect increased renal production of v egf than
elevated v egf levels in the systemic circulation.
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CHAPTER 11
Urinary glutathione S-transferase p1-1 excretion is markedly
increased in normotensive pregnancy 
as well as in preeclampsia
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Background: Glutathione S-transferases (gst ’s) are highly present in
the human kidney, where they demonstrate a speciﬁc distribution.
Assessment of urinary excretion of glutathione S-transferase alpha
(proximal tubules) and pi (distal and collecting tubules) might be helpful
in determining if, and to what degree renal tubular damage is present in
preeclampsia and whether such damage is in the proximal or distal
region. 
Material and methods: Urine samples were collected of 22 women with
severe preeclampsia and/or hellp syndrome (pe), 30 non-pregnant
women with a history of severe preeclampsia (hpe), 18 women with
uncomplicated pregnancies (pc) and 30 non-pregnant women with a
history of uncomplicated pregnancies (hpc). gsta1-1 and gst p1-1
were assayed by el isa and were expressed as nanograms per 10 mmol
creatinine.
Results: Median (5th – 95th percentiles) gst p1-1 concentrations were
signiﬁcantly higher during pregnancy in both preeclampsia; (62.2 (4.3-
291.2) (pe) vs. 22.3 (0-142.6) (hpe) ng/ 10 mmol creatinine; p < 0.001) as
in pregnant controls (82.6 (8.3-206.7) (pc) vs. 5.1 (0-66.7) (hpc) ng/10
mmol creatinine; p < 0.01), as compared to non-pregnant concentra-
tions. gst p1-1 concentrations were neither signiﬁcantly different
between the pe and pc group nor between the hpe and hpc groups of
women. gsta1-1 concentrations were not signiﬁcantly different
between the four groups. There were no correlations between the degree
of proteinuria or gestational age and urinary gst p1-1 or gsta1-1 con-
centrations.
Conclusion: Urinary gst p1-1 excretion is markedly increased in preg-
nancy. Preeclampsia, however, is not associated with a further increase
suggesting absence of renal tubular damage in this gestational disease.
i n t roduct ion
Preeclampsia complicates 5 to 7% of all pregnancies, resulting in the clin-
ical features hypertension and proteinuria [1]. Although the precise dis-
ease mechanisms are not fully understood, endothelial dysfunction is
recognised to be the key pathophysiological problem [2]. Proteinuria is a
hallmark of preeclampsia, reﬂecting renal endothelial dysfunction with
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glomerular endotheliosis being the classical lesion [3]. Furthermore, a
slight tubular damage has also been found in renal biopsies [4]. 
Renal hemodynamics are altered during normal pregnancy, based on
increased glomerular ﬁltration rate and renal perfusion ﬂow [5], whereas
in preeclampsia renal blood ﬂow and glomerular ﬁltration rate have been
reported to decrease by 62-84% [6]. The increased glomerular perme-
ability and disturbed renal tubular absorption, occurring in uncompli-
cated pregnancies, are even more pronounced in women with
preeclampsia [7].
Glutathione S-transferases (gst’s) are cytosolic enzymes (ec 2.5.1.18)
involved in the binding and detoxiﬁcation of toxic compounds [8]. In
humans four main gst classes are described being Alpha (A), Mu (M),
Pi (P) and Theta (T), each class subdivided into one or more isoforms. In
the kidney gsta is exclusively present in proximal tubular cells, whereas
the presence of gst p is conﬁned to the distal tubular and collecting duct
cells [9,10].
Therefore, assessment of gsta1-1 and gst p1-1 excretion in urine
could help in distinguishing whether proteinuria as a result of evolving
transient renal damage has a tubular origin and whether damage has
occurred in the proximal or distal tubular system.
In the present study we have examined the urinary excretion of
gsta1-1 and p1-1 in both pregnant and non-pregnant women with and
without (a history of) preeclampsia.
m at er i a l a nd methods
This study was part of a preeclampsia research project performed
between 1997 and 2001 at the University Medical Center Nijmegen, the
Netherlands. The Medical Ethical Review Committee has approved the
experimental protocol and all subjects gave written informed consent. 
For the purpose of this study urine samples were collected of 22
women with severe preeclampsia and/or hellp syndrome (pe), 30 non-
pregnant women with a history of severe preeclampsia (hpe), 18 women
with uncomplicated pregnancies (pc) and 30 non-pregnant women with
previous uncomplicated pregnancies (hpc). Severe preeclampsia was
deﬁned as a diastolic blood pressure of 110 mmHg or higher, measured at
least two times with an interval of four hours, and proteinuria of at least
300 mg/10 mmol creatinine, following the criteria of the International
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Society for the Study of Hypertension in Pregnancy (isshp). The
hellp syndrome was biochemically characterised as featuring a lactate
dehydrogenase concentration of at least 600 iu/l , alanine transferase
(a lt) and aspartate transferase (a st) of at least 70 iu/L and thrombo-
cytopenia with thrombocyte count rates below 100 x 109/L [11]. In all
pregnant women the presence of proteinuria was assessed using the dip-
stick method. When present it was further quantiﬁed at the routine clini-
cal chemistry laboratory. Neither the pregnant nor the non-pregnant
control women showed proteinuria over 300 mg/10 mmol in or outside
pregnancy. None of the participants suffered from chronic hyperten-
sion. Urine samples were collected in plastic tubes randomly during the
day. 
The collected samples were immediately transported to the laborato-
ry and centrifuged for 10 minutes at 3,000 g and the supernatant was
mixed with storage buffer ((1 m hepe s (pH 7.5), containing 5% (w/v)
bovine serum albumin, 1% (w/v) sodium azide, 1% (v/v) Tween 20, and
10% (v/v) glycerol)) to ascertain a stable pH and to prevent bacterial
growth. gsta1-1 and gst p1-1 were assayed by el isa as described earli-
er for blood plasma [12,13]. Creatinine was measured using standard
methods at the routine clinical chemistry laboratory.
gsta1-1 and gst p1-1 concentrations were expressed as nanograms
per 10 mmol creatinine. 
Statistical analysis
Comparisons between groups were performed using Kruskall-Wallis
tests. Further analysis of differences between hpc and pc , between
hpe and pe , between hpc and hpe , and between pe and pc groups of
women was done using Mann-Whitney-U tests. spss 9.0 for Windows
was used for statistical analyses. In order to correct for multiple testing a
p-value < 0.01 was considered signiﬁcant.
r e sults
The clinical characteristics of the four study groups (pe , hpe , pc , hpc)
are presented in Table 1. The diastolic blood pressure during pregnancy
was signiﬁcantly (p < 0.01) higher in pe compared to pc , whereas the
diastolic blood pressure in the non-pregnant state was not different. The
proteinuria values were not signiﬁcantly different between women with
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and without preeclampsia, neither during pregnancy nor in the non-
pregnant state. The median (range) intervals between the last delivery
and urine sampling were 2.7 (0.5-11.4) years and 3.3 (0.5-10.4) years in
hpc and hpe , respectively. 
The results of the urinary excretion of gst p1-1 and gsta1-1 are sum-
marised in Table 2. 
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Table 1 Clinical characteristics in non-pregnant and pregnant controls and pregnant women with
preeclampsia and with a history of preeclampsia
CONTROLS PREECLAMPSIA
Non-pregnant (HPC) Pregnant (PC) Non-pregnant (HPC) Pregnant (PE)
n = 30 n = 18 n = 30 n = 22
Age (yrs) 35 (29-45) 31 (25-38) 34 (23-46) 27 (21-37)*
Primiparity 6 (20%) 9 (50%) 17 (57%) 19 (86%)
Diastolic blood 
pressure (mmHg)(1) - 68 (58-70) - 115 (95-120)*
post partum 78 (60-94) 82 (66-105) -
Proteinuria (g/10 mmol)
during pregnancy - 0 - 5. 0 (0.0-12.0)
post partum 0.05 (0.0-0.09) - 0.66 (0.0-0.7) -
Data are expressed as medians (ranges) or numbers (%). (1) during pregnancy; * p < 0.05
Table 2 Urinary excretion of GSTP1-1 and GSTA1-1 in non-pregnant and pregnant controls and
pregnant women with preeclampsia and with a history of preeclampsia
CONTROLS PREECLAMPSIA
Non-pregnant Pregnant (PC) Non-pregnant Pregnant (PE)
(HPC) (HPC)
n = 30 n = 18 n = 30 n = 22
GSTP1-1 
(ng/10 mmol creatinine) 5.1 (0-66.7) 82.6 (8.3-206.7)* 22.3 (0-142.6) 62.2 (4.3-291.2)**
GSTA1-1 
(ng/10 mmol creatinine) 23.5 (1.0-44.3) 26.1 (4.3-233.1) 40.4 (0.9-360.4) 43.4 (4.3-291.2)
Data are presented as medians (5th and 95th percentiles). *p < 0.01 PC vs. HPC; **p < 0.01 PE vs. HPE
gst p1-1 concentrations were signiﬁcantly higher during pregnancy,
both in pe as in pc as compared to non-pregnant concentrations. The
elevated gst p1-1 concentrations were not signiﬁcant different between
the pe and pc group. Within the pe group there were no signiﬁcant dif-
ferences in gst p1-1 concentrations between women with (n = 13) and
without concurrent hellp syndrome (n = 9); respectively 65.3 (20.1 –
1068) vs. 59.1 (0 – 146) ng/ 10 mmol creatinine. 
There were no signiﬁcant differences between the four groups in uri-
nary gsta1-1 concentrations. We did not observe any correlation
between the degree of proteinuria or gestational age and urinary gst p1-
1 and gsta1-1 concentrations.
discussion
We measured higher urinary gst p1-1 levels during pregnancy, in
uncomplicated and preeclamptic pregnancies, and these higher levels
may point at distal tubular damage.
During physiological circumstances the majority of the glomerular ﬁl-
trate is reabsorbed in the proximal tubule. The distal tubule is almost
entirely impermeable for water, and controls the degree of urine concen-
tration by absorption of ions and becomes permeable for water only
under the inﬂuence of aldosterone and antidiuretic hormone.
The concentration of gst ’s in the urine is low under normal condi-
tions. Increased urinary gst p1-1 levels are associated with damage of the
distal tubules and the collecting tubes [9]. Higher urinary concentra-
tions during pregnancy are presumed to be a result of damage of tubular
cells rather than due to disturbed reabsorption since under normal con-
ditions gst ’s are not ﬁltered through the glomeruli. During normal preg-
nancyrenalplasmaﬂowandglomerularﬁltrationrateareincreased[5,14],
which might affect tubular function as well as glomerular ﬁltration. The
gst p1-1 levels in the non-pregnant state were substantial lower, indicat-
ing a temporarily effect of pregnancy on renal function. 
In earlier studies on the presence of tubular damage in normal preg-
nancy or preeclampsia urinary N-acetyl-β-D-glucosaminidase levels were
quantiﬁed as a marker for proximal tubular involvement [7,15]. However,
this lysosomal enzyme is also present in distal tubular ducts [16], and
therefore distal tubular involvement in normal pregnancy and pre-
eclampsia could not be excluded. Urinary gsta1-1 levels, which are spe-
ciﬁc for proximal tubular damage [17], were not elevated during preg-
nancy. gst ’s are cytosolic enzymes present in large amount in human
kidney. Damage of the tubules in various kidney diseases or hyperten-
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sion leads to leakage of these enzymes in urine [9,10]. When gst ’s are
released from other organs into blood, such as gst alpha from liver and
gst pi from blood cells in case of preeclampsia and hellp syndrome
[18,19], these are not expected to be ﬁltered through the glomeruli [20].
Urinary gst p1-1 levels were not found elevated in preeclamptic women
compared to normotensive women. The ﬁndings of Hayashi et al. (2002)
seem to be in contrast with this, demonstrating a further deterioration of
tubular function in women with preeclampsia as compared to women
with uncomplicated pregnancies [7]. gst pi is also present in podocytes
[9], thus increased gst p1-1 concentrations might also reﬂect damage of
glomerular cells instead of only distal tubular damage. However, if the
urinary gst p1-1 would be derived from podocytes we would expect
higher urinary gst p1-1 levels in women with preeclampsia due to
glomerular damage, being typical for preeclampsia. In our study there
was no correlation between proteinuria and gsta1-1 or gst p1-1 levels.
However, Branten et al. studying a group of non-pregnant patients with
glomerular disease, demonstrated a relationship between proteinuria
and urinary levels of gsta1-1 and gst p1-1, suggesting a toxic effect of
protein overload on the tubular membrane [17]. In preeclampsia, pro-
teinuria exists only for a short time, in contrast with proteinuria in
patients with glomerular disease, which could be an explanation for this
discrepancy. 
In conclusion, normal pregnancy results in temporary distal tubular
impairment, without a further deterioration in preeclamptic pregnan-
cies.
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Risk factors and follow-up 
of severe preeclampsia
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a bst r act
Aim: To investigate an association between a family history of cardiovas-
cular and severe preeclampsia and/or hellp syndrome (Haemolysis,
Elevated Liver enzymes and Low Platelets)
Material and methods: Hundred-and-twenty-eight women with a his-
tory of severe preeclampsia and/or hellp syndrome and 123 women
with previous uncomplicated pregnancies only were included in the
study. All participants completed questionnaires about diagnoses of car-
diovascular diseases, hypertension and hypercholesterolemia among
their ﬁrst-degree relatives, which were subsequently conﬁrmed by the
relatives’ general practitioners. The main outcome measures were the
prevalence of cardiovascular diseases, hypertension and hypercholes-
terolemia among ﬁrst-degree relatives of both groups. Statistical analysis
was done using χ2-analysis.
Results: The prevalence of familial cardiovascular disease among
women with a history of severe preeclampsia and/or hellp syndrome
(23%) compared to controls (19%) was not signiﬁcantly different (or 1.3,
95% ci 0.7-2.5). However, women with a history of severe preeclampsia
and/or hellp syndrome more often had one or more ﬁrst-degree rela-
tives with hypertension and/or hypercholesterolemia before the age of
60 years compared to controls (54% vs. 32%, respectively; or 2.6, 95%
ci 1.5-4.3). The prevalence of hypertension and hypercholesterolemia
among ﬁrst-degree relatives, irrespective of age, was also signiﬁcantly
higher among women with a history of severe preeclampsia and/or
hellp syndrome as compared to controls (60% vs. 42%, respectively;
or 2.0, 95% ci 1.2-3.4).
Conclusion: Severe preeclampsia is associated with a positive family
history of hypertension and/or hypercholesterolemia. 
i n t roduct ion
Preeclampsia complicates 5 to 7 percent of pregnancies of nulliparous
women and is one of the most important causes of maternal and perina-
tal morbidity and mortality [1]. The most important risk factors to devel-
op the disease are nulliparity, a history of preeclampsia and a family his-
tory of preeclampsia [2,3].
Women with a history of preeclampsia have an increased risk for
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developing hypertension and/or cardiovascular disease later in life. They
may have inherent abnormalities, which predispose to vascular disease
[4-10]. Thrombophilia and pre-existing endothelial dysfunction increase
the risk for preeclampsia and are also involved in the aetiology of chronic
hypertension and cardiovascular disease [8,11-13]. Obesity, insulin resis-
tance and dyslipidemia, features related to endothelial dysfunction, are
found to occur more frequently in preeclampsia and in cardiovascular
disease [8]. Lipid peroxidation is another common feature of preeclamp-
sia and is also associated with cardiovascular disease, and with endothe-
lial damage in particular [14,15].
Familial tendency, present in preeclampsia as well as in cardiovascular
disease [16,17], may be considered as another joint risk factor. Therefore,
women with a positive family history of cardiovascular disease may have
a higher risk to develop preeclampsia due to the underlying disorders as
mentioned above. Moreover, some genetical polymorphisms, such as in
angiotensinogen (agt), methylenetetrahydrofolate reductase (mthf r)
and endothelial nitric oxide synthase (enos) are described in relation
both to preeclampsia as well as to chronic hypertension and cardiovascu-
lar disease [18-22].
The purpose of the present study was to evaluate the prevalence of a pos-
itive family history of cardiovascular disease and the related risk factors
hypertension and hypercholesterolemia, among women with a history of
severe preeclampsia and/or hellp syndrome as compared to healthy
women with previous uncomplicated pregnancies only.
m at er i a l a nd methods
Between January 2000 and March 2001 a follow-up study among women
with a history of severe preeclampsia and/or hellp syndrome without
chronic hypertension and women with previous uncomplicated preg-
nancies only, was conducted. The study protocol was approved by the
ethics committee of the University Medical Center Nijmegen and
informed consent of the participants was obtained before entry.
We invited 241 women with a history of severe preeclampsia, admitted
to our hospital in the time period 1995 to 1999, to participate in this
study. At the time of disease in the past they had also been included in a
study on some pathophysiologic features of preeclampsia and hellp
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syndrome [23,24]. Forty-nine women (20%) did not want to participate
for various reasons such as no interest, distance, and emotional distress,
and 31 women (13%) could not be traced. Of the remaining 161 women
with a history of severe preeclampsia 134 women were included. For vari-
ous reasons the other 27 women were not included as they appeared to
have had either mild preeclampsia, pre-existing chronic hypertension, or
suffered from type i diabetes or lupus erythematosus.
At the time that the former patients were approached 130 healthy
women with previous uncomplicated pregnancies only were also recruit-
ed from the outpatient clinic, midwife practices and by advertising in
local newspapers. Six women with a history of severe preeclampsia
and/or hellp syndrome and seven control women were subsequently
excluded because it was impossible for them to obtain information of
their ﬁrst-degree relatives. Finally, 128 women with a history of severe
preeclampsia and/or hellp syndrome and 123 controls remained for
further study.
Preeclampsia was deﬁned according to the deﬁnitions of the Interna-
tional Society for the Study of Hypertension in Pregnancy (isshp).
Severe preeclampsia was deﬁned as a diastolic blood pressure of 110
mmHg or higher, measured two times or more often with an interval of
at least four hours, and proteinuria of at least 0.3 g/L. hellp syndrome
was biochemically characterised as lactate dehydrogenase concentration
≥ 600 iu/l , aminotransferases ≥ 70 iu/l and a thrombocytopenia < 100
x 109/L [25]. Information on cardiovascular disease, hypertension and
hypercholesterolemia among ﬁrst-degree relatives and the age of onset
of disease was gathered from mailed questionnaires. During a visit to the
outpatient clinic all answers were orally checked, as to whether their rela-
tives ever had visited a general practitioner or specialist for cardiovascu-
lar disease, hypertension or hypercholesterolemia. We presumed that if
the family members had never been seen by either a general practitioner
or a specialist in the ﬁeld of cardiovascular disease or hypertension, the
chances of having one of the above mentioned health problems would be
rather small. The general practitioners of identiﬁed ﬁrst-degree relatives
with one of the conditions mentioned above were asked to conﬁrm all the
diagnoses reported. General practitioners of ﬁrst-degree relatives with-
out any of these health problems were not approached.
Hypertension was deﬁned as diastolic blood pressure above 95 mmHg
or systolic blood pressure above 160 mmHg, repetitively measured in a
time period of three to ﬁve months and hypercholesterolemia was
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deﬁned as cholesterol levels above 6.5 mmol/L, both according to the
standards of the Dutch College of General Practitioners. Angina pec-
toris, myocardial infarction, cerebrovascular accident, transient ische-
mic attack, and intermittent claudication were considered as cardiovas-
cular disease. A family history of cardiovascular disease was deﬁned as
one or more ﬁrst-degree relatives with cardiovascular disease before the
age of 60 years [17]. 
For 18 formerly preeclamptic women and 20 controls with a positive
family history of hypertension, hypercholesterolemia or cardiovascular
disease it was not possible to have the diagnoses conﬁrmed by the gener-
al practitioners. For this reason the self-reported family diagnoses were
reconsidered and taken as true diagnoses if the involved family members
were or had been treated for the reported diagnosis.
Data on the obstetric history and demographic variables were also col-
lected from the questionnaires, including age, race, and educational lev-
els. Educational levels may be regarded as indicators of socio-economic
status [26]. The educational levels were categorised as low (primary edu-
cation, lower and intermediate vocational education and intermediate
secondary education) or high (higher secondary and vocational educa-
tion or university education).
Statistical analysis
Demographic data were compared by Student’s t tests and χ2 tests. The
prevalence of positive family history were compared for both groups
using Odds ratios and the corresponding 95% conﬁdence intervals (ci)
and were tested using χ2 tests. Additionally all data were analysed in a
stratiﬁed manner, correcting for low and high educational levels. Preva-
lence of self-reported diagnoses and conﬁrmed diagnoses were com-
pared using χ2 tests. A p-level below 0.05 was considered statistically sig-
niﬁcant. 
r e sults
Clinical and demographic data for women with a history of severe
preeclampsia and/or hellp syndrome and the control subjects are
shown in Table 1. Former patients were signiﬁcantly lower educated
compared to controls. 
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Consistent with the fact that former patients had a history of preeclamp-
sia the prevalence of chronic hypertension after the index pregnancy was
higher than in the control group. The interval between index pregnancy
and study was signiﬁcantly larger in the group of former preeclamptic
women. However, the age of all ﬁrst-degree relatives of women with a
history of severe preeclampsia was not signiﬁcantly different from the
control group.
No differences in prevalence of familial cardiovascular disease or
hypertension and /or hypercholesterolemia were found between women
with a history of severe preeclampsia only and those who had concurrent
hellp syndrome. All further analyses were therefore performed for the
whole study population of women with severe preeclampsia and/or
hellp syndrome.
The study and control group did not differ signiﬁcantly with regard to
prevalence of positive family history of cardiovascular disease (Table 2).
However, women with a history of severe preeclampsia and/or hellp
syndrome signiﬁcantly more often had one or more ﬁrst-degree relatives
with hypertension and/or hypercholesterolemia before the age of 60
years as compared to controls (or 2.6 (95% ci 1.5-4.3)) (Table 2). The
prevalence of hypertension and/or hypercholesterolemia among ﬁrst-
degree relatives, irrespective of age, was also signiﬁcantly higher among
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Table 1 Clinical and demographic data
Women with a  Women with 
history of severe uncomplicated 
PE/HELLP pregnancies
syndrome (controls)
n = 128 n = 123
Age (years) 34 (26-41) 33 (27-41)
Caucasian race 126 (99) 122 (99)
Low education level 84 (65)* 37 (30)
Chronic hypertension after 
index pregnancy 12 (9)* 1 (0.8)
Primiparous at index pregnancy 121 (95) -
Primiparity at study-entry 49 (39) 63 (51)
Interval between index 
pregnancy and study (months) 47 (10-109)* 24 (6-115)
Age of ﬁrst degree relatives (years) 48 (26-76) 55 (27-76)
PE = preeclampsia; HELLP = Haemolyis, Elevated Liver enzymes, Low Platelets
Data are presented as medians (5th-95th percentile) or numbers (%); * p < 0.01
women with a history of severe preeclampsia and/or hellp syndrome
as compared to controls, expressed as an or of 2.0 (95% ci 1.2-3.4)
(Table 3).
After stratiﬁcation for high and low educational levels, the prevalence of
cardiovascular disease, hypertension and/or hypercholesterolemia be-
fore the age of 60 years and hypertension and/or hypercholesterolemia
among all ages between ﬁrst-degree relatives of women with a history of
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Table 2 Family history of cardiovascular disease (CVD), hypertension, and hypercholesterolaemia before
60 years
Women with a  Women with Odds ratio
history of severe uncomplicated (95% CI)
PE/HELLP pregnancies
syndrome (controls)
(n = 128) (n = 123)
Positive family history of CVD
conﬁrmed data 30 (23%) 23 (19%) 1.3 (0.7-2.5)
self-reported data 49 (38%)* 34 (28%)† 1.6 (1.0-2.8)
Positive family history of 
hypertension and/or 
hypercholesterolaemia (< 60 yrs)
conﬁrmed data 69 (54%) 39 (32%) 2.6 (1.5-4.3)
self-reported data 87 (68%)* 61 (50%)* 2.2 (1.3-3.7)
Data are presented as numbers (%). Self-reported vs. conﬁrmed data: * p < 0.001; † ns
Table 3 Family history of hypertension and/or hypercholesterolaemia in family (irrespective of age)
Women with a  Women with Odds ratio
history of severe uncomplicated (95% CI)
PE/HELLP pregnancies
syndrome (controls)
n = 128 n = 123
Positive family history of hyper-
tension and/or hypercholesterolaemia
conﬁrmed data 77 (60%) 52 (42%) 2.0 (1.2-3.4)
self-reported data 86 (67%)† 64 (52%)† 2.3 (1.4-3.9)
PE = preeclampsia; HELLP = Haemolyis, Elevated Liver enzymes, Low Platelets
Data are presented as numbers (%). Self-reported vs. conﬁrmed data: † ns
severe preeclampsia and/or hellp syndrome and controls were com-
pared again. For a positive family history of cardiovascular disease in
women with a history of severe preeclampsia and/or hellp syndrome
the Odds ratio (or) in the high educated group was 1.8 (95% ci 0.7-4.2)
and in the low educated group 1.0 (95% ci 0.4-2.5). Odds ratios for
hypertension and/or hypercholesterolemia before the age of 60 years
among ﬁrst-degree relatives of women with a history of severe
preeclampsia and/or hellp syndrome with high and low educational
levels were 2.6 (95% ci 1.2-5.5) and 3.0 (95% ci 1.3-6.9), respectively.
Among women with a positive family history of hypertension and/or
hypercholesterolemia, irrespective of age, the high educated women had
an or of 3.6 (95% ci 1.6-8.0) compared to an or of 1.9 (95% ci 0.9-4.3)
among low educated women. 
Tables 2 and 3 also include the prevalence of self-reported diagnoses
among ﬁrst-degree relatives. Among women with a history of severe
preeclampsia and/or hellp syndrome the self-reported prevalence of a
positive family history of cardiovascular disease, hypertension and/or
hypercholesterolemia before the age of 60 years were signiﬁcantly high-
er than those conﬁrmed by the general practitioner, while the self-
reported prevalence of a positive family history of hypertension and/or
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Table 4 Family histories of cardiovascular disease, hypertension, and hypercholesterolaemia among
multiparous women with and without recurrent preeclampsia and/or HELLP syndrome
Women with a  Women with Odds ratio
history of severe uncomplicated (95% CI)
PE/HELLP pregnancies
syndrome (controls)
(n = 39) (n = 27)
Positive family history of CVD
(< 60 years) 6 (15%) 7 (26%) 0.5 (0.2-1.8)
Positive family history of 
hypertension and/or hyper-
cholesterolaemia (< 60 years) 19 (49%) 17 (63%) 0.6 (0.2-1.5)
Positive family history of 
hypertension and/or hyper-
cholesterolaemia (all ages) 24 (62%) 17 (63%) 0.9 (0.3-2.6)
PE = preeclampsia; HELLP = Haemolyis, Elevated Liver enzymes, Low Platelets. Data are presented as
numbers (%). 
hypercholesterolemia irrespective of age was not different. Among con-
trols the self-reported prevalence of family history of hypertension
and/or hypercholesterolemia among ﬁrst-degree relatives before the age
of 60 years was signiﬁcantly higher than the prevalence as conﬁrmed by
the general practitioner.
The prevalence of a positive family history of cardiovascular disease
or hypertension and/or hypercholesterolemia in formerly preeclamptic
patients did not differ between multiparous women with recurrent hyper-
tensive complications in at least one subsequent pregnancy and multi-
parous women with subsequent normotensive pregnancies (Table 4).
Self-reported and conﬁrmed data were not different in these groups.
discussion
The main ﬁndings of this study are that the prevalence of positive family
histories of hypertension and hypercholesterolemia with onset before
the age of 60 years and the prevalence of family histories of hypertension
and/or hypercholesterolemia with onset at all ages, were signiﬁcantly
higher among ﬁrst-degree relatives of women with a history of severe
preeclampsia and/or hellp syndrome as compared to ﬁrst-degree rela-
tives of controls. We found no differences between the two study groups
regarding the prevalence of family history of cardiovascular disease.
Although this study shows that a history of severe preeclampsia is a risk
factor for such positive family history, one could hypothesise that risk
factors involved in these families also predispose to the development of
preeclampsia. 
So far only a few studies on the familial history of hypertension and
cardiovascular disease as a risk factor for developing preeclampsia have
been performed. Eskenazi et al. (1991) reported a slightly higher Odds
ratio for patients with a family history of hypertension [2]. Stone et al.
(1994), however, found no evidence for a family history of hypertension
as a risk factor for developing preeclampsia [27]. Both studies abstracted
the information of family history of hypertension from medical charts
instead of questionnaires, which probably is less accurate than data con-
ﬁrmed by the general practitioner as obtained in our study. 
We did not ﬁnd a higher prevalence of positive family history of car-
diovascular disease. This may be due to the relatively young age of our
study population and of their ﬁrst-degree relatives, since the mean age in
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both study groups was 60 and 62 years, respectively. We hypothesise
that when repeating this study within one or two decades, a substantial
proportion of the ﬁrst-degree relatives, who now present with hyperten-
sion and/or hypercholesterolemia, will indeed have developed cardiovas-
cular disease.
An association between cardiovascular disease or risk factors for car-
diovascular disease and preeclampsia would be suggestive for common
pathogenic features such as endothelial dysfunction, lipid peroxidation,
thrombophilia, dyslipidemia, chronic hypertension, obesity, and dia-
betes [8,11,13-15,28-34]. 
An intriguing similarity between preeclampsia and cardiovascular
disease is their familial tendency [33,35]. Although familial inheritance
comprises more than genetic factors only, several genetic polymor-
phisms seem to be involved in preeclampsia as well as in chronic hyper-
tension and cardiovascular disease. 
Regarding preeclampsia there seems to be a cluster of polymorphisms
in conjunction with environmental factors, which predispose to the dis-
ease [19]. As the prevalence of preeclampsia in identical twin sisters does
not show concordance, polymorphisms are thought to be from maternal
as well as from foetal origin. Several genetic polymorphisms are associ-
ated with the development of preeclampsia such as polymorphisms in
genes for Factor v Leiden, mthf r , angiotensinogen, enos , glutathione
S-transferase p1 and microsomal epoxide hydrolase [18,36-39]. The
association of some other polymorphisms with preeclampsia remains
controversial [19]. 
Reduced mthf r activity coinciding with increased homocysteine
concentrations is also associated with a higher risk for cardiovascular
disease [11,22]. The t235 variant of the angiotensinogen gene is associat-
ed with raised angiotensin concentrations resulting in vasoconstriction
characterising both preeclampsia as well as chronic hypertension. How-
ever, although a role of the t235 variant is demonstrated in relation to
preeclampsia among Caucasian populations, no such an association was
seen among Mexican and Asian populations [19,40-42]. Defective
endothelial no synthase results in impaired vasodilatation, present in
both preeclampsia and cardiovascular disease [18,20]. 
Future research might elucidate how the above mentioned polymor-
phisms interact in the aetiology and pathophysiology of preeclampsia
and whether such involvement is present in all women with preeclampsia
or solely in subgroups.
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Low educational levels are known to be inversely associated with
hypertension and/or hypercholesterolemia [43,44]. However, in our
analysis stratiﬁed for high and low educational levels, the prevalence of
familial hypertension and hypercholesterolemia before the age of 60
remained signiﬁcantly higher among women with a history of severe
preeclampsia and/or hellp syndrome as compared to controls. Thus,
the high prevalence of hypertension and/or hypercholesterolemia
among ﬁrst-degree relatives of formerly preeclamptic patients cannot be
explained by the lower educational levels of this group.
Some authors reported higher prevalence of chronic hypertension,
later in life, among women who after their ﬁrst preeclamptic pregnancy
had recurrence of hypertensive complications during later pregnancies
compared to women with subsequent uncomplicated pregnancies
[4,6,8]. Pregnancy temporarily unmasks an underlying essential hyper-
tension in women who in later life develop hypertension or other cardio-
vascular problems [8,10]. In our study the diagnoses of cardiovascular
disease, hypertension and/or hypercholesterolemia of the ﬁrst-degree
relatives were conﬁrmed by the general practitioners. The prevalence of
self-reported diagnoses of positive family histories of cardiovascular dis-
ease among women with a history of severe preeclampsia and/or hellp
syndrome were signiﬁcantly higher than those of the conﬁrmed diag-
noses. This difference was largely due to the high prevalence of the self-
reported diagnosis ‘chest pain’, which was not classiﬁed as angina pec-
toris by the general practitioner. Kee et al. (1993) analysed the congruity
between reported and conﬁrmed family histories of myocardial infarc-
tion. When only self-reported data were used one third of the relatives at
risk was missed and the number of affected relatives was overestimated
by about one third [45]. Since we did not conﬁrm with the general practi-
tioner the absence of cardiovascular disease, hypertension and hyper-
cholesterolemia among the ﬁrst-degree relatives without reports of car-
diovascular disease or risk factor, we are not able to analyse our results
accordingly.
The prevalence of hypertension and hypercholesterolemia in The
Netherlands was 15% in the age group below 60 years and 57% in the
population at large, respectively [46,47]. As we deﬁned a positive family
history as hypertension and/or hypercholesterolemia our ﬁgures are in
line with the national prevalence.
In clinical practice it is not possible to conﬁrm all diagnoses of ﬁrst-
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degree relatives, but it is important to ask for detailed information on the
diagnoses provided by women attending the prenatal clinic. In conclu-
sion, hypertension and hypercholesterolemia among ﬁrst-degree rela-
tives before the age of 60 are associated with preeclampsia. This is possi-
bly due to pathogenic common pathways in preeclampsia and cardiovas-
cular disease, such as thrombophilia, dyslipidemia, endothelial dysfunc-
tion or certain genetic polymorphisms. 
We therefore suggest that every woman visiting the outpatient depart-
ment for her ﬁrst prenatal visit should be asked for the family history of
cardiovascular disease, hypertension and hypercholesterolemia, in order
to better estimate the possible risk of developing severe preeclampsia
and/or hellp syndrome.
r ef er ence s
1. Sibai BM, Caritis SN, Thom E, Klebanoff M, McNellis D, Rocco L et al.
Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous
pregnant women. The National Institute of Child Health and Human
Development Network of Maternal-Fetal Medicine Units. N Engl J Med
1993; 329:1213-1218.
2. Eskenazi B, Fenster L, Sidney S. A multivariate analysis of risk factors for
preeclampsia. ja m a 1991; 266:237-241.
3. Zhang J, Zeisler J, Hatch MC, Berkowitz G. Epidemiology of pregnancy-
induced hypertension. Epidemiol Rev 1997; 19:218-232.
4. Chesley LC. Hypertension in pregnancy: deﬁnitions, familial factor, and
remote prognosis. Kidney Int 1980; 18:234-240.
5. Svensson A, Andersch B, Hansson L. Prediction of later hypertension
following a hypertensive pregnancy. J Hypertens Suppl 1983; 1:94-96.
6. Sibai BM, el Nazer A, Gonzalez Ruiz A. Severe preeclampsia-eclampsia in
young primigravid women: subsequent pregnancy outcome and remote
prognosis. Am J Obstet Gynecol 1986; 155:1011-1016.
7. Nisell H, Lintu H, Lunell no , Mollerstrom G, Pettersson E. Blood pressure
and renal function seven years after pregnancy complicated by
hypertension. Br J Obstet Gynaecol 1995; 102:876-881.
8. Lindeberg SN, Hanson U. Hypertension and factors associated with
metabolic syndrome at follow-up at 15 years in women with hypertensive
disease during ﬁrst pregnancy. Hypertens Preg 2001; 19:191-198.
174 pa rt v
9. Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfusson N.
Death rates from ischemic heart disease in women with a history of
hypertension in pregnancy. Acta Obstet Gynecol Scand 1995; 74:772-776.
10. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular
risk: opportunities for intervention and screening? bm j 2002; 325:157-160.
11. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar Am A, Jaffa A et al.
Increased frequency of genetic thrombophilia in women with
complications of pregnancy. N Engl J Med 1999; 340:9-13.
12. Rodgers GM, Taylor RN, Roberts JM. Preeclampsia is associated with a
serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol
1988; 159:908-914.
13. Luscher TF, Noll G. The pathogenesis of cardiovascular disease: role of the
endothelium as a target and mediator. Atherosclerosis 1995; 118:s81-s90.
14. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA et
al. Atherosclerosis: basic mechanisms. Oxidation, inﬂammation, and
genetics. Circulation 1995; 91:2488-2496.
15. Hubel CA, Roberts JM, Taylor RN, Musci TJ, Rogers GM, McLaughlin
MK. Lipid peroxidation in pregnancy: new perspectives on preeclampsia.
Am J Obstet Gynecol 1989; 161:1025-1034.
16. Chesley LC, Annitto JE, Cosgrove RA. The familial factor in toxemia of
pregnancy. Obstet Gynecol 1968; 32:303-311.
17. Leijdekkers VJ, Vahl AC, Leenders JJ, Huijgens PC, Gans RO, Rauwerda
JA. Risk factors for premature atherosclerosis. Eur J Vasc Endovasc Surg
1999; 17:394-397.
18. Arngrimsson R, Hayward C, Nadaud S, Baldursdottir A, Walker JJ, Liston
WA et al. Evidence for a familial pregnancy-induced hypertension locus in
the enos-gene region. Am J Hum Genet 1997; 61:354-362.
19. Broughton Pipkin F. What is the place of genetics in the pathogenesis of
pre-eclampsia? Biol Neonate 1999; 76:325-330.
20. Scherrer U, Sartori C. Defective nitric oxide synthesis: a link between
metabolic insulin resistance, sympathetic overactivity and cardiovascular
morbidity. Eur J Endocrinol 2000; 142:315-323.
21. Wang JG, Staessen JA. Genetic polymorphisms in the renin-angiotensin
system: relevance for susceptibility to cardiovascular disease. Eur J
Pharmacol 2000; 410:289-302.
22. Winkelmann BR, Hager J, Kraus WE, Merlini P, Keavney B, Grant PJ et al.
Genetics of coronary heart disease: current knowledge and research
principles. Am Heart J 2000; 140:s11-s26.
r isk factor s a nd fol low-up of sev er e pr eecl a mpsi a 175
23. Knapen MFCM, Mulder TPJ, Van Rooij IALM, Peters WHM, Steegers
EAP. Low whole blood glutathione levels in pregnancies complicated by
preeclampsia or the hemolysis, elevated liver enzymes, low platelets
syndrome. Obstet Gynecol 1998; 92:1012-1015.
24. Raijmakers MTM, Zusterzeel PLM, Steegers EAP, Hectors MPC,
Demacker PNM, Peters WHM. Plasma thiol status in preeclampsia. Obstet
Gynecol 2000; 95:180-184.
25. Sibai BM. The hellp syndrome (hemolysis, elevated liver enzymes, and
low platelets): much ado about nothing? Am J Obstet Gynecol 1990; 162:311-
316.
26. Liberatos P, Link BG, Kelsey JL. The measurement of social class in
epidemiology. Epidemiol Rev 1988; 10:87-121.
27. Stone JL, Lockwood CJ, Berkowitz GS, Alvarez M, Lapinski R, Berkowitz
RL. Risk factors for severe preeclampsia. Obstet Gynecol 1994; 83:357-361.
28. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin
MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;
161:1200-1204.
29. Sibai BM, Abdella TN, Anderson GD. Pregnancy outcome in 211 patients
with mild chronic hypertension. Obstet Gynecol 1983; 61:571-576.
30. Suhonen L, Teramo K. Hypertension and pre-eclampsia in women with
gestational glucose intolerance. Acta Obstet Gynecol Scand 1993; 72:269-
272.
31. Sattar N, Bendomir A, Berry C, Shepherd J, Greer IA, Packard CJ.
Lipoprotein subfraction concentrations in preeclampsia: pathogenic
parallels to atherosclerosis. Obstet Gynecol 1997; 89:403-408.
32. Van Pampus MG, Koopman MM, Wolf H, Buller HR, Prins MH, van den
EA. Lipoprotein(a) concentrations in women with a history of severe
preeclampsia – a case control study. Thromb Haemost 1999; 82:10-13.
33. Higgins M. Epidemiology and prevention of coronary heart disease in
families. Am J Med 2000; 108:387-395.
34. Sattar N, Gaw A, Packard CJ, Greer IA. Potential pathogenic roles of
aberrant lipoprotein and fatty acid metabolism in pre-eclampsia. Br J Obstet
Gynaecol 1996; 103:614-620.
35. Cooper DW, Brennecke SP, Wilton AN. Genetics of pre-eclampsia.
Hypertens Preg 1993; 12:1-23.
36. Dizon Townson DS, Nelson LM, Easton K, Ward K. The factor v Leiden
mutation may predispose women to severe preeclampsia. Am J Obstet
Gynecol 1996; 175:902-905.
176 pa rt v
37. Ward K, Nelson L, Knowlton J, Hastings S, Varner M. Factor v Leiden and
the T235 variant of angiotensinogen as risk factors for preeclampsia: A
prospective study. J Soc Gynecol Invest 1998; 5:140a .
38. Zusterzeel PLM, Visser W, Peters WHM, Merkus JMWM, Nelen WLDM,
Steegers EAP. Polymorphism in the glutathione S-transferase P1 gene and
risk for preeclampsia. Obstet Gynecol 2000; 96:50-54.
39. Zusterzeel PLM, Peters WHM, Visser W, Hermsen KJM, Roelofs HMJ,
Steegers EAP. A polymorphism in the gene for microsomal epoxide
hydrolase is associated with pre-eclampsia. J Med Genet 2001; 38:234-237.
40. Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C et al. 
A molecular variant of angiotensinogen associated with preeclampsia.
Nat Genet 1993; 4:59-61.
41. Bashford MT, Heﬂer LA, Vertrees TW, Roa BB, Gregg AR.
Angiotensinogen and endothelial nitric oxide synthase gene
polymorphisms among Hispanic patients with preeclampsia. Am J Obstet
Gynecol 2001; 184:1345-1350.
42. Sethi AA, Nordestgaard BG, Agerholm-Larsen B, Frandsen E, Jensen G,
Tybjaerg-Hansen A. Angiotensinogen polymorphisms and elevated blood
pressure in the general population: the Copenhagen City Heart Study.
Hypertension 2001; 37:875-881.
43. Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a
review of the literature. Circulation 1993; 88:1973-1998.
44. Hoeymans N, Smit HA, Verkleij H, Kromhout D. Cardiovascular risk
factors in relation to educational level in 36 000 men and women in The
Netherlands. Eur Heart J 1996; 17:518-525.
45. Kee F, Tiret L, Robo JY, Nicaud V, McCrum E, Evans A et al. Reliability of
reported family history of myocardial infarction. bm j 1993; 307:1528-1530.
46. Schelleman H, Klungel OH, Kromhout D, de Boer A, Stricker BH,
Verschuren WM. Prevalence and determinants of undertreatment of
hypertension in the Netherlands. J Hum Hypertens 2004; 18:317-324.
47. Mantel-Teeuwiss AK, Verschuren WM, Klungel OH, Kromhout D,
Lindemans AD, Avorn J et al. Undertreatment of hypercholesterolemia:
population based study. Br J Clin Pharmacol 2003; 55:389-397.
r isk factor s a nd fol low-up of sev er e pr eecl a mpsi a 177

CHAPTER 13 
Physical wellbeing in women with a history 
of severe preeclampsia
Eva Maria Roes, Maarten T.M. Raijmakers, 
Marieke Schoonenberg, Natasha Wanner, 
Wilbert H.M. Peters, Eric A.P. Steegers
Submitted
r isk factor s a nd fol low-up of sev er e pr eecl a mpsi a 179
a bst r act
Aim: To evaluate physical and mental health in women with a history of
severe preeclampsia
Material and methods: In a historical cohort study 131 former patients
with a history of severe preeclampsia and 127 control women received
questionnaires about experienced physical and mental complaints after
delivery. At a follow-up visit blood pressure, body mass index, and pro-
teinuria were measured and venous blood was drawn.
Results: Former patients experienced signiﬁcantly (p < 0.001) more
frequent problems of headache (31% vs. 2%), right upper quadrant pain
(16% vs. 1%), visual disturbances (21% vs. 1%), tiredness (66% vs. 27%),
subjective loss of concentration (37% vs. 16%), and mental health (37% vs.
6%) compared with controls. When present, these health problems,
except for tiredness, lasted signiﬁcantly more often beyond six months
postpartum compared to controls. Admittance to the intensive care unit
was associated with headache, and subjective loss of memory and con-
centration over a longer period of time. The risk of recurrence of severe
preeclampsia was subject of concern in 20% of former patients. At fol-
low-up, systolic and diastolic blood pressures were signiﬁcantly higher 
(p < 0.001) among former patients.
Conclusion: Patients with a history of severe preeclampsia more fre-
quently reported physical and mental complaints, also during a longer
period of time. 
i n t roduct ion
Severe preeclampsia has a signiﬁcant impact on maternal morbidity
[1,2]. One of the most typical hallmarks of this disease is the spontaneous
resolution after delivery. In general, recovery, such as normalisation of
blood pressure and platelet counts, takes places within one or two
months postpartum, though this depends on the severity of disease and
underlying other diseases [3-6]. Nevertheless, with respect to other
health aspects, such as tiredness, headache, and mental problems, recov-
ery may be different as compared to uncomplicated pregnancies.
In large, unselected populations of young mothers physical and emo-
tional health problems up to 18 months postpartum were reported to
occur in 75 to 94% of the interviewed women and only part of those
women sought professional help for this [7]. 
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Postpartum maternal morbidity after preeclamptic pregnancy may be
directly related to the multi-organ involvement of the disease [9,10].
Moreover, the psychosocial impact of the disease and the state of health
of the new-born child may also affect the woman’s mental health [11,12].
Women with severe preeclampsia are often admitted to the intensive
care unit, which in itself may also inﬂuence psychological outcome [13]. 
A better knowledge of physical and mental wellbeing and experienced
complaints might be helpful in providing care for women with a history
of severe preeclampsia. Therefore, we investigated the presence of com-
plaints and measured several haematological, biochemical, and clinical
parameters among women with a history of severe preeclampsia, com-
pared with women with a history of uncomplicated pregnancies only.
m at er i a l a nd methods
Between January 2000 and March 2001 a follow-up study among women
with a history of severe preeclampsia was conducted. The study protocol
was approved by the ethics committee of the University Medical Center
Nijmegen and informed consent was obtained from all participants.
Severe preeclampsia was deﬁned as a diastolic blood pressure of 110
mmHg or higher, measured two times or more with an interval of at least
four hours, and a proteinuria of at least 0.3 g/L or the occurrence of
hellp syndrome, deﬁned as lactate dehydrogenase concentration ≥
600 iu/l , aminotransferases ≥ 70 iu/l , and a thrombocytopenia < 100 x
109/L, in combination with gestational hypertension or preeclampsia.
We invited 241 women with a history of severe preeclampsia, admitted
to our hospital in the time period 1995 to 1999, to participate in this
study. At the time of disease in the past, they had also been included in a
study on some pathophysiologic features of preeclampsia and hellp
syndrome [14,15]. Forty-nine women (20%) did not want to participate
for various reasons such as no interest, distance, and emotional distress,
and 31 women (13%) could not be traced. The remaining 161 women
(67%) received additional information by mail, in which the purpose and
content of the follow-up study was explained. 
For various reasons the other 27 women were not included as they
appeared to have had either mild preeclampsia, pre-existing chronic
hypertension, or suffered from type i diabetes or lupus erythematosus.
Control women (n = 135) with an uncomplicated obstetrical history,
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were recruited from the outpatient clinic, midwife practices, and by
advertising in local newspapers. Since these women were randomly
selected, this was a non-matched cohort group. Five control women
appeared to have had a complicated obstetric history for some form of
chronic or gestational hypertension, recurrent early pregnancy loss, or
premature delivery and were therefore excluded. Three women with a
history of severe preeclampsia and three control women did not com-
plete the questionnaire appropriately and were not included in the study.
Finally, 131 women with a history of severe preeclampsia and 127 con-
trols remained for further analysis of questionnaires. Hundred-and-
twenty former patients and 123 controls visited the out-patient-clinic for
blood sampling and a conﬁned physical examination. In short, the study
consisted of a questionnaire, measurement of body mass index, blood
pressure, heart rate, proteinuria, and a venous blood draw for the analy-
sis of concentrations of haemoglobin, haematocrite, platelet count, crea-
tinine, uric acid, aminotransferases, lactate dehydrogenase, γ-glutamyl-
transferase, and bilirubin. Blood pressure was measured in sitting posi-
tion with a sphygmomanometer; the diastole was recorded at phase V
Korotkoff sound.
In the questionnaire, the health complaints as below mentioned, were
listed and women were asked if they had experienced these health com-
plaints following the index pregnancy (former patients) or their ﬁrst
pregnancy (controls). The following health complaints or disorders were
asked for: hypertension, renal disease, headache, right upper quadrant
pain, visual disturbances, tiredness, subjective loss of memory or con-
centration and mental or other problems. Renal disease was not further
deﬁned in the questionnaire; mental problems were not speciﬁed in
detail. Furthermore it was noted whether the complaints lasted more
than six months. 
All participating women received the questionnaire some weeks
before their visit to our outpatient clinic. During their visit the reported
answers were verbally veriﬁed in the groups of former patients and con-
trols and additional information was obtained on whether they had been
admitted to the Intensive Care Unit and their desire to become pregnant
again after their index or ﬁrst pregnancy, respectively.
Information on the obstetric history, blood pressure, and body mass
index before the index pregnancy as well as on age, race, parity, educa-
tional levels, and the time interval between the index pregnancy and this
study was also obtained from the questionnaires. Educational levels may
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be regarded as indicators of socio-economic status [16]. They were cate-
gorised as low (primary education, lower and intermediate vocational
education, or intermediate secondary education) or high (higher sec-
ondary and vocational education, or university education).
Statistical analysis
The prevalence of experienced health complaints and the period of time
they lasted were compared between former patients and controls, using
Odds ratios and the corresponding 95% conﬁdence intervals (ci) and
were tested using Chi-square analysis.
Haematological, biochemical, and clinical parameters were compared
using Students’ t test or Mann-Whitney-U test, as appropriate. The num-
ber of women, whose biochemical parameters exceeded the reference
values of our local laboratory were compared between both groups using
Chi-square analysis. Epi-info 6.0 and spss 6.0 were applied for analy-
ses.
r e sults
In Table 1 the characteristics of the two groups are presented. Maternal
age, race, and primiparity were not different between the groups though
patients had signiﬁcantly (p < 0.01) lower educational levels than con-
trols. As expected gestational age and birth weight of the index pregnan-
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Table 1 Clinical and demographic data of former patients and controls
Former patients Controls
n = 131 n = 127
Age (yr) 34 (26-43) 33 (27-41)
Caucasian race 128 (98) 125 (98)
Low education level 84 (61)* 37 (29)
Primiparity at follow-up 52 (40) 62 (49)
Interval between index pregnancy 
and study (mnths) 47 (11-109)* 23 (6-128)
Gestational age at index pregnancy / 
ﬁrst pregnancy 32+4 (27+3-38+4)** 40 (37+4-42)
Birthweight (g) 1325 (612-3123)** 3315 (2775-4300)
Data are presented as medians (5th – 95th percentiles) or number (%); 
* p < 0.01; p < 0.0001
cy were signiﬁcantly lower among patients (p < 0.01). The women with a
history of severe preeclampsia (n = 80) who had chosen not to participate
in this study had a median age of 34 years (27-41) and 94% of them were
Caucasians. This was not different from the patient cohort, though
other characteristics were not known since we had not been able to inter-
view them.
The interval between the index pregnancy and completion of the ques-
tionnaire was signiﬁcantly (p < 0.01) longer in former patients as com-
pared with controls.
Table 2a shows the prevalence of experienced health and mental com-
plaints in former patients and controls. Eighty-ﬁve percent of the pa-
tients reported at least one health complaint some time after their index
pregnancy, which is signiﬁcantly (p < 0.001) higher compared to 45% of
the controls, who reported some kind of health or mental problem after
their ﬁrst ongoing pregnancy. Headache, right upper quadrant pain,
visual disturbances, tiredness, and some loss of concentration were
reported signiﬁcantly (p < 0.001) more often by the former patients, even
as mental problems (p < 0.01). Moreover, they reported signiﬁcantly (p <
0.001) more often that these health problems were still present six
months postpartum compared to controls (Table 2b). Under the heading
‘other problems’ six patients reported some kind of dumb feeling, weak-
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Table 2A Experienced health complaints in all former patients and controls
Former patients Controls 95% CI for difference
n = 131 n = 127 between groups
Experienced health complaints 110 (84%)** 57 (45%) 28%-50%
Hypertension 45 (34%)** 0 26%-43%
Renal disease 19 (15%)** 0 9%-21%
Headache 41 (31%)** 2 (2%) 21%-38%
Right upper quadrant pain 21 (16%)** 1 (1%) 9%-22%
Visual disturbances 27 (21%)** 1 (1%) 13%-27%
Tiredness 87 (66%)** 34 (27%) 28%-51%
Some loss of memory 51 (39%) 40 (31%) -4%-19%
Some loss of concentration 49 (37%)** 20 (16%) 11%-32%
Mental problems 48 (37%)* 7 (6%) 22%-40%
Other problems 22 (17%) 22 (17%) -10%-9%
Data are presented as numbers (%). * p < 0.01; ** p < 0.001
ness, and tingling of their limbs compared to one woman of the control
group.
There was no difference in prevalence of reported health or mental
problems, between patients who experienced perinatal mortality and
who did not. The overall perinatal mortality rate among patients in our
study was 10%, whereas there was none in the group of controls. 
Table 3a shows the experienced health complaints of patients according
as to whether they had been admitted to the intensive care unit (icu).
Overall, patients who had been admitted to the icu did not more often
report health complaints. However, persistence of problems of head-
ache, and subjective loss of concentration and memory beyond 6 months
postpartum were signiﬁcantly (p < 0.01) more frequent in patients who
had been admitted to the icu (Table 3b).
Seventy-eight former patients had become pregnant again (47%), 51%
of the control women became pregnant again after their ﬁrst pregnancy.
Twenty former patients were still aiming for another pregnancy (15%)
whereas 31 women (25%) had chosen not to become pregnant again after
the index pregnancy.
Forty-one former patients (31%) feared preeclampsia to recur. In this
group, 14 women (11%) did not want another pregnancy because of this
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Table 2B Health complaints lasting more than 6 months among former patients and con-
trols who reported health complaints
Former patients Controls 95% CI for difference
n = 110 n = 57 between groups
Health complaints > 6 months 
post partum 68 (62)* 23 (40) 6%-37%
Hypertension 21 (47)** 0 12%-26%
Renal disease 11 (58)** 0 4%-16%
Headache 25 (61)* 0 15%-31%
Right upper quadrant pain 10 (48)# 0 4%-14%
Visual disturbances 15 (56)* 0 7%-20%
Tiredness 55 (63)# 17 (51) 5%-35%
Some loss of memory 36 (71) 20 (51) -18%-13%
Some loss of concentration 33 (67)# 9 (45) 1%-27%
Mental problems 32 (67)** 2 (29) 16%-35%
Other problems 0 0 -
Data are presented as numbers (%).* p < 0.01; ** p < 0.001
fear, while 11 women said to aim for another pregnancy despite their fear
to develop preeclampsia again, and 16 of them had already been preg-
nant. None of the control women reported any fear for a new pregnancy.
The overall recurrence rate of some kind of hypertensive complications
in a subsequent pregnancy was 58%.
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Table 3A Experienced health complaints among former patients in relation to 
admittance to ICU
Patients  Patients not 95% CI for difference 
previously been in ICU between groups
been in ICU
n = 56 n = 75
Health troubles 50 (89) 60 (80) -3%-21%
Hypertension 21 (38) 24 (32) -11%-22%
Renal disease 6 (11) 13 (17) -18%-5%
Headache 22 (39) 19 (25) -2%-30%
Right upper quadrant pain 9 (16) 12 (16) -13%-13%
Visual disturbances 14 (25) 13 (17) -7%-22%
Tiredness 40 (71) 47 (63) -7%-25%
Subjective loss of memory 26 (46) 25 (33) -4%-30%
Subjective loss of concentration 25 (45) 24 (32) -4%-29%
Mental problems 20 (36) 28 (37) -18%-15%
Data are presented as numbers (%).
Table 3B Experienced health complaints (> 6 months) among former patients in relation
to admittance to ICU
Patients  Patients not 95% CI for difference 
previously been in ICU between groups
been in ICU
n = 56 n = 75
Health troubles 32 (64) 36 (60) -8%-26%
Hypertension 12 (57) 9 (38) -4%-22%
Renal disease 5 (83) 6 (46) -9%-11%
Headache 18 (82)* 7 (37) 9%-37%
Right upper quadrant pain 5 (56) 5 (42) -7%-12%
Visual disturbances 10 (71) 5 (38) 0%-23%
Tiredness 29 (73) 26 (55) 0%-34%
Some loss of memory 23 (88)* 13 (52) 8%-39%
Some loss of concentration 21 (84)* 12 (50) 6%-37%
Mental problems 12 (60) 20 (71) -20%-9%
Data are presented as numbers (%). * p < 0.01
Haematological and biochemical parameters of former patients and con-
trols are depicted in Table 4. Uric acid and γ-glutamyltransferase were
both signiﬁcantly (p < 0.01) higher in former patients compared to con-
trols. However, the number of women in whom laboratory values were
outside the laboratory reference value were very small and not signiﬁ-
cantly different between the groups.
Systolic and diastolic blood pressure at follow-up were signiﬁcantly
higher among women with a history of severe preeclampsia (Table 5).
Twelve former patients (9%) and none of the controls were shown to be
hypertensive.
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Table 4 Biochemical parameters in patients and controls at follow-up
Former patients Controls
n = 123 n = 97
Haemoglobin (mmol/L) 8.0 (7.3-8.0) 8.1 (7.3-8.9)
Haematocrite (L/L) 0.38 (0.34-0.42) 0.39 (0.35-0.43)
Platelet count (.109 /L) 253 (178-375) 254 (178-361)
Creatinine (mmol/L) 81 (69-93) 80 (68-97)
Uric acid (mmol/L) 0.26 (0.19-0.38)* 0.24 (0.17-0.35)
AST (U/L) 13 (12-29) 17 (12-27)
ALT (U/L) 16 (9-33) 15 (9-29)
LDH (U/L) 307 (248-384) 314 (250-407)
γ-Glutamyltransferase (U/L) 14 (9-29)* 12 (7-31)
Unconjugated bilirubin (mmol/L) 7 (4-18) 6 (4-14)
Conjugated bilirubin (mmol/L) 1 (1-3) 1 (1-3)
Proteinuria (g/10 mmol creatinine) 0.06 (0.02-0.23) 0.05 (0.02-0.19)
Data are presented as medians (5th – 95th percentiles). * p < 0.01
Table 5 Clinical parameters in patients and controls at follow-up
Former patients Controls
BMI (kg/m2) 24.9 (19.8-35.8) 23.4 (19.8-32.5)
N total 121 125
Systolic blood pressure (mmHg) 124 (106-160)* 112 (100-130)
N total (n > 160 mmHg) 119 (2) 123 (0)
Diastolic blood pressure (mmHg) 82 (70-108)* 75 (60-85)
N total (n > 95 mmHg) 119 (10) 123 (0)
Heart rate (beats/min) 68 (56-80) 64 (56-80)
N total 117 118
Data are presented as medians (5th – 95th percentiles). 
BMI = body mass index. * p < 0.001
discussion
This is the ﬁrst study on physical wellbeing of women after severe pre-
eclampsia. Our ﬁndings demonstrate that women with a history of
severe preeclampsia experienced health complaints more often and for a
longer period of time than women who had uncomplicated pregnancies
only. icu admittance prolonged the time of duration of headache and
subjective loss of concentration and memory.
One third of our patient group had complaints of headache, lasting for
more than six months in 61% of this group. Vasospasms of the cerebral
vasculature appear up to 3 months post partum in women after pre-
eclampsia [17]. This may be related to the complaints of headache, as dur-
ing disease headache is associated with abnormal cerebral perfusion
pressure [18]. A direct relationship between chronic hypertension and
headache can not explain its high frequency, since the prevalence of
chronic hypertension after the index pregnancy was 9% in our study. The
frequency of headache is only two percent in our control group, which is
much lower than the reported ﬁfteen percent in the study of Glazener et
al., which however, consisted of an unselected group of women with
regard to obstetrical history [7].
Active episodes of the hellp syndrome are characterised by right
upper quadrant pain or epigastric pain [19]. Sixteen percent of the for-
mer patients still experienced such a pain once in a while. Involvement of
liver injury is characterised by an initial rise of aminotransferases fol-
lowed by that of alkaline phosphatase and γ-glutamyl transferase concen-
trations, which is suggestive of cholestasis. Eight weeks after delivery,
liver enzymes are normalised [20]. In our study γ-glutamyl transferase
levels were slightly higher among former patients, though within normal
ranges. Since liver enzymes concentrations in the former patients were
within normal ranges, the aetiology of this pain post partum may not be
the same as during the hellp syndrome, especially as the median inter-
val between the complaints and blood sampling was four years. 
Visual loss is a symptom of preeclampsia, which has been associated
with increased blood pressure, cerebral oedema, as well as with gener-
alised vascular dysfunction [21]. In our study complaints of visual loss
varied from permanent impairment of vision to temporary cortical
blindness, and was not directly associated with chronic hypertension.
Tiredness is a common problem in women who recently have given birth
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and is unrelated to parity or method of delivery [7,8]. Severe preeclamp-
sia and especially hellp syndrome are associated with general malaise
and fatigue as well [19], which may be related to the higher incidence of
tiredness we found among former patients. In both study groups, subjec-
tive memory loss was reported equally frequent, although former
patients who were admitted to the intensive care unit more often had
subjective memory problems beyond six months than women who were
not admitted. Possibly, the more severely ill patients, being admitted
more often to the icu , need a longer recovery period. Both the incidence
and duration of subjective loss of concentration were signiﬁcantly higher
and longer among former patients. The effect of pregnancy on cognitive
functions has been subject of many studies, though the conclusions are
contradictory [22,23]. Several important endocrinological changes are
associated with changes in cognition and mood, during as well as after
pregnancy [24]. A direct relationship between preeclampsia and concen-
tration problems has not been reported, though might be suspected
since the central nervous system is involved in the pathophysiology of
preeclampsia [9]. Up to 37% of the former patients reported some kind
of mental problems compared to 6% of the controls. Studies on the psy-
chosocial sequel of severe preeclampsia, however, are scarce [11]. Psy-
chosocial health of former icu patients has been more related to the
level of perceived physical health rather than whether or not the patient
had been admitted to the icu [13,25]. 
In a recent publication, preeclampsia was not identiﬁed as a predictor
for post traumatic stress disorder [26]. There is no information on the
association between preeclampsia and the occurrence of post partum
depression [27]. The care and concern for the preterm born infant, who
is often admitted to the neonatal intensive care unit, results in a substan-
tial psychosocial stress on women and their partners, as demonstrated in
previous reports [12,28]. A direct effect of preeclampsia on postpartum
tiredness, loss of concentration, and mental problems will therefore be
difﬁcult to identify. A control group of parents of prematurely born chil-
dren after normotensive pregnancy was not available to us.
The postpartum recovery of clinically recognisable disease and especial-
ly of the platelet count and liver function tests took place in the ﬁrst
weeks after delivery [3,4,6]. During preeclampsia, increased uric acid
concentrations are associated with decreased renal clearance but also
with increased oxidative stress [29,30]. Slightly higher levels of uric acid
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in former patients might suggest an ongoing as well as an underlying
renal problem or an increased antixodant defence [31]. Nisell et al.
reported a higher incidence of chronic hypertension among women
seven years after they experienced gestational hypertension or pre-
eclampsia [32]. Our ﬁndings of higher systolic and diastolic blood pres-
sures among formerly patients compared to controls, conﬁrm the results
of that study [32]. Blood pressure was only measured once in our study.
However, also elevated blood pressures measured only once, have shown
to be associated with future development of hypertension and cardiovas-
cular disease [33]. 
For 11% of the former patients their fear for recurrence was reason to
refrain from a new pregnancy, which is lower than the rate of 34% as
reported by Van Pampus et al. [34]. In our study 31% of the former
patients feared recurrence, though the percentage of women who deﬁ-
nitely refrained from a new pregnancy was much lower. Since control
women did not experience complicated pregnancies, we could not make
a clear comparison between these groups. There are no data on fear for a
new pregnancy of women with prematurely born infants.
In our study, the time period between the questionnaire and the index
pregnancy might have inﬂuenced the recall of postnatal health problems.
However, recall of pregnancy related events in women 30 years or more
after delivery was reproducible and reasonably accurate [35]. Other
reports on maternal recall demonstrated no substantial deterioration
over time either [36,37]. One may argue that women with a history of
severe preeclampsia might be more focussed to recall some kind of
symptoms than control women. Since all questionnaires were verbally
checked with former patients as well as control women, we probably
have removed such an effect.
In conclusion, physical and mental wellbeing of women with a history
of severe preeclampsia seems to be impaired and sufﬁcient support for
these group of women is needed.
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Epilogue
Within the multifactorial aetiology of preeclampsia the role of oxidative
stress has generally been accepted [1-3]. Maternal sources of oxidative
stress derive from different pre-existing conditions such as hypertension
and insulin sensitivity syndrome or a deﬁciency of antioxidant defence
for example by a genetic predisposition [4-6]. The foetoplacental com-
partment, which is composed of maternal and paternal factors, has a
substantial role in supplying oxidative stress. The paternal share in pre-
eclampsia has been previously suggested based on the effect of changing
paternity on the incidence of preeclampsia [7,8]. 
In normal pregnancy a burst of oxidative stress occurs in the tro-
phoblastic tissue around the ninth weeks of gestation, due to a rapid
increase of oxygen tension in the trophoblastic layer, followed by (mito-
chondrial) free radical generation. At that time, cellular antioxidant
defence may be temporarily overwhelmed [9]. If antioxidant defences of
the trophoblastic tissue are inappropriate or oxidative stress is too pro-
nounced, proper placentation might be endangered leading to pre-
eclampsia [2,10]. To date, it was not possible to demonstrate a disturbed
antioxidant defence early in pregnancy in placental tissue of women later
developing preeclampsia.
Reactive oxygen species are continuously produced within the cell [11]
and exert critical actions such as signal transduction, gene transcription,
and regulation of soluble guanylate cyclase activity [12,13]. Low levels of
nitric oxide regulate relaxation and proliferation of vascular smooth
muscle cells, vascular tone and hemodynamics [14] and even serve as
neurotransmitters or mediators of immune response [15]. The expres-
sion of several antioxidants, such as glutathione S-transferases, glu-
tathione peroxidase and superoxide dismutase are directly or indirectly
regulated by the antioxidative response element in response to oxidative
stress [16,17]. Obviously, there are two faces of free radicals in biology in
that they serve as signalling and regulatory molecules at physiological
levels, but they must also be regarded as highly deleterious and cytotoxic
oxidants at pathological levels [15].
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The basic assumption of the study presented in chapter 6 was to achieve
a reduction in oxidative stress through administration of the antioxidant
N-acetylcysteine in order to stabilise preeclampsia. N-acetylcysteine
administration to healthy volunteers, whether or not with oxidative
stress, decreased plasma homocysteine concentrations (chapters 3 and
4), which proved our persuasion of the antioxidant properties of nac .
Furthermore, nac exerted a positive effect on the foetoplacental vascu-
lature of preeclamptic pregnancies by inﬂuencing the nitric-oxide path-
way (chapter 5). However, the double blind randomised N-acetylcysteine
placebo controlled trial could not demonstrate a beneﬁcial effect on the
course of preeclampsia and/or hellp syndrome, neither as a signiﬁcant
prolongation of pregnancy nor show a signiﬁcant impact on whole blood
and plasma thiol or f r a p levels, the latter as a measure of oxidative
stress. Administration of nac did not succeed in stabilisation of the dis-
ease process. How can we explain this? Was the treatment started too
late in the course of the disease? Was the dose of N-acetylcysteine too
low or were the included numbers too small? Possibly all of these sugges-
tions might account to the study results, though the most plausible expla-
nation may be the timing of initiation of N-acetylcysteine therapy.
Other antioxidants, such as vitamins c and e administered to patients
with preeclampsia in randomised controlled studies during established
preeclampsia had no beneﬁcial effect on maternal and neonatal outcome
either [18,19].
The ultimate purpose of all research in the ﬁeld of preeclampsia is to
deﬁne a preventive strategy for preeclampsia. Since true prediction and
primary prevention of preeclampsia is hardly possible, early recognition
of preeclampsia before the onset of clinical symptoms, is the second best
option. Invasive diagnostic research of the placenta early in pregnancy
for measuring signs of local ischemia and oxidative stress, by taking a
chorion villous sample, is no option. Theoretically, sampling of plasma,
serum or urine could be an acceptable alternative to get informed about
placental oxidative stress, by measuring concentrations of lipid perox-
ides, t ba r s , carbonyls, or malondialdehyde acetate (mda) [20,21].
Maternal dna sampling for determining the genetic risk proﬁle of the
antioxidant defence could be helpful, though is not conclusive for the
antioxidant defence in the foetoplacental compartment, which is from
foetal origin. To date, there are no reliable markers of oxidative stress in
early pregnancy, which adequately predict the later development of
preeclampsia [22].
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An interesting new development is the elevated amount of cell-free
foetal dna in women with preeclampsia. Cell-free foetal dna is
thought to be a marker of cell death. In preeclamptic pregnancies, in-
creased levels of foetal dna are found, which probably originate from
necrotic or apoptotic syncytiotrophoblast fragments as a result of pla-
cental ischemia. Recently, a study demonstrated a two-stage elevation of
cell-free foetal dna with an initial elevation between 17-28 weeks of ges-
tation before clinical onset of the disease [23].
The novel, non-invasive technique, Proton-Magnetic Resonance
Spectroscopy has been applied for in vivo measurement of vitamin c and
glutathione concentrations in other ﬁelds of medicine [24,25] and might
be useful for in vivo determination of antioxidant levels in placenta dur-
ing the ﬁrst trimester.
In Chappell’s study women were identiﬁed as being at increased risk
of preeclampsia by abnormal uterine-artery Doppler analysis or a previ-
ous history of preeclampsia. Administration of vitamins c and e started
at 16 to 22 weeks of gestation, resulted in a signiﬁcant lower incidence of
preeclampsia compared to the placebo group [26]. This small study is
now followed by a large randomised trial of antioxidants to prevent
preeclampsia in a non-selected population of 10,000 pregnant women in
the United Kingdom. 
In the light of the physiological role of controlled oxidative stress it
would be interesting to know whether administration of antioxidants
could also have a negative effect on these physiological processes [27].
There are a few reports on the hazardous effects of excess of antioxi-
dants, such as dietary supplementation of high doses of vitamin c (260
mg/day) plus iron (14 mg ferrous sulphate/day) causing dna oxidation
in human leukocytes [28] and a decreased ability of anti-inﬂammatory
response has been associated with high dietary vitamin e levels [29]. 
A woman’s medical history as well as her family history can also be help-
ful in determining the risk of developing preeclampsia. The association
between a positive family history of hypertension and hypercholestero-
laemia and a history of severe preeclampsia and/or hellp syndrome
may largely be explained by shared polymorphisms, such as in factor v
Leiden, mthf r , angiotensinogen, enos , glutathione S-transferase p1
and microsomal epoxide hydrolase [6,30-33], suggestive for common
pathogenic features such as endothelial dysfunction, thrombophilia, dys-
lipidemia, chronic hypertension, obesity, and diabetes (chapter 12) [4,34-
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39]. This might also explain the higher prevalence of chronic hyperten-
sion later in life among women with a history of preeclampsia [4,40,41].
Pregnancy complicated by preeclampsia may temporarily unmask an
underlying essential hypertension or other cardiovascular problems [4].
With respect to short term health effects, these group of women deserve
extra attention since women with a history of severe preeclampsia, more
often and for a longer period of time, do experience health complaints
such as headache, tiredness, loss of concentration and mental problems
(chapter 13). Probably the largest impact of preeclampsia are the neonatal
consequences of early severe preeclampsia and/or hellp syndrome,
affecting both parents and children. Most infants born after early, severe
preeclampsia are admitted to the neonatal intensive care unit because of
iatrogenic prematurity and very often complicated with serious intra-
uterine growth restriction resulting in respiratory distress syndrome,
necrotising enterocolitits, sepsis or neonatal death [42]. Regarding the
long-term effect on these neonates it is known that adults who were
undernourished in early gestation are more prone to various cardiovas-
cular diseases in later life, according the results of the Dutch Famine
study [43]. Large follow-up studies should evaluate adult health of
growth restricted and premature born children, to consider the long-
term effects of gestational diseases such as preeclampsia. 
Final conclusion
The results of the uk study on antioxidant administration to a large un-
selected group of low risk pregnant women may further elucidate the
role of oxidative stress in preeclampsia. In the meantime we should con-
tinue our work on prospective, longitudinal studies in order to ﬁnd accu-
rate and reliable predictors of preeclampsia. Next to markers of oxidative
stress, research should include markers for endothelial dysfunction,
polymorphism in antioxidant enzymes, cell-free foetal dna and uterine-
artery Doppler ﬂow patterns.
The multifactorial nature of preeclampsia probably necessitates a
combination of several biomarkers in order to achieve an acceptable, pre-
dictive value. Early intervention, whether or not by antioxidant adminis-
tration, should start long before initiation of clinical symptoms of
preeclampsia to exert a signiﬁcant effect on short- and long-term mater-
nal and neonatal outcome.
198 epilogue
r ef er ence s
1. Stark JM. Pre-eclampsia and cytokine induced oxidative stress. Br J Obstet
Gynaecol 1993; 100:105-109.
2. Walsh SW. Maternal-placental interactions of oxidative stress and
antioxidants in preeclampsia. Semin Reprod Endocrinol 1998; 16:93-104.
3. Davidge ST. Oxidative stress and altered endothelial cell function in
preeclampsia. Semin Reprod Endocrinol 1998; 16:65-73.
4. Lindeberg SN, Hanson U. Hypertension and factors associated with
metabolic syndrome at follow-up at 15 years in women with hypertensive
disease during ﬁrst pregnancy. Hypertens Preg 2001; 19:191-198.
5. Broughton PF, Roberts JM. Hypertension in pregnancy. J Hum Hypertens
2000; 14:705-724.
6. Zusterzeel PLM, Visser W, Peters WHM, Merkus JMWM, Nelen WLDM,
Steegers EAP. Polymorphism in the glutathione S-transferase P1 gene and
risk for preeclampsia. Obstet Gynecol 2000; 96:50-54.
7. Feeney JG, Scott JS. Pre-eclampsia and changed paternity. Eur J Obstet
Gynecol Reprod Biol 1980; 11:35-38.
8. Robillard PY, Hulsey TC, Alexander GR, Keenan A, de Caunes F,
Papiernik E. Paternity patterns and risk of preeclampsia in the last
pregnancy in multiparae. J Reprod Immunol 1993; 24:1-12.
9. Jauniaux E, Watson AL, Hempstock J, Bao YP, Skepper JN, Burton GJ.
Onset of maternal arterial blood ﬂow and placental oxidative stress. A
possible factor in human early pregnancy failure. Am J Pathol 2000;
157:2111-2122.
10. Walker JJ. Antioxidants and inﬂammatory cell response in preeclampsia.
Semin Reprod Endocrinol 1998; 16:47-55.
11. Halliwell B, Gutteridge JM, Cross CE. Free radicals, antioxidants, and
human disease: where are we now? J Lab Clin Med 1992; 119:598-620.
12. Zheng M, Storz G. Redox sensing by prokaryotic transcription factors.
Biochem Pharmacol 2000; 59:1-6.
13. Lander HM. An essential role for free radicals and derived species in signal
transduction. fa seb J 1997; 11:118-124.
14. Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling
molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999;
34:879-886.
15. Fridovich I. Fundamental aspects of reactive oxygen species, or what’s the
matter with oxygen? Ann-N-Y-Acas-Sci 1999; 893:13-18.
16. Schafer G, Cramer T, Suske G, Kemmner W, Wiedenmann B, Hocker M.
epilogue 199
Oxidative stress regulates vascular endothelial growth factor-A gene
transcription through Sp1- and Sp3 dependent activtion of two proximal
GC-rich promoter elements. J Biol Chem 2003; 278:8190-8198.
17. Itoh K, Ishii T, Yamamoto M. Regulatory mechanisms of cellular response
to oxidative stress. Free Radic Res 1999; 31:319-324.
18. Gulmezoglu AM, Hofmeyr GJ, Oosthuisen MM. Antioxidants in the
treatment of severe pre-eclampsia: an explanatory randomised controlled
trial. Br J Obstet Gynaecol 1997; 104:689-696.
19. Stratta P, Canavese C, Porcu M, Dogliani M, Todros T, Garbo E et al.
Vitamin e supplementation in preeclampsia. Gynecol Obstet Invest 1994;
37:246-249.
20. Trevisan M, Browne R, Ram M, Muti P, Freudenheim J, Carosella AM et al.
Correlates of markers of oxidative status in the general population. Am J
Epidemiol 2001; 154:348-356.
21. Diedrich F, Renner A, Rath W, Kuhn W, Wieland E. Lipid hydroperoxides
and free radical scavenging enzyme activities in preeclampsia and hellp
(hemolysis, elevated liver enzymes, and low platelet count) syndrome: no
evidence for circulating primary products of lipid peroxidation. Am J Obstet
Gynecol 2001; 185:166-172.
22. Myatt L, Miodovnik M. Prediction of preeclampsia. Semin Perinatol 1999;
23:45-57.
23. Levine RJ, Qian C, LeShane ES, Yu KF, England LJ, Schisterman EF et al.
Two-stage elevation of cell-free fetal dna in maternal sera before onset of
preeclampsia. Am J Obstet Gynecol 2004; 190:707-713.
24. Terpstra M, Gruetter R. (1)h nmr detection of vitamin c in human brain
in vivo. Magn Reson Med 2004; 51:225-229.
25. Mueller SG, Trabesinger AH, Boesiger P, Wieser HG. Brain glutathione
levels in patients with epilepsy measured by in vivo (1)h-mr s . Neurology
2001; 57:1422-1427.
26. Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ et al. Effect of
antioxidants on the occurrence of pre-eclampsia in women at increased
risk: a randomised trial. Lancet 1999; 354:810-816.
27. Halliwell B. Free radicals, antioxidants, and human disease: curiosity,
cause, or consequence?. Lancet 1994; 344:721-724.
28. Rehman A, Collis CS, Yang M, Kelly M, Diplock AT, Halliwell B et al. The
effects of iron and vitamin c co-supplementation on oxidative damage to
dna in healthy volunteers. Biochem Biophys Res Commun 1998; 246:293-
298.
200 epilogue
29. Calder PC, Kew S. The immune system: a target for functional foods? Br J
Nutr 2002; 88:s165-s177.
30. Arngrimsson R, Hayward C, Nadaud S, Baldursdottir A, Walker JJ, Liston
WA et al. Evidence for a familial pregnancy-induced hypertension locus in
the enos-gene region. Am J Hum Genet 1997; 61:354-362.
31. Ward K, Nelson L, Knowlton J, Hastings S, Varner M. Factor v Leiden and
the T235 variant of angiotensinogen as risk factors for preeclampsia: A
prospective study. J Soc Gynecol Invest 1998; 5:140a .
32. Zusterzeel PLM, Peters WHM, Visser W, Hermsen KJM, Roelofs HMJ,
Steegers EAP. A polymorphism in the gene for microsomal epoxide
hydrolase is associated with pre-eclampsia. J Med Genet 2001; 38:234-237.
33. Grandone E, Margaglione M, Colaizzo D, Cappucci G, Scianname N,
Montanaro S et al. Prothrombotic genetic risk factors and the occurrence
of gestational hypertension with or without proteinuria. Thromb Haemost
1999; 81:349-352.
34. Hubel CA, Roberts JM, Taylor RN, Musci TJ, Rogers GM, McLaughlin
MK. Lipid peroxidation in pregnancy: new perspectives on preeclampsia.
Am J Obstet Gynecol 1989; 161:1025-1034.
35. Suhonen L, Teramo K. Hypertension and pre-eclampsia in women with
gestational glucose intolerance. Acta Obstet Gynecol Scand 1993; 72:269-
272.
36. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA et
al. Atherosclerosis: basic mechanisms. Oxidation, inﬂammation, and
genetics. Circulation 1995; 91:2488-2496.
37. Sattar N, Bendomir A, Berry C, Shepherd J, Greer IA, Packard CJ.
Lipoprotein subfraction concentrations in preeclampsia: pathogenic
parallels to atherosclerosis. Obstet Gynecol 1997; 89:403-408.
38. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar Am A, Jaffa A et al.
Increased frequency of genetic thrombophilia in women with
complications of pregnancy. N Engl J Med 1999; 340:9-13.
39. Higgins M. Epidemiology and prevention of coronary heart disease in
families. Am J Med 2000; 108:387-395.
40. Chesley LC. Hypertension in pregnancy: deﬁnitions, familial factor, and
remote prognosis. Kidney Int 1980; 18:234-240.
41. Sibai BM, el Nazer A, Gonzalez Ruiz A. Severe preeclampsia-eclampsia in
young primigravid women: subsequent pregnancy outcome and remote
prognosis. Am J Obstet Gynecol 1986; 155:1011-1016.
42. Friedman SA, Schiff E, Kao L, Sibai BM. Neonatal outcome after preterm
delivery for preeclampsia. Am J Obstet Gynecol 1995; 172:1785-1788.
epilogue 201
43. Roseboom TJ, van der Meulen JH, Osmond C, Bleker OP. Effects of
prenatal exposure to the Dutch famine on adult disease in later life: an
overview. Mol Cell Endocrinol 2001; 185:93-98.
202 epilogue
Summary
Preeclampsia and hellp syndrome have been studied for many decades
because of its enormous impact on maternal and foetal health. In the
western countries, maternal death due to eclampsia, preeclampsia
and/or the hellp syndrome accounts for approximately 25% of all
maternal death in the last century. Preeclampsia presents the most fre-
quent cause of maternal death in the Netherlands. In the third world
countries, maternal mortality is even a much larger health problem, due
to the lack of antenatal care in many (rural) areas. Therefore, approxi-
mately 90% of maternal deaths (more than 0.5 million deaths each year)
occur in developing countries. In daily practice in the Netherlands, we
are sporadically dealing with maternal death, however we are often fac-
ing severely ill mothers, growth restricted foetuses or iatrogenic prema-
turity as a result of preeclampsia. An early prediction of impending pre-
eclampsia and an effective preventive therapy could diminish the mater-
nal and foetal morbidity and mortality.
Within the scope of this thesis further research towards the under-
standing and treatment of preeclampsia was performed, with special
attention to oxidative stress: the (im)balance between oxidants and
antioxidants.
pa rt i
Chapter 1 contains a short general introduction, where the objectives of
the thesis are outlined. These objectives can be summarised as follows:
1. To assess the effects of N-acetylcysteine administration in:
a. healthy non-pregnant volunteers with and without oxidative stress
b. women with severe preeclampsia and/or hellp syndrome
2. To search for additional biochemical parameters of preeclampsia/
hellp syndrome – mainly related to maternal detoxiﬁcation – either
in blood or urine.
4. To study the balance between oxidants and antioxidants in normal
pregnancy and puerperium.
3. To search for additional risk factors for preeclampsia and to investi-
gate physical and mental health after severe preeclampsia and/or
hellp syndrome.
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These studies were conducted in a collaboration between the depart-
ments of Obstetrics & Gynaecology and Gastroenterology, University
Medical Center Nijmegen.
In chapter 2 the theoretical background for performing a study on oral
N-acetylcysteine administration in women with severe preeclampsia
and/or hellp syndrome is presented.
Oxidative stress may contribute to the pathology of preeclampsia and
hellp syndrome; it may not only explain the impaired trophoblast inva-
sion during the ﬁrst trimester but also the maternal symptoms caused by
endothelial dysfunction. In earlier studies, we found a signiﬁcant reduc-
tion of the antioxidant glutathione in whole blood of women with severe
preeclampsia and hellp syndrome. Therefore we hypothesised that
correction of an imbalance in oxidants and antioxidants (such as glu-
tathione) with N-acetylcysteine (as precursor of glutathione) may con-
tribute to the stabilisation of the disease process and therefore may
reduce maternal and foetal morbidity and mortality.
pa rt ii
Part ii of this thesis is dedicated to the administration of N-acetylcys-
teine to healthy volunteers with and without oxidative stress, and to an in
vitro study on N-acetylcysteine in a placenta-perfusion model. The main
part describes the outcome of the double-blind placebo controlled study
in women with severe preeclampsia and/or hellp syndrome. 
In chapter 3 it is shown that oral N-acetylcysteine administration in
nine young healthy females induces a quick and highly signiﬁcant
decrease in plasma homocysteine levels. In addition, whole blood con-
centrations of the antioxidant glutathione are increased. Chapter 4
describes a study on the effect of methionine loading with and without
subsequent N-acetylcysteine administration, on some blood parameters
of oxidative stress in healthy volunteers. After methionine loading,
whole blood levels of free and oxidised cysteine and homocysteine and
total plasma levels of homocysteine were increased, whereas total plas-
ma cysteine levels were lower in both groups. N-acetylcysteine adminis-
tration, however, seemed to be able to partly prevent excessive increase
of homocysteine in plasma and oxidised homocysteine in whole blood,
and may thus contribute to the prevention of oxidative stress. In chapter
5 the effect of N-acetylcysteine on the nitric oxide (no)-pathway in the
human foetoplacental circulation was investigated by ex vivo cotyledon
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perfusion in placentas of preeclamptic and control pregnancies. Pre-
eclampsia is associated with a dysfunction of the no-pathway, as demon-
strated by a diminished maximal l -na me induced rise in foetoplacental
arterial pressure. Addition of N-acetylcysteine in the placental perfusion
model increased no-mediated effects in the foetoplacental circulation in
preeclamptic placentas as well as in healthy control placentas. In chapter
6 a randomised, double blind, placebo-controlled trial is presented on
oral N-acetylcysteine administration in women with severe preeclampsia
and/or hellp syndrome. N-acetylcysteine administration neither
resulted in stabilisation of disease nor showed a beneﬁcial effect on
maternal or neonatal outcome. In addition, N-acetylcysteine administra-
tion did not signiﬁcantly effect the course of whole blood and plasma thi-
ols in women with severe preeclampsia and/or hellp syndrome. Expla-
nations for these unexpected results are discussed.
pa rt iii
In part iii , studies on whole blood and plasma thiols and of the antioxi-
dants vitamin c and e before, during and after pregnancy are described. 
In chapter 7 a longitudinal study on whole blood and plasma thiols
and vitamins c and e before, during and after uncomplicated and hyper-
tensive pregnancies has been described. In normal pregnancy there
seems a balance between antioxidants and oxidants, despite modest
oxidative stress. In mild hypertensive pregnancies a marginal imbalance
of antioxidants and oxidants may occur.
The study presented in chapter 8 was dedicated on the postpartum
period in women with uncomplicated pregnancies, either after vaginal
delivery or caesarean section. During the ﬁrst three days postpartum,
whole blood free and oxidised thiol levels increased signiﬁcantly. Irre-
spective of way of delivery, plasma vitamin e levels dropped not before
24 hours postpartum. Prolonged fasting after caesarean section resulted
in a signiﬁcant fall in levels of whole blood free cysteine, oxidised cys-
teine, homocysteine and glutathione and plasma cysteine and homocys-
teine, 24 hours postpartum.
pa rt i v
In part i v several biochemical systems that may be involved in pre-
eclampsia and hellp syndrome are discussed.
In chapter 9 the plasminogen activator (pa) system in maternal and
umbilical cord plasma of patients with severe preeclampsia and controls
summ a ry 205
with normotensive pregnancies is described. We found lower pa i-2 lev-
els in maternal plasma of women with severe preeclampsia, which proba-
bly is associated with placental insufﬁciency. The higher maternal tpa
levels in the same group correspond well with the already known
endothelial dysfunction. The higher pa i-1 levels and lower upa levels in
umbilical cord of these patients are suggestive for decreased ﬁbrinolysis
in the foetal circulation.
In the chapters 10 and 11, some data are presented on urine samples
collected of women with and without severe preeclampsia and/or
hellp syndrome. We found high urinary v egf concentrations in
patients with severe preeclampsia, which might reﬂect increased renal
production of v egf rather than elevated v egf levels in the systemic cir-
culation.
Assessment of urinary excretion of glutathione S-transferase a1-1
(proximal tubules) and glutathione S-transferase p1-1 (distal and collect-
ing tubules) might be helpful in determining if, and to what extent renal
tubular damage is present in preeclampsia, and whether such damage is
in the proximal or distal region. Urinary gsta1-1 concentrations, how-
ever, did not change during the course of pregnancy, whether or not com-
plicated by hypertension. Urinary gst p1-1 excretion markedly increased
during normal pregnancy, however, values did not differ as compared to
those of preeclamptic pregnancies.
pa rt v
The last two chapters are derived from a large follow-up study on women
with a history of severe preeclampsia and/or hellp syndrome and
women with uncomplicated pregnancies. Within the scope of this study
all women completed questionnaires on their own obstetric history, fam-
ily history and their physical and mental well being after their pregnan-
cies.
In chapter 12 the study on family history of cardiovascular disease,
hypertension and hypercholesterolemia has been described. Preeclamp-
sia is associated with a higher frequency of chronic hypertension and
cardiovascular disease in later life. Inherent (vascular) abnormalities,
such as thrombophilia, pre-existing endothelial dysfunction and oxida-
tive stress may predispose to vascular disease in later life, and also are
known risk factors for developing preeclampsia. Both preeclampsia and
cardiovascular disease are diseases with familial tendencies, associated
with the above-mentioned abnormalities. This study revealed that severe
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preeclampsia is associated with a positive family history of hypertension
and/or hypercholesterolemia. In chapter 13 the physical and mental
health in women with a history of severe preeclampsia was compared to a
group of women with a history of uncomplicated pregnancies. Former
preeclamptic patients more frequently experienced problems of head-
ache, right upper quadrant pain, visual disturbances, tiredness, loss of
concentration and problems of mental health, as compared with con-
trols.
In conclusion, there is still a need for accurate and reliable predictors of
preeclampsia. Prospective, longitudinal studies should be designed to
discover and test the predictive value of sensitive markers of oxidative
stress and endothelial dysfunction as well as other markers such as poly-
morphism in antioxidant enzymes, cell-free foetal dna and uterine-
artery Doppler ﬂow patterns. The multi-factorial nature of preeclampsia
probably necessitates a combination of several biomarkers in order to
achieve an acceptable, predictive value. Early intervention, whether or
not by antioxidant administration, should start long before the initiation
of clinical symptoms of preeclampsia to exert a signiﬁcant effect on
short- and long-term maternal and neonatal outcome.
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Samenvatting
Preëclampsie en het hellp syndroom zijn al decennia lang onderwerp
van onderzoek vanwege de grote negatieve invloed op de maternale en
perinatale mortaliteit en morbiditeit. In de westerse wereld is ongeveer
25% van de maternale sterfte gerelateerd aan het optreden van eclampsie,
preëclampsie en het hellp syndroom. Maternale mortaliteit is met
name in derdewereldlanden een groot probleem door het gebrek aan
goede prenatale zorg in veel (plattelands)gebieden. Ongeveer 90% van
de maternale sterfte treedt op in de Derde Wereld, meer dan 500.000
vrouwen overlijden daar jaarlijks aan de gevolgen van een zwangerschap.
In Nederland behoort preëclampsie tot de belangrijkste maternale
doodsoorzaken, maar gelukkig heeft men in de dagelijkse praktijk zelden
van doen met maternale sterfte. Vrouwen kunnen echter wel ernstig ziek
worden ten gevolge van preëclampsie en het hellp syndroom. Boven-
dien leidt deze ziekte vaak tot intra-uteriene groeivertraging en resul-
teert het vaak in een iatrogene vroeggeboorte. Vroege predictie van pre-
eclampsie en een effectieve (secundaire) preventie zou de incidentie en
ernst van de maternale en perinatale morbiditeit en mortaliteit fors kun-
nen verminderen.
Dit proefschrift richt zich op de etiologie en mogelijkheden om de
behandeling van deze ziekte te optimaliseren. Hierbij is speciale aan-
dacht besteed aan de rol van oxidatieve stress: de (dis)balans tussen oxi-
danten en antioxidanten.
deel i
In hoofdstuk 1 wordt een korte algemene introductie gegeven, waarin de
doelen van het proefschrift worden besproken.
Deze doelen kunnen als volgt worden samengevat:
1. Het beoordelen van de effecten van toediening van N-acetylcysteïne
bij:
a. gezonde niet-zwangere vrijwilligers met en zonder oxidatieve stress,
b. vrouwen met ernstige preëclampsie en het hellp syndroom.
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2. Het bestuderen van additionele biochemische parameters van pre-
eclampsie en het hellp syndroom, vooral gerelateerd aan maternale
ontgifting, zowel in bloed als urine.
3. Het bestuderen van de balans tussen oxidanten en antioxidanten in de
ongestoorde zwangerschap en het kraambed.
4. Het zoeken naar additionele risicofactoren voor preëclampsie en het
hellp syndroom en het bestuderen van de fysieke en mentale
gezondheid na ernstige preëclampsie en het hellp syndroom.
Deze studies werden uitgevoerd in het kader van een samenwerkingsver-
band tussen de afdelingen Obstetrie & Gynaecologie en Gastro-entero-
logie van het umc Nijmegen. 
In hoofdstuk 2 wordt de theoretische achtergrond gepresenteerd van de
orale toediening van N-acetylcysteïne aan vrouwen met ernstige pre-
eclampsie en het hellp syndroom. Oxidatieve stress speelt hoogst-
waarschijnlijk een belangrijke rol bij de etiologie en pathofysiologie van
preëclampsie en het hellp syndroom. Het verklaart niet alleen de
gestoorde trofoblast-invasie in het eerste trimester, maar ook de mater-
nale symptomen door endotheeldisfunctie. In een eerdere studie van
onze onderzoeksgroep werden bij vrouwen met ernstige preëclampsie
en het hellp syndroom signiﬁcant lagere volbloedwaarden gevonden
van het intracellulaire antioxidant glutathion. Om die reden veronder-
stelden wij dat correctie van een disbalans tussen oxidanten en antioxi-
danten (zoals glutathion) door het toedienen van N-acetylcysteïne (een
precursor van glutathion) mogelijk zou kunnen bijdragen aan de stabili-
satie van het ziekteproces en daarmee de maternale en perinatale morbi-
diteit en mortaliteit zou kunnen verminderen.
deel ii
Dit deel van het proefschrift is gericht op de toediening van N-acetylcys-
teïne aan gezonde vrijwilligers met en zonder oxidatieve stress en een in
vitro studie met N-acetylcysteïne in een ex vivo placenta-perfusiemodel.
Het belangrijkste deel is de beschrijving van de uitkomsten van de geran-
domiseerde, dubbelblinde, placebogecontroleerde studie waarbij N-ace-
tylcysteïne wordt toegediend aan vrouwen met ernstige preëclampsie
en/of het hellp syndroom. 
In hoofdstuk 3 wordt getoond dat toediening van orale N-acetylcys-
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teïne aan jonge gezonde vrouwen resulteert in een snelle en signiﬁcante
afname van homocysteïneconcentraties in plasma en een stijging van
volbloedwaarden van glutathion. Hoofdstuk 4 beschrijft een onderzoek
naar het effect van methioninebelasting, met en zonder toediening van
orale N-acetylcysteïne, op een aantal bloedparameters van oxidatieve
stress in gezonde vrijwilligers. In beide groepen waren na methioninebe-
lasting de volbloedwaarden van vrij en geoxideerd cysteïne en homocys-
teïne en de waarden van homocysteïne in plasma signiﬁcant gestegen,
terwijl de plasma cysteïnewaarden gedaald waren. De toediening van N-
acetylcysteïne voorkwam ten dele de excessieve stijging van plasma
homocysteïne en geoxideerd homocysteïne in volbloed. Mogelijk draagt
N-acetylcysteïne via dit mechanisme bij aan de preventie van oxidatieve
stress. In hoofdstuk 5 werd het effect van N-acetylcysteïne op de bijdra-
ge van het stikstofmonoxide (NO) aan de basale vaattonus in de humane
foeto-placentaire circulatie bestudeerd via een ex vivo cotyledon per-
fusiemodel in placenta’s van vrouwen met preëclamptische en met on-
gestoorde zwangerschappen. Preëclampsie wordt geassocieerd met een
verminderde bijdrage van NO aan de basale vaattonus, zoals werd aange-
toond met een afgenomen maximale L-NAME geïnduceerde stijging in de
foeto-placentaire arteriële druk. Toevoeging van N-acetylcysteïne aan
het placenta-perfusiemodel resulteerde in een toename van no geregu-
leerde effecten op de foeto-placentaire circulatie, zowel in het geval van
preëclampsie als bij ongecompliceerde zwangerschappen. 
In hoofdstuk 6 wordt een gerandomiseerde, dubbelblinde, placeboge-
controleerde studie met toediening van N-acetylcysteïne aan vrouwen
met ernstige preëclampsie en/of het hellp syndroom gepresenteerd.
Toediening van N-acetylcysteïne resulteerde niet in een stabilisatie van
het ziektebeeld of verbetering van maternale en/of perinatale uitkom-
sten. Er werd ook geen signiﬁcant effect gezien op de concentraties van
thiolen in volbloed en plasma. Mogelijke verklaringen voor het uitblijven
van een positief resultaat worden in dit hoofdstuk bediscussieerd.
deel iii
In deel iii worden enkele studies gepresenteerd over het beloop tijdens
en na de zwangerschap van plasma- en volbloed thiolen en van vitamine
c en e . In hoofdstuk 7 wordt het longitudinale beloop van volbloed- en
plasma thiolen en de antioxidanten vitamine c en e beschreven vóór, tij-
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dens en na ongecompliceerde en hypertensieve zwangerschappen. Tij-
dens ongecompliceerde zwangerschappen leek er een goede balans te
zijn tussen oxidanten en antioxidanten ondanks milde oxidatieve stress.
In geval van hypertensieve zwangerschappen werd een lichte verstoring
van deze balans gezien.
In hoofdstuk 8 worden de concentraties van thiolen in volbloed en
plasma en van de antioxidanten c en e beschreven bij vrouwen in het
kraambed, zowel na een vaginale partus als na een primaire sectio caesa-
rea. Gedurende de eerste drie dagen waren in beide groepen de volbloed-
waarden van vrije en geoxideerde thiolen signiﬁcant toegenomen. 
Vitamine e concentraties daalden niet tot 24 uur postpartum, onafhan-
kelijk van de wijze van bevallen. Langdurig vasten na een electieve sectio
caesarea leidde 24 uur na de partus tot een signiﬁcante daling van zowel
de volbloedwaarden van vrij- en geoxideerd cysteïne, homocysteïne en
glutathion als van de plasmawaarden van cysteïne en homocysteïne.
deel i v
In deel i v worden verscheidene biochemische systemen beschreven die
mogelijk betrokken zijn bij preëclampsie en het hellp syndroom. In
hoofdstuk 9 wordt het plasminogeen activator inhibitor (pa i) systeem in
maternaal- en navelstrengbloed van patiënten met ernstige preëclampsie
en/of het hellp syndroom beschreven. De lagere pa i-2-concentraties
in plasma van vrouwen met ernstige preëclampsie vergeleken met die van
vrouwen met een ongecompliceerde zwangerschap zijn hoogstwaar-
schijnlijk geassocieerd met placentaire insufﬁciëntie, terwijl de hogere
tpa-concentraties worden verklaard door de endotheeldisfunctie. Hoge-
re pa i-1-concentraties en lagere upa-concentraties in navelstrengbloed
van vrouwen met ernstige preëclampsie lijken te wijzen op een afgeno-
men ﬁbrinolyse in de foetale circulatie. In de hoofdstukken 10 en 11 wor-
den de resultaten gepresenteerd van bepalingen in urinemonsters van
vrouwen met ernstige preëclampsie en/of het hellp syndroom. Er wer-
den hogere concentraties van Vascular Endothelial Growth Factor
(v egf) gevonden in de urine van vrouwen met ernstige preëclampsie.
Dit weerspiegelt eerder een toegenomen renale productie van v egf dan
systemisch verhoogde v egf waarden. De bepaling van de urinaire
excretie van glutathion S-transferase a1-1 (proximale tubuli) en gluta-
thion S-transferase p1-1 (distale- en verzameltubuli) kan nuttig zijn bij
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het bepalen van de mate en locatie van renale schade bij patiënten met
preëclampsie. In onze studie vonden we geen signiﬁcante verandering
van urinaire gsta1-1-excretie in de zwangerschap, ook niet in de hyper-
tensieve zwangerschap. De excretie van gst p1-1 in de urine daarentegen
was signiﬁcant toegenomen tijdens de ongestoorde zwangerschap. 
Tijdens ernstige preëclampsie was de excretie niet signiﬁcant verschil-
lend.
deel v
De laatste twee hoofdstukken beschrijven een omvangrijke vervolgstu-
die onder vrouwen die in het verleden ernstige preëclampsie en/of het
hellp syndroom hebben doorgemaakt en onder een groep vrouwen
met ongestoorde zwangerschappen. Alle vrouwen vulden een vragenlijst
in over hun eigen voorgeschiedenis, obstetrische voorgeschiedenis, fami-
liaire voorgeschiedenis en hun fysieke en mentale gezondheid. In hoofd-
stuk 12 werd de familieanamnese ten aanzien van cardiovasculaire ziek-
ten, hypertensie en hypercholesterolemie beschreven. Preëclampsie
wordt geassocieerd met een hogere frequentie van chronische hyperten-
sie en cardiovasculaire ziekten in het latere leven. Inherente (vasculaire)
afwijkingen, zoals tromboﬁlie, preëxistente endotheeldisfunctie en oxi-
datieve stress zijn ook bekend als risicofactor voor het ontwikkelen van
preëclampsie. Preëclampsie en cardiovasculaire ziekten hebben een
familiaire tendens en zijn geassocieerd met bovengenoemde afwijkin-
gen. In deze studie werd een associatie gevonden tussen het voorkomen
van preëclampsie en een positieve familieanamnese voor hypertensie
en/of hypercholesterolemie. In hoofdstuk 13 werd de fysieke en mentale
gezondheid van vrouwen met ernstige preëclampsie en/of het hellp
syndroom vergeleken met vrouwen met een ‘blanco’ obstetrische voor-
geschiedenis. Vrouwen met preëclampsie in de anamnese rapporteerden
vaker hoofdpijn, bovenbuikpijn, visusstoornissen, moeheid, concentra-
tieverlies en mentale problemen vergeleken met de controlegroep.
Concluderend kunnen we vaststellen dat er een grote behoefte bestaat
aan precieze en betrouwbare voorspellers (biomarkers) van preëclamp-
sie. Prospectieve, longitudinale studies moeten worden ontworpen om
nieuwe sensitieve markers van oxidatieve stress en endotheeldisfunctie
te ontdekken en de predictieve waarden te onderzoeken van andere mar-
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kers zoals polymorﬁsmen in antioxidant-enzymen, foetaal dna in
maternaal bloed en Doppler-patronen in de arteria uterina.
Het multifactoriële karakter van preëclampsie vraagt waarschijnlijk
om een combinatie van verschillende biomarkers ten einde een accepta-
bele predictieve waarde te verkrijgen voor het voorspellen van de ziekte.
Vroege interventie, wel of niet door toediening van antioxidanten, moet
plaatsvinden lang vóór het verschijnen van de eerste ziektesymptomen,
om een relevant gunstig effect te genereren op zowel de korte als de lange
maternale en perinatale uitkomst.
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Dankwoord
Dit proefschrift is totstandgekomen dankzij de hulp van talloze mensen
die ik daarvoor van harte dank. Als eerste noem ik de initiatoren van dit
onderzoek: mijn promotor prof. dr. Eric Steegers en copromotor dr. Wil-
bert Peters. 
Beste Eric, met je niet-aﬂatende enthousiasme, tomeloze energie en
nieuwsgierigheid heb je me enthousiast gemaakt en gehouden voor het
onderzoek naar preëclampsie en het hellp syndroom. Altijd stond je
klaar met goede adviezen, hulp en weer een nieuw onderzoeksplan, ook
na je vertrek naar Rotterdam. Ik voel me vereerd de eerste promovendus
te zijn bij wie jij als promotor optreedt.
Beste Wilbert, van het begin af aan heb ik met ontzettend veel plezier
op ‘jullie laboratorium’ gewerkt, al deed soms mijn opvliegende gedrag
het tegendeel vermoeden, als een bepaling voor de zoveelste keer misluk-
te of het apparaat niet deed wat ik wilde. Jouw nuchtere en relativerende
kijk op onderzoek (doen) was een verademing.
Geachte professor Merkus, u hebt het mede mogelijk gemaakt dat het
onderzoek naar N-acetylcysteïne ter stabilisatie van preëclampsie en het
hellp syndroom van start kon gaan. Hoewel uw aandachtsgebied niet
binnen de verloskunde lag, had u altijd waardevolle aanvullingen op de
onderzoeken die we verricht hebben.
Geachte professor Jansen, zoals u al aankondigde bij de promotie van
Maarten Raijmakers, zou er nog één proefschrift van de gst-groep vol-
gen. Hier ligt het dan en bij deze wil ik u danken voor de mogelijkheden
die u geboden hebt voor de samenwerking tussen onze afdelingen.
De klinische opzet van de onderzoeken, zoals beschreven in dit proef-
schrift, impliceren reeds dat dit een onderzoek was ín de kliniek. De ‘kli-
niek’ is groot, zowel qua omvang als qua diversiteit aan mensen. Ik wil
dan ook alle verpleegkundigen en andere medewerkers van de kraamaf-
deling, de verloskamers en polikliniek, de tweedelijns verloskundigen,
arts-assistenten, staﬂeden en secretaresses die op welke manier dan ook
hebben meegewerkt aan de uitvoering van dit onderzoek, van harte dan-
ken voor hun hulp, inzet en niet-aﬂatende belangstelling. In die dank
betrek ik de mensen van het Laboratorium Maag, Darm en Leverziekten:
Hennie, René, Elise en Annie.
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Anneke Geurts-Moespot, dr. Chris Thomas en professor Fred Sweep
van het ace lab dank ik voor de bijdrage die zij aan verscheidene van de
onderzoeken in dit proefschrift hebben geleverd. Dr. Jan Hendriks en dr.
Theo de Boo van de afdeling Epidemiologie en Biostatistiek wil ik dan-
ken voor hun hulp bij de statistische analyses.
Ook dank ik alle wetenschappelijke stagiaires – Marieke Schoonen-
berg, Renske Sieben, Marloes Langeslag, Hilde Renkema, Natasha Wan-
ner en Jente Lange – voor hun inzet en enthousiasme bij het bedenken en
uitvoeren van de verschillende onderzoeken.
Mijn dank gaat natuurlijk ook uit naar mijn copromovendus Maarten
Raijmakers voor de geslaagde en af en toe knallende samenwerking van
de afgelopen jaren. Door de inspanningen van onze voorgangers Maar-
ten Knapen en Petra Zusterzeel lag er al veel voor ons klaar en konden we
doorgaan op het reeds ingeslagen pad.
Ook alle collega-artsonderzoekers dank ik voor de goede en gezellige
sfeer tijdens onze onderzoeksjaren: in het bijzonder Marieke, René en
Jesper voor de warme uren op de zó koude kamer. En natuurlijk dank aan
alle anderen: Annemarie, Cathelijne, Erik, Iris, Marcel, Michael, Pascal,
Petra, Ron, Ruben, Sabina, Tanya, Wai Yee en Willianne.
In gedachten dank ik Nelleke Hamel-Verbruggen, research nurse avant-
la-lettre, die mij heel veel geholpen heeft. Ik had haar zó graag dit ‘boekje’
willen laten zien.
Het uiteindelijke doel van het onderzoek naar preëclampsie en het
hellp syndroom is niet alleen de wetenschap, maar juist het verder hel-
pen van patiënten. Het was lang niet altijd makkelijk ernstig zieke vrou-
wen en hun overdonderde partners om hun medewerking te vragen,
maar juist het intensieve contact met hen was een dankbaar en uitdagend
deel van het onderzoek. Daarom wil ik alle patiënten, hun partners en
kinderen bedanken voor hun belangeloze deelname. Daarnaast hebben
vele vrijwilligsters, met en zonder eventuele partners en kinderen hun
bijdrage geleverd, waarvoor ik ook hen van harte dank zeg.
Zeker mag ik in al deze dankbetuigingen alle (oud) arts-assistenten
obstetrie en gynaecologie uit het cluster Nijmegen niet ongenoemd laten,
evenmin als alle lieve en belangrijke vriendinnen, vrienden en familie die
mij gesteund en gestimuleerd hebben met hun belangstelling voor mijn
onderzoek.
Dit alles geldt natuurlijk heel in het bijzonder voor Alex Eggink. Lieve
Alex, wat ik je wil zeggen zal ik tussen ons laten. Op naar het volgende
‘boekje’.
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De laatste alinea is misschien wel de moeilijkste van het hele boek.
Lieve Hanneke, jouw interesse, meeleven en ook trots hebben me in deze
jaren van onderzoek en schrijven enorm gesteund. Dankzij het enthou-
siasme en de steun van Jan en jou heb ik kunnen bereiken wat ik wilde.
Hoe moeilijk was het de afgelopen zestien maanden om zonder Jan door
te gaan en hoe ontzettend jammer is het dat hij de afronding hiervan, de
voltooiing van mijn proefschrift en de verdediging daarvan, niet meer
meemaakt. Het feit dat jij mij als paranimf bijstaat betekent heel veel voor
me en hopelijk kunnen we nog vele bijzondere momenten delen met
elkaar en met al degenen die zich van lieverlee om ons hebben verenigd.
Eva Maria Roes
Nijmegen, september 2004
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